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ABSTRACT  
Diabetes (DM) increases mortality after myocardial infarction and deteriorates post-
ischaemic cardiac remodelling. This study investigated possible implications of thyroid 
hormone (TH) signalling in either reducing or preventing this response. TH signalling 
has a regulatory role in metabolism, cardiac function, growth and ischaemic stress.  
Acute myocardial infarction (AMI) was induced in age–match healthy control rats 
(AMI-C) and in streptozotocin (STZ)-induced type I diabetic (DM) animals (DM+AMI) 
using 35 mg/kg body weight while sham operated animals served as controls (SHAM). 
The results show that AMI in tissue hypothyroidism caused significant down-regulation 
of TH receptors, TRα1 and TRβ1, in the diabetic myocardium without changes in T3, 
T4 levels in plasma. This response was associated with increased expression of β-MHC 
and distinct changes in cardiac function and geometry.  Ejection fractions (EF%) was 
decreased in DM-AMI as compared to DM+AMI animals. Systolic and diastolic 
chamber dimensions were increased without concomitant increase in wall thickness and 
thus, WTI (the ratio of LVIDd/2*Posterior Wall thickness), an index of wall stress, was 
significantly elevated. The absence of wall thickening in DM+AMI hearts was 
associated with changes in stretch-induced kinase hypertrophic signalling p38 MAPK. 
In contrast, ERK, p-ERK and p-p38 MAPK levels were not changed in DM+AMI as 
compared to non-infarcted hearts (DM+SHAM). TH administration after AMI 
prevented hypothyroidism and resulted in decreased β-MHC expression, increased wall 
thickening and normalized wall stress, while stretch-induced p38 MAPK activation was 
restored. The results show that diabetes can exacerbates post-ischaemic cardiac 
remodelling and tissue hypothyroidism and TH treatment can prevent this response and 
improve cardiac haemodynamics. 
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WT- Wall thickness 
WTI – Wall tension index 
α-MHC – Alpha Myosin Heavy Chain 
αSKA  - Adult isoforms of sarcomeric gene  
βAR – Beta adrenergic receptor  
β-MHC – Beta Myosin Heavy Chain  
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The Mammalian Heart 
The mammalian heart is a four-chambered muscular organ situated in the anterior medi-
astinum, immediately posterior to the sternum and encapsulated by the pericardium 
(figure 1.1). Its pumping ability is central to the functioning of the circulatory system 
wherein blood is pumped through a network of blood vessels namely arteries, veins, 
arterioles, venules and capillaries. These blood vessels can be subdivided into a 
pulmonary circuit carrying blood to and from gas exchange surfaces of the lungs and a 
systemic circuit through which blood is transported to and from the rest of the body 
(Sherwood, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The mammalian heart. Components are described in the text(Image courtesy 
www.beyondbiology.org) 
 
 
As shown in figure 1.1, the right and left atria and the right and left ventricles make up 
the four chambers of the mammalian heart. Two chambers of the heart may be 
associated with each circuit; the right atrium receives blood from the systemic circuit 
through the superior vena cava and the inferior vena cava and allows inflow into the 
right ventricle passing through the right atrio-ventricular (AV) or tricuspid valve.  Blood 
is then pumped into the pulmonary circuit eventually being collected by the left atrium 
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and emptied into the LV through the left AV or bicuspid valve. Semi-lunar valves are 
situated between the ventricles and the major blood vessels of the heart and open and 
close passively due to pressure gradients. Blood pumped from the right atrium into the 
pulmonary trunk passes through the pulmonary valve and blood leaves the left ventricle 
through the aortic valve into the ascending aorta. The atria are separated by the inter-
atrial septum and the ventricles by a much thicker inter-ventricular septum that houses 
electrical conduction tissue. Innervation of the heart is by both vagal and sympathetic 
fibres. The SA node and the atria are predominantly innervated by the rightvagus 
whereas the left vagus nerve supplies the AV node and the bundle of His (Vander et al., 
2007). The ventricles of the myocardiumare only sparsely innervated by vagal efferents. 
Although rhythmic contraction of the heart is initiated in the SA node, cardiac function 
is mediated by neural activation.The release of noradrenaline (NA) by sympathetic 
nerves and the subsequent activation of beta adrenergic receptors result in positive 
chronotropy,inotropy and dromotropy as well as enhanced metabolism. In contrast, 
parasympathetic nerves (vagus) release acetylcholine (ACh) that acts on muscarinic 
receptors in the heart leading to negative dromotropic, inotropic and chronotropic 
effects. The cardiac action potential that initiates contraction is generated in the sino-
atrial (SA) node and spreads through the atria before converging upon the AV node for 
distribution to the ventricles by the specialised Bundle of His, right and left bundle 
branches and Purkinje fibre network. 
The walls of the atria are thinner than those of the ventricles, particularly the LV whose 
wall is 3-4 times thicker than the right ventricle at a corresponding position (Vander et 
al., 2007).  The wall of the heart is typically described to be made up of 3 layers; the 
outer epicardium (visceral pericardium) is a serous membrane consisting of an exposed 
mesothelium and a layer of smooth connective tissue that is attached to the 
myocardium. The inner surfaces of the heart (including the valves) are lined by the 
endocardium that consists of squamous epithelial cells continuous with the endothelium 
of blood vessels. The myocardium is the middle muscular wall of the heart that forms 
both atria and ventricles. This layer encompasses several types of cells including atrial 
and ventricular contractile ‘working’ myocytes that comprise muscle fibres, nodal cells, 
purkinje fibres, smooth muscle cells and fibroblasts (Levy et al., 2006). Cardiac 
myocytes account for 70% to 75% of the myocardium by cell volume but only 25% to 
30% by cell number (Miner and Miller, 2006). Cardiac fibroblasts that synthesize 
proteins of the ECM are the most abundant cell type of the myocardium. 
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The Extracellular Matrix (ECM) 
 
The muscle fibre array of the myocardium is surrounded and interspersed by the ECM, 
a fibrillar, highly differentiated structure consisting of an organised hierarchy of 
connective tissue that provides structural support and functional integrity to the heart. 
The ECM is broadly differentiated into an epimysium encircling the endo- and 
epicardium, a perimysium that groups myofibrils into bundles and an endomysium that 
surrounds individual myocytes and provides connection to the vasculature (Fedak et al., 
2005).  It comprises of a complex network of structural proteins (collagen and elastic 
fibres) and adhesive proteins (fibronectin, laminin) within a hydrated proteoglycan and 
glycosaminoglycan-rich milieu (Horn et al., 2008). Coiled fibres of the ECM act to 
store energy produced during systole, and hence re-lengthening of cardiac myocytes 
during diastole (Miner and Miller, 2006).Apart from the provision of a structural 
network that translates developed force in individual myocyteinto regular synchronous 
contraction and passive stiffness, the ECM also functions to prevent myocyte slippage, 
overstretch and interstitial oedema. Once considered an inert physical scaffolding, 
ongoing research has established diverse roles of the ECM in trans-membrane 
signalling, MAPK activation, growth factor mediation,cytoskeletal rearrangement, 
modulation of cell phenotype and among other, regulatory roles in hypertrophy and 
ontogenic development (Fedak et al., 2005; Horn et al., 2008; Bowers et al., 2010; 
Hutchinson et al 2010). ECM trans-membrane mechanoreceptors known as integrins 
constitute another important feature that transduces mechanical forces and changes in 
ECM structure, through signals from the extracellular compartment to the cytoskeleton 
and vice versa.  Integrins consist of two different chains, α (120±150 kDa) and β 
(110±190 kDa), linked by non covalent bounds. They modulate signals instigated by 
ionic channels, hormone receptors and growth factors, and participate in various 
transduction processes including those concerned with cell motility, division, 
differentiation and programmed death (Spinale, 2007; Horn et al., 2008; Bowers et al., 
2010).  
The ECM is a dynamic entity and component proteins are maintained by a finely 
controlled homeostatic balance between deposition and degradation. Different families 
of MMPs that favour or inhibit matrix degradation, regulate the ECM in both normal 
and pathological conditions. Collagenases or matrix metalloproteinases (MMP-1) cleave 
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collagens in fragments which in turn constitute the substrate of proteases including the 
gelatinases (MMP-2, MMP9) that are responsible for the degradation of type IV 
collagen and fibronectin (Bowers et al., 2010). These zinc-dependent enzymes are 
regulated by a class of proteins called tissue inhibitor metalloproteinases (TIMPs). The 
ability to synthesize ECM components differs among cells in the heart and varies 
depending upon the inciting stimulus. For example, myocytes produce type IV and VI 
collagensincluding laminin and proteoglycans. Collagen type I and III and fibronectin, 
as well as MMPs are synthesised by the surrounding fibroblasts (Banerjee et al. 2006; 
2007). Integrin activation also induces the synthesis of collagens and gelatinases, which 
regulate the synthesis and type of ECM proteins (Spinale, 2007). Modulation of these 
various components regulates mechanical, chemical and electrical signalling between 
cells (Miner and Miller, 2006). 
 
The Cardiomyocyte 
 
 A ventricular myocyte is an elongated cell containing contractile myofibrils that give it 
a striated appearance (figure 1.2A). Ventricular myocytes are typically uni-nucleated, 
have a variable branching morphology, extensive capillary supply and are connected to 
adjacent cardiomyocytes at blunt ends by specialised intercalated discs. The intercalated 
discs of neighbouring cells are physically connected by types of cell junction i.e. gap 
junctions and desmosomes that together orchestrate and integrate cardiac electro-
mechanical activity. As a result, the entire myocardium functions as a single unit known 
as a ‘syncyctium’ with a single contraction of the atria followed by a single contraction 
of the ventricles (Vander et al., 2007). 
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A. 
 
 
B.  
 
 
Figure 1.2: Diagrams showing typical (A) cardiacmyocytes and (B) internal structures of 
a myocyte (Taken from Vander et al, 2007) 
 
An exquisitely specialised cardiac microanatomy coordinates the processes of orderly 
spread of action potentials, contraction of cardiac chambers and the pumping action of 
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the heart. Similar in many respects to skeletal muscle cells, the fundamental contractile 
unit within the myocyte is the sarcomere containing inter-digitating thick and thin 
filaments of the contractile apparatus, namely the proteins actin, myosin, the troponin 
complex and tropomyosin (Tm).  Three proteins, Troponin T, I and C (TnT, TnI, TnC) 
make up the thin filament complex and together mediate the extent of crossbridge 
formation whilst contributing to the structural integrity of the sarcomere (figure 2.1B, 
Sherwood, 2008). Within the cardiomyocyte, each myofibril is surrounded by the 
sarcoplasmic reticulum (SR), a highly organised  Ca
2+
 handling organelle made up of 
membranous tubules that regulate cytocolic Ca
2+
 flux in conjuction with key 
sarcoplasmic proteins namely SERCA), the regulatory protein of SERCA, 
phospholamban (Plb),and the Ca
2+
 release channels (figure 1.2B). Another specialised 
component of the cardiomyocyte is the sarcolemma, a lipid bilayer combination of the 
plasma membrane and the basement membrane that contains membrane receptors, 
pumps and channels that regulate contractility. The sarcolemma forms the intercalated 
disks and penetrates deep into the cell to form the Transverse ‘T’ tubular system that 
bring in close proximity ion channels and the SR calcium handling proteins, thus 
playing a pivotal role in cell contractility (Vander et al., 2007) (figure 1.2). Although 
not given in the figure, integrins are interwoven throughout the sarcolemma and form an 
importantcollagen-integrin-cytoskeletal relation.  
A more complete appreciation of the functional anatomy (contraction and relaxation) of 
myocyte ultra-structure perhaps comes from studies on ventricular myocyte.  An over 
simplified process of contraction and relaxation of the heart is described below.  
At the resting membrane potential (corresponding to phase 4 of the action potential 
(figure1.3), the sarcolemma is only permeable to K
+
, a condition maintained by the 
combined activities of the inward K
+
 rectifier, Na
+
/K
+
 ATPase and the Na
+
/Ca
2+
 
exchanger operating in forward mode (figure 1.4). Depolarisation of the plasma 
membrane beyond an inherent threshold voltage results in the activation of voltage 
gated Na
+
 and Ca
2+
channels. Opening of fast Na
+
 channels results in the rapid upstroke 
characteristic of phase 0 of the action potential whereas the subsequent inward current 
that maintains the plateau of the action potential is primarily due to Ca influx via L-type 
Ca
2+
  channels, with Na
+
/Ca
2+
  exchanger playing a minor role. Rapid inactivation of the 
fast Na
+
 channels (2-10 ms) and a transient net outward current of K
+
  along the 
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electrochemical gradient contributes to an early, brief repolarisation (notch) during 
phase 1 of the action potential  (figure 1.3). The small influx of Ca
2+
 that enters the cell 
after initial depolarisation triggers Ca
2+
  release from the SR by activating SR Ca
2+
  
release channels culminating in a transient rise in cytosolic free calcium concentration 
to micro-molar concentrations (10 µmole/litre) from a resting (diastolic) nanomolar 
concentration (100 nano-moles/L). A central feature of ECC is the gating of the SR Ca
2+
 
release channels by ryanodine receptors (RyR) located within terminal cisternae of the 
SR.This ‘calcium-induced calcium release’, activates the contractile machinery and 
initiates contraction in the myocyte by a mechanism termed Excitation-Contraction 
Coupling (EC coupling) (Bers,1991a/b; Vander et al., 2007).  
 
 
 
 
 
Figure 1.3: A diagram of the cardiac action potential showing the different phases.Phase 
0, the upstroke, corresponds to rapid depolarization. The upstroke is followed by phase 
1, a brief early repolarization, phase 2 or plateau, phase 3 or rapid repolarization, and 
phase 4, which corresponds to the resting membrane potential. (Taken from Vander et 
al, 2007). 
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Under resting conditions, lower intracellular Ca
2+
 favours the shift of the Tn-Tm 
complex towards the outer grooves of the actin filament and thereby blocks actin-
myosin interaction. Rise in Ca
2+
 concentrations during the action potential and 
subsequent binding to TnC strengthens TnC-TnI interaction and detaches TnI from the 
actin molecule by a conformational shift of the Tn-Tm complex, enabling crossbridge 
formation (figure 1.4). The available literature suggests that thin filament activation is 
achieved by the movement of Tm over the surface of actin and this motion permits force 
generation and shortening. After crossbridge formation, i.e. the attachment of the 
myosin head of the thick filament to the actin molecules of the thin filament, the myosin 
head changes confirmation ‘pivoting’ towards the M-line, with concomitant ATP 
hydrolysis to ADP that generates force causing the thin filament to slide over the thick 
filament and the sarcomere to shorten, altogether resulting in contraction. Binding of 
adenosine triphosphate (ATP) to the myosin head causes detachment of cross-bridges 
and (re)exposure of active sites making possible interaction with another cross-bridge 
(figure 1.4). 
 
 
 
Figure 1.4: Diagram showing the processes involved in cardiac muscle contraction 
(sliding filament) (Taken Bers, 1991b). 
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 This highly dynamic phenomenon termed the ‘sliding filament theory’ moves the 
filaments approximately 10nm with an average velocity of 0.98 µm/s(Levy et a,, 2006). 
Factors such as SR Ca
2+
 release, sensitivity of the myo-filaments to Ca
2+
, number of 
crossbridges formed, duration of the action potential and ATP stores appear to 
decisively affect cardiomyocyte contraction. Following contraction, relaxation and is 
achieved by the removal of Ca
2+
 (that activates myofilaments) from the cytosol by 
cellular Ca
2+
transport systems. This phase corresponds to repolarisation or phase 3 of 
the action potential, wherein decay of the calcium transient occurs due to the reuptake 
of Ca
2+ 
into the SR by SERCA and the extrusion of Ca
2+ 
from the myocyte, primarily by 
the Na
+
/Ca
2+
 exchanger (figure 1.5). This phase is characterised by the closure of 
sarcolemmal Ca
2+ 
channels and increased K
+
 conductance through the (slow and rapid) 
delayed rectifier K+ currents corresponding to a negative change in membrane 
potential. When membrane potential is restored to -80 to -85 mV , conductance is 
limited to the inward rectifier K+ channels that together set the resting membrane 
potential (phase 4) (Bers,1991a/b; Walker and Spinale 1999;Vander et al 2007). 
Within the cardiomyocyte, membrane depolarization by an action potential activates 
voltage-dependent L-type Ca
2+
 channels that initiate Ca
2+
 influx (Barry and Bridge, 
1993). This further triggers a transient rise of [Ca
2+
]i (typically from a basal level of 100 
nm to a peak of 1-2 um 20-40 ms following depolarisation (Beuckelmann and Weir, 
1988) via Ca
2+
 releasechannels of the sarcoplasmic reticulum (SR)through a Ca
2+
-
induced Ca
2+
 release mechanism (figure 1.4). Cardiacforce development and/or 
contraction results from diffusion of Ca
2 
through the cytosolic space to reach contractile 
proteins, bindingto troponin C, the cessation of the inhibition producedby troponin I and 
initiation of the sliding action of thin and thick filaments. The decay of the Ca
2+
 
transient is brought about mainly by activation of the SR Ca
2+
 pump (SERCA2a), the 
sarcolemmal Na
+
-Ca
2+
 exchanger, and the sarcolemmal Ca
2+
ATPase resulting in  [Ca
2+
]i 
to return todiastolic levels (Bers, 1991; 2002; Boudina and Abel, 2007). 
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Figure 1.5: A schematic diagram showing Ca
2+
 cycling in the heart. Schematic 
illustration of the main pathways involved in Ca
2+
 cycling and the site of protein 
phosphorylation (solid circle) during -adrenergic receptor (AR) stimulation. Ca2+ 
enters the cell through L-type Ca
2+
 channels (and possibly reverse Na
+
: Ca
2+
 
exchange) to trigger calcium –induced calcium release (CICR) from the SR. Ca2+  
released from the SR then binds to troponin C to produce cell shorting. Relaxation 
occurs because cytosolic Ca
2+
 is lowered by uptake into the SR and also by extrusion 
across the sarcolemma (Diagram drawn for power point presentation) 
 
Regulation of Ca
2+
 in normal cardiac muscle. 
 Normal EC coupling depolarization of the sarcolemmal membrane results in    
contraction of the cell. A key event in the excitation-contraction coupling process is the 
opening of the dihydropyridine-(DHP) sensitive L-type Ca
2+
 channels, which permit an 
influx of a small amount of Ca
2+
 into the cell. This Ca
2+
 entry, measured as the slow 
inward Ca
2+
 current, is an essential trigger for the release of Ca
2+
 from the sarcoplasmic 
reticulum (SR) (Bracken, et al., 2003). Ca
2+
 released from the SR then binds to troponin 
C on the myoflaments to produce contraction of the cell. Relaxation is achieved after 
free [Ca 
2+
]i is lowered by a combination of reuptake into the SR and extrusion across 
the sarcolemmal membrane  by the Na
+
:Ca
2+
 exchanger and the Na
+ 
K
+
-ATPase pump 
(see figure 1.5). 
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Heart and response to stress - Cardiac Structural Remodelling  
Structural and functional integrity of the heart is orchestrated by a fine balance between 
several neuro-hormonal and haemodynamic influences. Disruptions in this ‘fine tuning’ 
(e.g. in duress or injury) activate a complex, progressive process of diverse adaptive 
responses at transcriptional, molecular, cellular and functional levels that allow the heart 
to adjust to new working conditions and can be collectively termed ‘remodelling’ 
(Pantos et al 2007).  For the intents and purposes of this work, cardiac remodelling may 
be broadly defined as alterations in cardiac structure resulting from altered 
hemodynamic load and/or cardiac injury. While remodelling may be physiological or 
pathological and by extension adaptive or maladaptive, in the present context the above 
definition excludes all aspects gestational or developmental as well as favourable 
remodelling that follows intensive exercise and is restricted to acquired structural 
rearrangement in the left myocardium (Pantos, 2007).  
Cardiac remodelling is a common denominator in the aetiology of several primary 
cardiovascular diseases notably DM, coronary atherosclerosis, hypertension, 
cardiomyopathy, myocarditis (Swynghedauw, 1999). As shown in figure 1.6, HF may 
be viewed as a progressive disorder that is initiated in response to an index event (that 
may be acute i.e. MI, chronic i.e. DM or hereditary) that results in a loss/damage of 
functioning myocytes or alternatively produces a decline in the ability of the heart to 
function as a pump. Irrespective of the inciting event, several neurohormonal and 
inflammatory pathways are activated, including the renin–angiotensin–aldosterone 
system (RAAS), adrenergic system, inflammatory cytokine systems, and a host of other 
autocrine and paracrine mechanisms as compensatory mechanisms to maintain stroke 
volume at a reduced ejection fraction (Packer, 1992; Fedak et al., 2005). 
 
Thus far, a multitude of proteins, hormones, neurotransmitters and other  mediators 
including norepinephrine, angiotensin II, endothelin, aldosterone, TGFβ1, tumor 
necrosis factor (TNF) have been implicated in to disease progression of the failing heart 
(Maytin and Colucci, 2002; Fedak et al., 2005; Swynghedauw et al., 2010). These 
processes are initially compensatory and beneficial, and in most instances, patients 
remain asymptomatic or minimally symptomatic following the initial decline in 
pumping capacity of the heart, or will develop symptoms only after the dysfunction has 
been present for some time (Maytin and Colucci, 2002).  As such, the index event 
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produces remodelling of the LV frequently along one of two patterns: hypertrophy or 
dilation. 
 
 Myocardial hypertrophy associated remodelling results in increased LV mass without 
any effects on LV volume in a process termed ‘concentric remodelling’ that is 
associated with preserved function as the ventricle is capable of generating greater force 
and higher pressure. The onset of LV dilation is characterised by ‘eccentric 
remodelling’ and substantial increases in intra-ventricular volume with comparable 
increases in LV mass that represents a compensatory response to augment cardiac 
output in the face of  diminished contractile function. Eventually, functional demands 
override physiological compensatory mechanisms. It follows that the hypertrophic 
reserve of the myocardium is met; LV dilation progresses without appreciable increases 
in LV mass and in accordance with the Law of Laplace induces excessive wall stresses 
known to be typically antecedent to overt HF (Swynghedauw, 1999) (figure 1.5).   Self-
sustaining neuro-hormonal and cytokine input becomes deleterious in the long term and 
the overexpression of the portfolio of bioactive molecules are known to contribute to 
disease progression independently of haemodynamic status by exerting direct 
cardiotoxic effects. Targeting neuro-hormonal input is therefore the basis of current HF 
treatment. 
.  
Altogether, the triggers that stimulate the development of HF and varied and diverse 
and sustained LV remodelling are associated with a poor prognosis, gradual myocardial 
deterioration and a critical step towards transition to decompensation. However, it is 
important to appreciate that cardiac remodelling is a biological adaptive processes 
triggered by environmental stress, and the onset of HF represents the limits of said 
adaptation. 
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Figure 1.6: Heart failure pathogenesis. Currently accepted scheme of HF development 
and progression states that HF beginsin response to an index event that produces an 
initial decline in pumpingcapacity of the heart following which a variety of 
compensatory mechanismsare activated to restore homeostatic CV function, including 
the adrenergic nervous system, therenin angiotensin system and the cytokine system.  
Although beneficial in the short term, sustained activation of these systems can lead to 
worsening LV remodelling and cardiac decompensation that underscores the transition 
to symptomatic HF. (Image taken from Mann et al., 2009) 
 
 
 
Molecular signature of cardiac structural remodelling 
 
Cardiac remodelling occurs in response to cues generated by mechano-sensors 
(Connexins, integrins) that couple cellular signalling pathways to altered or mechanical 
stress/ injury. Where the nature and extent of signals that are transitorily activated are 
far from fully understood, it is accepted that the myocardial response to injury or altered 
mechanical load involves profound alterations in gene expression including the 
activation of those that are normally involved in embryogenesis, also known as the 
foetal gene program (Swynghedauw, 1999). In the context of MI-induced cardiac 
remodelling alone, genome-wide analyses have revealed significant co-ordinated 
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changes in over 1400 genes early and 125 genes late in the infarct zone, and nearly 600 
genes early and 100 genes late in the non-infarct zone (La-Framboise et al., 2005). 
Fetal gene reprogramming, characteristic of pathological remodelling frequently 
involves an up-regulation of fetal isoforms of genes whose products regulate cardiac 
contractilityand Ca
2+ 
handling and paralleled by a down-regulation of their adult 
isoforms (i.e., up-regulation of ß-MHCvs. down-regulation of -MHC) and often 
includes decreased SERCA2a and increased NCX (sodium calcium exchanger) 
expression (Hilfiker-Kleiner et al., 2006). Another important feature of the foetal gene 
phenotype markedly expressed in the remodelled myocardium is that of the natriuretic 
peptides, ANP and BNP, often detectable in the circulation where they are used as an 
indirect marker for myocardial injury/overload (Kapoun et al, 2004).These 
transcriptional changes culminate in several molecular and cellular alterations that 
characterise myocardial remodelling. For the purposes of this work, they are broadly 
categorised into those that occur in the myocyte and changes that occur in the volume 
and composition of the ECM.  
Within the myocyte, in addition to the functional changes described in the previous 
section, the remodelling process is invariably associated with sarcomeric reorganisation; 
Dilation of the heart is associated with myocyte re-lengthening, mediated by the 
generation of new sarcomeres in series and an enhancement of the length-to width ratio 
whereas a hypertrophic phenotype is the result parallel addition of new sarcomeres. At 
the molecular levels, hypertrophy appears tobe characterized by increased expression of 
adult isoforms ofsarcomeric genes (i.e., αMHC, cardiac αSKA) and is often 
concomitant with increased natriuretic peptide synthesis (Hilfiker-Kleiner et al., 2006). 
Furthermore, biomechanical stretch signalling, altered redox states and pathological 
stimuli including HG and TGFβ1 may induce the activation of the phosphatidylinositol 
3-kinase (PI3-K)/proteinkinase B (Akt)-p70S6K,and/or activation of extracellular 
signal-regulated kinases(ERK) which co-ordinate the hypertrophic response (Selvetella 
et al., 2004, Wu and Derynck, 2009) 
Much experimental evidence suggests that the gradual loss of myocytes through 
necrotic and apoptotic cell death contributes to progressive and LV remodelling and 
cardiac dysfunction in the failing heart (Sabbah 2000; Wenker et al., 2003; Foo et al., 
2005). Particularly in relation to apoptosis, this point of view has received increasing 
support with the recognition that DNA damage characteristic of apoptotic cell death 
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occurs in myocytes from failing hearts (Sabbah, 2000). Apoptotic events are 
characterised by the activation of caspase-8 and subsequently procaspase-3, an event 
initiated by the activation ofcell surface death receptors (e.g., Fas/FasL). On activation, 
caspase-3 activates downstream pro-apoptotic effector proteinssuch as Bax and Bad and 
subsequently the release of cytochromec (cyt c) and other apoptogens from 
mitochondria (Hilfiker-Kleiner et al., 2006). Additionally, caspases may also cleave 
myocardialcontractile proteins and promote systolic dysfunction.Therefore, treatment 
with caspaseinhibitors after myocardial infarction has been shown to 
preservemyocardial contractile proteins, reduce systolic dysfunctionand attenuate 
adverse ventricular remodelling and reduce infarct size after MI (Chandrashekar et al., 
2004).   
Despite the undeniable intrinsic appeal of programmed cell death as a potentially 
important mechanism for disease progression in the failing heart, a definitive role for 
cell death has not been established on account of several considerations; (1). As 
catecholamines can provoke apoptosis, there is the possible over-stimation of myocyte 
apoptosis frequency assessed in explanted hearts obtained from patients awaiting 
cardiac transplantation, many of whom receive inotropic support (Narula et al., 1996; 
Olivetti et al., 1997). (2). Data concerning myocyte cell death in mild to moderate HF is 
not forthcoming, casting doubt over whether apoptosis contributes to failure or whether 
it is a phenomenon that is observed only in end-stage HF.  (3) Lastly there is 
considerable disparity in the published literature over estimates of apoptotic processes, 
ranging from 0.003%/year to to clinically unrealistic estimates of '5% to 35% (estimated 
myocyte loss> 100%/year) (Mann, 1999). Thus, it is difficult to definitively ascertain 
whether myocyte cell loss is an important contributor to HF pathogenesis, occurs early 
and continually in HF or, instead, only in end-stage hearts. 
Outside changes in the myocyte, structural remodelling in the myocardium is associated 
with alterations in the structure and function of the ECM. Indeed, ECM deposition is a 
widely recognized alteration in the failing heart and the notion that progressive fibrosis 
underlies LV dilatation and HF progression has been engendered by several 
experimental and clinical studies (Cohn, 1995; Mann, 1999; Maytin and Colucci, 2002; 
Fedak et al., 2005, Miner and Miller, 2006; Bowers et al., 2010). In pathological 
conditions, the ECM can be temporarily remodelled, reversibly remodelled or fully 
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adapt to the changes in biomechanical load. However, prolonged overload results in 
detrimental collagen deposition that can render the heart electrically and structurally 
heterogenous, result in excessive diastolic stiffness  (Van Heerebeek, 2008) and/or 
induce LV dilatation altogether resulting in overt HF. Particular emphasis is given to the 
collagenolytic MMPs and their inhibitors, the TIMPs in underlying LV dilatation. The 
balance of proteolytic and anti-proteolytic activity appears to be an important 
determinant of the rate of ventricular enlargement. The general view is that disruption of 
this balance results in progressive MMP activation leading to degradation of the ECM, 
myocyte slippage, thinning of the ventricular wall, and ventricular dilation that occurs 
in end stage HF (Swynghedauw, 1999; Maytin and Colucci, 2006; Yan et al., 2009).  
In support of this premise, pharmacologic MMP inhibition in a pacing-induced animal 
model of heart failure improved LV dimensions and performance when administered 
early in the remodelling process (Spinale et al., 1999). Chronic pharmacologic 
inhibition of MMP activity in rats with HF of hypertensive origin resulted in an 
attenuation of ventricular dilation and dysfunction that was sustained throughout the 4 
months of therapy (Peterson et al., 1999). Similarly, targeted deletion of MMPs has 
been shown to limit maladaptive remodelling in experimental models (Yan et al., 2000) 
altogether indicating the potential therapeutic relevance of MMP inhibition which may 
be exploited in the near future. Studies employing transgenic mice clearly show therole 
of MMPs and TIMPs in mediating the preservation of normal cardiac geometryand 
function, and are consistentwith less deleterious cardiac remodelling in animal models 
treatedwith pharmacological MMP inhibitors (Graham and Trafford, 2007). 
 
KINASE SIGNALLING AND CARDIAC REMODELING 
Structure and function of MAPKs  
There are four classic MAPK subfamilies (see figure 1.7). Each of these family 
members has been studied extensively in a multitude of cellular settings and has been 
reviewed in great detail by others (Barr and Bogoyevitch, 2001; diwan and Dorn, 2007; 
Kyriakis and Avruch, 2001; Pearson et al, 2001; Pentassuglia and Sawyer, 2009; 
Ramos, 2008; Roux and Blenis, 2004).  
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A. ERK1/2 
First discovered in the early 1980s for its ability to phosphorylate microtubule-
associated protein-2 (MAP-2) in 3T3-L1 adipocytes in response to insulin stimulation 
(Avruch, 2007), extracellular signal-regulated kinases (ERKs) are now one of the most 
widely studied signalling pathways in cellular biology. ERK1 and ERK2 are 83% 
identical, share most of the same signalling activities, and, as a result, are usually 
referred to simply as ERK1/2. However, these two proteins are not completely 
functionally redundant as demonstrated by gene knockout experiments. ERK1 null mice 
have, in general, a normal phenotype (Gerits et al, 2007; Pages et al, 1999), but ERK2 
null mice are embryonic lethal between E6.5 and E8.5 (Gerits et al, 2007; Hatano et al, 
2003; Saga-El-Leill et al, 2003; Yao et al, 2003). ERK1/2 is ubiquitously expressed and 
has many diverse cellular and physiological functions. At the cellular level, ERK1/2 
regulates cell cycle progression, proliferation, cytokinesis, transcription, differentiation, 
senescence, cell death, migration, GAP junction formation, actin and microtubule 
networks, and cell adhesion (Ramos, 2008). ERK1/2's role in cellular biology translates 
it into a prominent player in physiological settings, influencing the immune system and 
heart development and contributing to the response of many hormones, growth factors, 
and insulin. Furthermore, because of its role in so many biological processes, ERK1/2 
has likewise been shown to play a significant part in various pathologies including 
cancer, diabetes, and cardiovascular disease. This extensive and diverse functional 
ability is the result of ERK1/2's ability to phosphorylate over 100 possible substrates 
(Yoon and Seger, 2006).  
ERK1/2 is activated via a canonical three-tiered kinase cascade by both extracellular 
and intracellular stimuli). Growth factors, serum, and phorbol esters strongly activate 
the pathway, but it can also be activated by G protein-coupled receptors, cytokines, 
microtubule disorganization, and other stimuli.  Prototypically, growth factor (such as 
fibroblast growth factor, FGF) binding to their respective receptor tyrosine kinase 
(RTK) activates Ras which recruits and activates Raf (MAP3K) at the plasma 
membrane. Once activated, Raf phosphorylates and activates MEK1/2 (MAP2K). 
MEK1/2 in turn activates ERK1/2 by phosphorylation of the Thr and Tyr residues in the 
conserved Thr-Glu-Tyr motif within its regulatory loop. Activated ERK1/2 can 
40 
 
phosphorylate downstream proteins in the cytoplasm or nucleus, including many 
transcription factors.  
MAPK signalling is subject to many mechanisms of modulation that determine the 
specificity and magnitude of the signalling outcome. Interactions with scaffold proteins 
are one of these mechanisms. ERK has a number of known scaffold proteins including 
kinase suppressor of Ras (KSR), MEK partner 1 (MP1), MAPK organizer 1 (MORG1), 
and β-arrestin (Dhanasekaran et al, 2007). Structural studies also reveal specific docking 
site motifs that help direct the specificity of ERK1/2 signalling, including the ERK 
docking (ED) motif, the docking site for ERK and FXFG (DEF) motif, and the common 
docking (CD) motif (Raman et al, 2007). Protein phosphatases are a third mechanism 
that contributes to MAPK regulation. ERK signalling has been shown to be regulated by 
various phosphatases including dual-specificity MAPK phosphatases (MKP1,-2, -3, and 
-4), protein serine/threonine phosphatases (PP2A, PPM1α), and protein tyrosine 
phosphatases (SHP-2 PTP, hematopoietic PTP, STEP, PTP-ε) (Juntilla et al, 2008). The 
final way that MAPK activity is regulated is by positive and negative feedback 
regulation from other components of the MAPK signalling network. This includes 
negative regulation of ERK by other MAPKs such as JNK and p38 (Juntilla et al, 2008).  
 
B. JNK 
In the early 1990s, 10 years after the discovery of ERK, JNK was discovered as a 
second subfamily of MAPKs for its ability to phosphorylate microtubule-associated 
protein 2 in rat liver following cycloheximide injection. It was further detailed for its 
ability to phosphorylate the transcription factor c-jun at two sites following UV 
radiation (Hibi et al, 1993; Kyriakis and Avruch, 1990; Kyriakis et al, 1991). JNK1, 
JNK2, and JNK3 are encoded by three separate genes, and alternative splicing can 
produce 10 different protein sequences that share >80% homology (Barr and 
Bogoyevitch, 2001). JNK1 and JNK2 are ubiquitously expressed, while JNK3 is 
predominantly found in the brain, heart, and testis (Davis, 2000). While there is some 
redundancy in the functions of the three isoforms, gene knockout studies have shown 
specific roles for different JNK isoforms in vivo (Bogoyevitch, 2006; Gerits et al, 
2007). Like ERK, JNK plays a role in a number of different biological processes 
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including cell proliferation, differentiation, apoptosis, cell survival, actin reorganization, 
cell mobility, metabolism, and cytokine production (Bogoyevitsch and Kobe, 2006; 
Davis, 2000; Raman et al, 2007). This translates into JNK's physiological role in insulin 
signalling, the immune response and inflammation, and its pathological role in 
neurological disorders, arthritis, obesity, diabetes, atherosclerosis, cardiac disease, liver 
disease, and cancer (Bogoyevitsch, 2006).  
Activation of the JNK pathway occurs in response to a number of different stimuli. As a 
stress-activated protein kinase, JNK responds most robustly to inflammatory cytokines 
and cellular stresses such as heat shock, hyperosmolarity, ischemia-reperfusion, UV 
radiation, oxidant stress, DNA damage, and ER stress (Bogoyevitsch, 2006; Raman 
etal, 2007). However, they are also activated to a lesser extent by growth factors, G 
protein-coupled receptors, and noncanonical Wnt pathway signalling (Pandur et al, 
2002). Once stimulated, JNK is activated by the previously described three-tiered kinase 
cascade. After the cell is stimulated, signaling occurs which eventually leads to the 
activation of the first tier. The MAP3Ks that can activate JNKs are MEKK1, MEKK2, 
and MEKK3, as well as mixed lineage kinase 2 and 3 (MLK2 and MLK3) and others 
(Raman et al, 2007). These kinases then activate the MAP2Ks involved in the JNK 
cascade, MKK4 and MKK7. MKK4/7 then activates JNK by phosphorylation on a 
conserved Thr-Pro-Tyr motif. It has been shown that MKK4 has a preference for Tyr 
phosphorylation while MKK7 has a preference for Thr in the TPY motif, allowing these 
two kinases to work synergistically in JNK activation (Lawler et al, 1998). Activated 
JNK has a large number of downstream substrates, including nuclear and cytoplasmic 
proteins. Similar to the other MAPKs, JNK has the ability to shuttle between the 
cytoplasm and the nucleus to exert its effects depending on the specific cellular stimuli. 
The diversity of JNK signalling can be conferred by signalling via more than 25 nuclear 
substrates and more than 25 nonnuclear substrates for any specific stimulus 
(Bogoyevitsch and Kobe, 2006).  
JNKs, like all MAPKs, utilize the same mechanisms to impart specificity and degree of 
magnitude to its signalling. Interaction with scaffold proteins such as JNK-interacting 
proteins (JIP1, JIP2), JNK/stress-activated protein kinase-associated protein 1 
(JSAP1/JIP3), JNK-associated leucine-zipper protein (JLP), and plenty of SH3 (POSH) 
help direct the specificity of this pathway (Dhanasekaran et al, 2007). The specificity of 
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JNK's interaction with these scaffold proteins and its up and downstream partners is also 
mediated, in part, through specific docking sites, including D motifs, MAPK-docking 
sites, and others (Raman et al, 2007). Like all protein kinases, JNK activity is also 
counterregulated by phosphatases including dual specific phosphatases MKP1, -2, -5, 
and -7.  
 
C. p38 
p38 was originally isolated as a tyrosine phosphorylated protein found in LPS-
stimulated macrophages (Han et al, 1994; Han etal, 1993). At the same time, it was also 
reported as a molecule that binds pyridinyl imidazoles which inhibit the production of 
proinflammatory cytokines (Lee et al, 1994). Since then, four different p38 isoforms 
have been identified, including the prototypic p38α (often referred to as simply p38), 
p38β (Jiang et al, 1996), p38γ (Li et al, 1996), and p38δ (Lechner et al, 1996). p38 and 
p38β are ubiquitously expressed, while p38γ is expressed primarily in skeletal muscle 
and p38δ is found in lung, kidney, testis, pancreas, and small intestine (Ono and Han, 
2000). The four isoforms share structural similarities (>60% homology within the group 
and even higher in their kinase domains) and substrate similarities as well. However, it 
is unclear in vivo if activity towards a given substrate can vary between isoforms and if 
each isoform also has its own set of specific substrates. This is demonstrated by gene 
knockout experiments in which deletion of the p38α gene leads to embryonic lethality 
due to placental and erythroid differentiation defects (Mudgett et al, 2000; Tamura et al, 
2000), but mice carrying deletion of any of the other three isoforms are phenotypically 
normal (Gerits et al, 2007). Like other MAPK subfamilies, p38 kinases also play 
numerous biological roles. Most prominently, p38 signalling is involved in the immune 
response, promoting expression of proinflammatory cytokines [interleukin (IL)-1β, 
tumor necrosis factor (TNF)-α, and IL-6], cell adhesion molecules (VCAM-1), and 
other inflammatory related molecules and regulating the proliferation, differentiation, 
and function of immune cells (Kyriakis and Avruch, 2001; Rincón and Davis, 2009). 
p38 also plays a role in many other biological functions, namely, apoptosis, cell 
survival, cell cycle regulation, differentiation, senescence, and cell growth and 
migration (Thornton and Rincón, 2008; Zarubin and Han, 2005). Physiologically, this 
translates into a role for p38 in chronic inflammatory diseases (rheumatoid arthritis, 
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Crohn's disease, psoriasis, and chronic asthma), tumorgenesis, cardiovascular disease, 
and Alzheimer's disease (Cuenda and Rousseau, 2007).  
As a stress-activated kinase, p38 responds to most of the same stimuli as JNK as well as 
others that are specific to p38. p38 can be activated by such stimuli as UV radiation, 
heat, osmotic shock, pathogens, inflammatory cytokines, growth factors, and others. 
Making this pathway complicated, p38 can respond to over 60 different extracellular 
stimuli in a cell-specific manner, making it challenging to elucidate its exact functional 
role in vivo (Ono and Han, 2000). Regardless of the exact stimuli, the canonical 
pathway of p38 activation is the same as for ERK and JNK. A number of upstream 
kinases are implicated in the phosphorylation cascades leading to the activation of p38, 
including MEKK1–4, TAK1, and ASK1 at the MAP3K level and MKK3, -6, and, 
possibly, -4 at the MAP2K level. These MAP2Ks activate p38 by phosphorylation of its 
conserved Thr-Gly-Tyr motif. Of interesting note, p38 can be activated in noncanonical 
ways as well. One way is TAB-1-mediated autophosphorylation (Geet al, 2002; Tanno 
et al, 2003), and another is T-cell receptor-induced activation of p38 through ZAP70 ( 
Salvador et al, 2005). Once activated, p38 can function in the cytoplasm or translocate 
to the nucleus. Substrates for p38 include transcription factors, other nuclear proteins, 
and cytoplasmic proteins (Ono and Han, 2000).  
The magnitude of the signal and the specificity of the p38 pathway are determined by 
similar mechanisms as both ERK and JNK. While scaffold proteins have been shown to 
be important in p38 signalling, there have only been three such proteins identified so 
far: osmosensing scaffold for MEKK1 (OSM), JIP2, and JLP (Dhanasekaran et al, 
2007). p38 also utilizes specific domains, such as CD motifs, ED motifs, and D motifs 
to facilitate its interaction with other proteins (Raman et al, 2008). Finally, protein 
phosphatases are yet another form of p38 regulation, including dual specific MKPs 
(MKP1, -2, -5, -7) and protein Ser/Thr phosphatases (PP2C) (Juntilla et al, 2008).  
 
D. ERK5 
ERK5 is the final classic MAPK subfamily and the least studied among the four. 
Discovered in the mid 1990s by two groups simultaneously, many questions remain to 
be answered, although progress is rapidly being made on many fronts. The first group 
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identified ERK5 using a yeast two-hybrid screen with the upstream activator MEK5 as 
the bait (Bao  et al, 1995), while the second group used a degenerate PCR strategy to 
clone novel MAPKs ( Lee et al, 1995). The most distinguishing feature of this MAPK is 
its size, 816 amino acids, making it more than twice the size of the other MAPK family 
members (thus the alternative name big MAPK or BMK). This increased size is due to a 
large 396-amino acid COOH-terminal extension. While only one ERK5 gene has been 
identified, it undergoes alternative splicing to produce four different protein species: 
ERK5a, ERK5b, ERK5c, and ERK-T. ERK5a is the most prominently expressed, and 
the other three appear to function as negative regulators of ERK5a (McCaw et al, 2005; 
Yan et al, 2001). This kinase is ubiquitously expressed, and gene knockout studies show 
global deletion of ERK5 is embryonic lethal due to what was initially thought to be 
cardiac defects (Regan et al, 2002). However, cardiomyocyte specific inactivation of 
ERK5 results in normal development, indicating that the lethality from the global 
knockout is due to defects in vascular formation (Hayashi et al, 2004; Hayashi and Lee, 
2004). Diverse biological roles of ERK5 are also identified, including cell survival, 
differentiation, proliferation, and growth. ERK5 is reported to play a physiological role 
in neuronal survival, endothelial cell response to sheer stress, prostate and breast cancer, 
cardiac hypertrophy, and atherosclerosis (Hayashi and Lee, 2004; Nishimoto and 
Nishida, 2006; Wang and Tournier, 2006).  
ERK5 is activated in response to both growth and stress stimuli. This includes a wide 
variety of growth factors [epidermal growth factor, nerve growth factor, vascular 
endothelial growth factor (VEGF), FGF-2], serum, phorbol ester, hyperosmosis, 
oxidative stress, laminar flow sheer stress, and UV radiation (Hayashi and Lee, 2004). 
Once activated, ERK5 exerts its kinase activity on a number of other protein kinases 
and transcription factors in both the cytosol and the nucleus. Furthermore, unlike other 
MAPKs, ERK5 has been shown to function directly as a transcriptional activator 
(Akaike et al, 2004; Kasler et al, 2000).  
ERK5 signalling, in true MAPK fashion, is influenced by such things as scaffold 
proteins, docking sites, phosphatases, and other members of the MAPK family. 
However, because ERK5 is less well studied than the other MAPKs previously 
discussed, less is known about these forms of regulation. Adaptor and scaffold proteins 
such as Lck-associated adaptor (Lad) and Grb-2-associated binder 1 (Gab 1) as well as 
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muscle specific A-kinase anchoring protein (mAKAP) have all been shown to play an 
integral role in ERK5 signalling (Wang and Tournier, 2006). Furthermore, MEK5 (the 
MAP2K of ERK5) uses its Phox/Bem 1P (PB1) domain to bind and tether together the 
upstream MAP3K (MEKK2/3) and the downstream ERK5 to facilitate signalling 
(Nakamura et al, 2006; Nakamura and Johnson, 2003). While regulation of ERK5 
activity has been shown to be regulated by specific protein phosphatases, such as MKP1 
and -3 (Kamakura et al, 1999) and the phosphotyrosine specific phosphatases PTP-SL 
(Buschbeck et al, 2002), much less is known about this type of regulation than is with 
the other MAPKs.  
 
MITOGEN-ACTIVATED PROTEIN KINASES IN HEART FUNCTION AND 
DISEASE 
The following sections focus on the role of MAPKs in various pathological aspects of 
cardiac diseases, with particular emphasis on hypertrophy, cardiac remodelling, and 
myocardial cell death.  
Cardiac hypertrophy is a common response to external stressors, including mechanical 
overload, neurohormonal stimulation, and oxidative stress. Hypertrophy can be a 
compensatory response to augment contractility and maintain cardiac output without 
adverse pathology. However, when stressors persist, this compensatory process can 
evolve into a decompensated state with profound changes in gene expression profile, 
contractile dysfunction, and extracellular remodelling (Diwan and Dorn, 2007; 
Selvetella et al, 2004). Although physiological versus pathological hypertrophy can be 
clearly differentiated by a number of qualitative and quantitative parameters, the 
underlying mechanisms and their interrelationship remain controversial. Most 
importantly, the signalling mechanisms mediating the critical transition from 
compensated hypertrophy to decompensated heart failure remain poorly understood 
(Dorn and Force, 2005; Frey and Olson, 2003; Selvetella et al, 2004). Furthermore, 
while some cardiomyopathies are genetic and others idiopathic, many are the result of 
some sort of insult or injury to the myocardium. Myocardial ischemia and/or infarction 
due to partial or complete occlusion of a coronary artery and the subsequent reperfusion 
of the tissue (ischemia-reperfusion or IR) are among the most significant causes of 
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injury to the heart. Most of the efforts in the past have focused on the underlying 
mechanisms of IR-induced myocardial injury or on cardiac protection offered by 
preconditioning or postconditioning (Balakumar et al, 2008). The signalling 
mechanisms involved in these events (injury versus cardiac protection) are distinctly 
different. However, recent work has shown that protective events are diminished in 
various pathological conditions commonly associated with cardiovascular disease 
(hyperglycemia, hypertension, cardiac hypertrophy, aging, obesity), pointing to the 
importance of understanding the signalling pathways involved (Balakumar et al, 2009). 
Finally, pathological manifestations in end-stage failing hearts share many common 
features regardless of the underlying etiologies, such as ventricular wall thinning, 
chamber dilation, cardiomyocyte dropout, and dramatically increased interstitial fibrosis 
(Dorne and Force, 2005), suggesting that intracellular signalling pathways elicited by 
different stressors may converge to some common targets. As highly conserved 
signalling pathways, MAPKs may be common mediators in these pathological 
remodelling processes. Normal cardiac function and pathological remodelling involve 
fibroblasts, the coronary vascular system, and inflammatory cells. Although much of the 
recent progresses are made through advanced wizardry of genetic manipulation in 
model organisms such as mice, it is important to appreciate some of the limitations of 
this powerful approach. Genetic manipulation through complete knockout and 
nonphysiological overexpression can produce a phenotype that may not truly reflect the 
functional role of the targeted molecule or pathway in a particular pathological 
condition. Compensatory, secondary, or off-target effects can arise from such non-
physiological manipulation to obscure correct interpretations. In addition, some of the 
genetic manipulation itself can lead to unwanted side effects, including cytotoxicity of 
GFP, Cre, and tamoxifen induction (Buerger et al, 2006; Huang et al, 2000; Koitabashi 
et al, 2009). Therefore, results from genetic studies should be interpreted with plenty of 
caution by taking into account some of these caveats.  
 
A. ERK1/2 
 
1. Cardiac hypertrophy 
Many studies have implied a role for the Ras/Raf/MEK1/ERK signalling pathway in 
promoting cardiac hypertrophy. Hunter et al. (1995) initially showed that transgenic 
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expression of a constitutively active Ras (H-Ras-V12) in mouse heart led to left 
ventricular hypertrophy associated with cardiomyocyte hypertrophy but not increased 
cardiac fibrosis. Subsequently, Zheng et al. (2004) observed characteristic features of 
familial hypertrophic cardiomyopathy (HCM) in another H-Ras-V12 transgenic model, 
including fetal-gene induction, myofilament disarray, and interstitial fibrosis which led 
to diastolic dysfunction (Zheng et al, 2004). While both of these studies used the same 
constitutively activated H-Ras-V12 mutant, different promoters were used to drive its 
expression (MLC-2v versus α-MHC, respectively), possibly reflecting dose-dependent 
effects of Ras signalling driving hypertrophy versus cardiomyopathy. Gene expression 
profiling in temporally regulated αMHC-H-Ras-V12 transgenic mice suggests that 
overactivation of this pathway induces early response genes, loss of mitochondria 
function, and alteration in ion channel proteins, all of which lead to pathological 
changes in the extracellular matrix, reduced cardiac output, and electrophysiological 
abnormalities (Mitchell et al, 2006). Ras mRNA expression in HCM patients identified 
a positive correlation with the severity of hypertrophy (Kai etal, 1998). Likewise, 
patients suffering from so-called RAS/MAPK syndromes, a group of autosomal 
dominant disorders linked to mutations causing augmented Ras/Raf/MEK/ERK activity 
(e.g., Noonan and LEOPARD syndromes), exhibit hypertrophic cardiomyopathy 
(Aokiet al, 2008). Finally, in response to mechanical unloading afforded by use of a left 
ventricular assist device (LVAD), reverse remodelling and reduction in myocyte 
hypertrophy in the post-LVAD heart is associated with decreased ERK activity (Flesch 
et al, 2001). Conversely, an endogenous inhibitor of the ERK pathway, Sprouty-1, has 
been reported to be induced in human hearts during hypertrophy regression following 
LVAD support (Huebert et al, 2004). Overexpression of MEK 1, the upstream activator 
of ERK1/2, has shown similar overactivation of Ras. Constitutively active MEK1 leads 
to cardiomyocyte hypertrophy in vitro, while dominant negative MEK1 attenuates this 
response (Ueyama et al, 2000). In vivo, cardiac-specific expression of constitutively 
activated MEK1 also promotes hypertrophy (Bueno et al, 2000). However, unlike Ras 
overactivation, the MEK1 transgenic heart has no increase in fibrosis and displays 
preserved cardiac function, suggesting MEK-ERK may not be the critical downstream 
signalling pathway for Ras-induced pathological remodelling.  
Complimentary to these gain-of-function approaches, Harris et al. (2004) have 
demonstrated that inhibition of the ERK pathway via dominant negative Raf attenuated 
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hypertrophy and fetal gene induction in response to pressure overload. Likewise, 
Yamaguchi et al. (2004) have shown that cardiac specific deletion of c-raf-1 leads to 
heart failure without hypertrophy in the absence of external stress. Both groups found 
that, while there was an apparent lack of hypertrophy, there was a significant increase in 
apoptosis associated with Raf inactivation. This is consistent with the observation that 
overactivation of the ERK pathway causes both hypertrophy and a partial resistance to 
apoptosis (Bueno et al, 2000). However, the antiapoptotic activity of Raf appears to be 
primarily due to Raf binding to and directly suppressing the proapoptotic kinases Ask1 
and Mst2 independent of MEK/ERK activities (Chen and Sytkowski, 2005; Chen et al, 
2001;Yamaguchi et al, 2004). Similar results were also obtained when the protein 
tyrosine phosphatase Shp2 was deleted from the myocardium. Shp2 is an essential 
component of RTK signalling through the Ras/Raf/MEK/ERK pathway, and a gain-of-
function mutation in this protein causes craniofacial and cardiovascular defects in 
Noonan syndrome. Deletion of Shp2 in the myocardium leads to dilated 
cardiomyopathy without transition through hypertrophy at baseline or following 
pressure overload associated with diminished ERK activation (Kontaridis etal, 2008). 
These findings, specifically the onset of dilated cardiomyopathy without transitioning 
through hypertrophy, are similar to what was observed in the c-raf-1 knockout animals. 
Furthermore, GSK3α has been shown to block cardiac hypertrophy both in vitro and in 
vivo via inhibition of ERK signalling (Zhai et al, 2007). While all of these findings 
strongly suggest that ERK contributes to hypertrophy in the myocardium, one study by 
Purcell et al. (2007) suggests that reduction in ERK activity is not sufficient to prevent 
hypertrophy in response to various forms of hypertrophic stimuli in vivo. Achieved by 
either overexpression of dual specific phosphatase 6 or deletion of ERK (ERK1
−/−
 or 
ERK2
+/−
), these modifications led to an increase in apoptosis without a significant 
impact on hypertrophy. These results suggest that ERK activity is an important pathway 
for cardioprotection but that cardiac hypertrophy can proceed via ERK-independent 
mechanisms.  
In addition to growth factor-mediated signalling through RTKs (Clerk et al, 2006), 
signalling via G protein-coupled receptors (GPCRs) has also been shown to promote 
cardiac hypertrophy (Salazar et al, 2007), and in a number of settings, this has been 
shown to be mediated via ERK signalling. β-adrenergic agonists promote 
cardiomyocyte hypertrophy via direct interaction between ERK and β-arrestin ( Barki-
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Harrington et al, 2004; Salazar et al, 2007). Interestingly, signalling from β-adrenergic 
receptors, which can lead to detrimental effects in the failing heart, utilize β-arrestin to 
transactivate RTK signalling via ERK (Noma et al, 2007). This β-arrestin-dependent, G 
protein-independent signalling by those receptors is thought to be cardioprotective. This 
is exemplified by the recent discovery that carvedilol, a nonsubtype-selective β-
adrenergic receptor antagonist that has been shown to be particularly effective in 
treatment of heart failure, promotes signalling via β-arrestin-dependent ERK1/2 
activation in the absence of G protein activation (Wisler et al, 2007). Likewise, other 
GPCRs, including α-adrenergic receptors (Kuster et al, 2005; Xiao et al, 2001; Xiao 
etal, 2002), angiotensin receptors (Aoki et al, 2000; Yang et al, 2007), and endothelin 
receptors (Chen et al, 2005; Cullingford et al, 2008; Kennedy et al, 2006;Lu et al, 2009; 
Yue et al, 2000), have been shown to signal through ERK to promote cardiomyocyte 
hypertrophy. In addition to arrestin-mediated ERK activation, Wright et al. (2008) 
provided other evidence that nuclear targeted α-adrenergic receptor might activate ERK 
located in caveolae, although the underlying molecular basis remains unclear. More 
recently, Lorenz et al. (2009) have identified heterotrimeric G protein-mediated 
autophosphorylation of ERK as yet another hypertrophic signaling mechanism leading 
to ERK activation. In these studies, activation of Gq-coupled receptors was sufficient to 
mediate a protein-protein interaction between Gβγ and ERK, leading to 
autophosphorylation and translocation to the nucleus and activation of prohypertrophic 
substrates. This novel autophosphorylation-mediated ERK activation was sufficient to 
induce hypertrophy both in vitro and in vivo and was also shown to be present in failing 
human hearts. Finally, a recent report by Cervante et al. (2010)  suggest that cross-talk 
of GPCRs can be orchestrated by arrestin to achieve spatiotemporal activation of ERKs 
in nucleus versus cytoplasm, leading to different functional outcome. In addition to 
ligand-mediated mechanisms, Ras activation can be facilitated by direct oxidative 
modification of its thiol groups (Kuster et al, 2005; Yamamoto et al, 2003), thus 
providing another possible molecular link between oxidative stress and the onset of 
cardiac hypertrophy. In short, Ras-Raf-MEK1-ERK1/2 pathway is generally regarded as 
a prohypertrophic and prosurvival pathway that can be a significant but not a necessary 
signaling component in cardiomyocyte hypertrophy.  
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2. Cardioprotection versus myocardial cell death 
The cardioprotective effects of two classes of drugs commonly used to treat cardiac 
related diseases, Ca
2+
 channel blockers and β-adrenergic receptor blockers, have been 
reported to be mediated in part through ERK1/2 activity (Kovacset al, 2009). In vivo 
studies in which c-Raf-1 activity in the heart was lost showed an increase in apoptosis 
both at baseline and in response to pressure overload (Harris et al, 2004; Yamaguchi et 
al, 2004). Similarly, the Molkentin group has identified specific MEK-ERK2 signalling 
as a mediator of cardioprotection (Lips et al, 2004). In response to ischemia-reperfusion 
injury, MEK transgenic hearts were better protected from injury and apoptosis than 
wild-type controls, an effect that was lost when ERK2 was specifically deleted. Indeed, 
ERK1/2 signalling has been identified as one of the major components of the RISK 
(reperfusion injury salvage kinase) pathway. A plethora of studies have subsequently 
shown that activation of the ERK pathway by various stimuli leads to cardioprotection 
during reperfusion (reviewed in Ref. Hausenloy and Yellon, 2007). While the role of 
ERK signaling in preventing reperfusion-induced injury is well established, its role in 
preconditioning is less well understood, and conflicting results have been reported 
(Downey et al, 2007; Hausenloy et al, 2005). ERK's cardioprotective role has also been 
investigated in relation to the chemotherapeutic agent doxorubicin (DOX). DOX is 
known to induce myocardial damage, including cardiomyopathy and myocyte apoptosis 
(Takemura and Fujiwara, 2007). While the mechanism of DOX-induced cardiac damage 
is multifaceted, downregulation of ERK1/2 activity has been suggested to play a role. 
Indeed, DOX-induced cardiotoxicity was prevented by the administration of substrates 
that increased ERK1/2 activity (Suet al, 2006; Xiang et al, 2009). Conversely, recent 
work done in cultured myocytes has suggested a functional link between ERK1/2 and 
p53 actually promotes apoptosis in response to DOX (Liuet al, 2008).  
While much work has been done identifying upstream activators of cardioprotective 
ERK1/2 signaling, much less is known regarding the exact mechanism by which it 
imparts this protection. Multiple mechanisms may exist for prosurvival effects of 
ERK1/2. Work by Das et al. (2007) has shown that the protective effect of ANG II-
mediated preconditioning is due in part to ERK1/2 dissociating from caveolin. 
Similarly, ERK1/2 has been shown to play a role in cGMP-dependent protein kinase 
(PKG)-mediated cardioprotection in response to IR (Das et al, 2009; Das et al, 2008). 
ERK1/2 activation in this case resulted in increase expression of inducible nitric oxide 
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synthase (iNOS), endothelial NOS (eNOS), and Bcl-2. ERK1/2 has also proposed to 
exert its cardioprotective effects by phosphorylating and activating the transcription 
factor GATA4, which can then increase the expression of antiapoptotic proteins in 
neonatal ventricular myocytes (Arier et al, 2004; Kobayashi et al, 2006; Liang et al, 
2001;Morimoto et al, 2000). However, recent work has shown that this does not hold 
true in adult cells. While GATA4 still promotes survival, it was found not to be 
downstream of ERK1/2 signalling in response to α1-adrenergic receptors, a previously 
described survival pathway in cardiomyocytes (Huang et al, 2008, Huang et al, 2007). 
ERK1/2 may also promote survival of cardiomyocytes by interacting with other 
signalling pathways. IL-10 mediated ERK1/2 activation was shown to inhibit TNF-α-
induced apoptotic signalling by blocking IKK phosphorylation and subsequent NFκB 
activation (Dhingra et al, 2009). Likewise, ERK1/2 has also been shown to compensate 
for loss of Akt activity in postinfarct myocardium and promote cardioprotection in 
response to erythropoietin (Miki et al, 2007). Finally, ERK1/2 has been found to 
suppress gap junction permeability in response to mitoKATP channel opening during IR, 
thus reducing myocardial damage (Naitoh et al, 2006). As noted above, the ERK-
independent cardioprotective activity of Raf is mediated through direct suppression of 
proapoptotic kinases, Ask1 and Mst2 (Chen and Sytkowski, 2005; Chen et al, 2001; 
Yamaguchi et al, 2004). In short, Ras-Raf-MEK-ERK1/2 may exert strong 
cardioprotective effects via multiple downstream targets, but much remains to be done 
to delineate their specific contribution under particular circumstances.  
 
3. Cardiac remodeling 
As discussed above, unregulated Ras-Raf-MEK-ERK signalling can lead to both 
hypertrophy and pathological remodelling in heart. Gene expression profiling in 
temporally regulated α-MHC-H-Ras-v12 transgenic mice suggests that overactivation of 
this pathway induces early response genes, loss of mitochondrial function, and 
alteration in ion channel proteins, all of which can contribute to extracellular matrix 
remodelling, reduced cardiac output, and electrophysiological abnormalities observed in 
HCM (Mitchell et al, 2006). In addition, Ras activation can have a direct impact on SR 
calcium cycling in ventricular myocytes both in vitro and in vivo. In vitro expression of 
Ha-Ras-V12 in cultured myocytes leads to downregulation of L-type Ca
2+
 channel 
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expression and activity in an ERK-dependent manner (Ho et al, 2001). Furthermore, 
activation of Ras leads to decreased expression of SERCA in cultured myocytes (Ho et 
al, 1998). In vivo studies, while finding no change in L-type Ca
2+
 channels or 
sarcomeric structure, showed decreased Ca
2+
 transients secondary to suppressed SR 
Ca
2+
 uptake as a result of decreased SERCA expression and hypophosphorylation of 
phospholamban (Zheng et al, 2004). More recently, Ruan et al. (2007) reported that 
Giα1 induction and subsequent impairment of PKA signaling appears to be one of the 
key downstream mediators in Ras-induced SR calcium defects and arrhythmia. Yada et 
al. (2007) also reported a role for another Ras-like small GTPase, Rad, in modulating 
calcium homeostasis and electrophysiological properties in ventricular myocytes. 
Therefore, unregulated Ras signalling may have a direct impact on cardiac function and 
electrophysiology, but downstream signalling appears to be different from the canonical 
MEK-ERK cascade. The molecular basis is just beginning to emerge. LIF, a 
hypertrophic stimulus in cardiomyocytes, leads to increased L-type Ca
2+
 transients in an 
ERK-dependent manner (Hagiwara et al, 2007; Takahashi et al, 2004). These findings 
imply that the specific outcomes of ERK activation may be dependent on the activating 
stimulus, again demonstrating the complexity of these signalling networks. In addition 
to playing a role in Ca
2+
 channel regulation, ERK signalling also plays a role in 
regulation of other ion channels including potassium channels and the Na
+
/H
+
 
exchanger in the myocardium (Fliegel, 2008; Fliegel, 2009; Teos et al, 2008; Walsch et 
al, 2001). In short, the Ras-Raf-MEK-ERK pathway can induce SR calcium defects and 
arrhythmias in the heart by modulating ion channels, exchangers, and pumps and serves 
as a potential contributor to the contractile defects and sudden cardiac arrest prevalent in 
hypertrophic cardiomyopathy.  
In summary, both classic RTK-mediated and GPCR-mediated ERK activation have 
significant roles in cardiac hypertrophy and cardioprotection. However, the functional 
outcome of ERK activation can be modulated and altered by scaffolds in a specific 
spatiotemporal pattern. This complexity in ERK pathway leads to different phenotypes 
from “physiological” form of compensated hypertrophy and cardioprotection to 
pathological form of hypertrophic cardiomyopathy and remodelling. Therefore, the 
intricate ERK activation mechanisms must be carefully considered when we attempt to 
target ERK pathway as a potential therapy for heart failure.  
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B. JNK 
1. Cardiac hypertrophy 
The role that JNK plays in cardiac hypertrophy is less clear. JNK activity is 
substantially upregulated (as quickly as 10–15 min after application of pressure 
overload) and reaches a maximal level at ∼30 min (Fischer et al, 2001; Nadruz et al, 
2004). While JNK2 is activated in the cytosol, there is a significant increase in 
translocation of activated JNK1 to the nucleus (Nadruz et al, 2004). The transient 
activation of JNK is clearly seen in severe pressure overload (85% constriction of the 
aorta) but not volume-overloaded hearts. In pressure overload, activation peaks between 
10 and 30 min (Sopontammaraket al, 2005). In contrast, mild pressure overload (35% 
constriction of the aorta) exhibits a transient increase in JNK activity at 30 min, but 
higher levels are seen at 1 and 2 days post-constriction. In contrast, another recent study 
in rat has shown that in response to pressure overload, JNK activity is actually 
decreased in the first 24 h post-aortic banding (Roussel et al, 2008). In this particular 
study, ERK activity was also decreased despite an upregulation of angiotensin 
receptors. These findings fit with other findings which show that there was no 
significant increase in JNK1/2 activity after 24 h in either pressure- or volume-overload 
experiments (Miyamoto et al, 2004). Mechanical stretch of cultured myocytes also 
activates JNK in a rapid and phasic manner (Nadruz et al, 2005; Pan et al, 2005). 
Furthermore, exercise, an acute form of stress, has been shown to also cause a rapid 
transient increase in JNK activity that is not present in exercised trained rats which 
exhibited a physiological cardiac hypertrophy (Boluyt et al, 2003). Taken together, 
these findings indicate that JNK activation is most likely a dynamic signalling event that 
can be influenced by the nature of the stimuli and that different JNK isoforms may play 
separate, nonredundant roles in the process.  
Initial studies in cultured neonatal cardiomyocytes indicated that overactivation of JNK 
by MKK7, an upstream MAP2K, and leads to a hypertrophic phenotype (Wang et al, 
1998). Correspondingly, dominant negative MKK4, another upstream MAP2K, was 
able to attenuate the endothelin-1-induced hypertrophic response in cultured myocytes 
(Choukroun et al, 1998). Likewise, initial in vivo studies in rats showed that dominant 
negative MKK4 abrogated JNK activity and pressure overload-induced hypertrophy 
(Choukroun et al, 1999). These findings would suggest that JNK activity is responsible, 
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in part, for the promotion of cell hypertrophy. In contrast, recent work by Lui et al. 
(2009) has shown that cardiac-specific deletion of MKK4 sensitizes the myocardium to 
pathological hypertrophy following pressure overload or chronic β-adrenergic 
stimulation. Similarly, disruption of JNK activity (dominant negative JNK) in the heart 
contributes significantly to hypertrophy following pressure overload (Lianget al, 2003). 
This is shown to be due in part to the ability of JNK to inhibit the translocation of the 
prohypertrophic transcription factor NFAT into the nucleus (Liang et al, 2003; Liu et al, 
2009; Molkentin et al, 2004). Deletion of JNK shows similar results. In one study, 
JNK1
−/−
, JNK2
−/−
, and JNK3
−/−
 mice all show hypertrophy after pressure overload; 
however, the degree of hypertrophy is not significantly greater than wild-type mice 
(Tachibana et al, 2006). The same studies indicated that JNK1 in particular was 
required to maintain cardiac contractility and prevent heart failure under sustained 
mechanical overload. As mentioned previously, JNK1 is found to have increased 
translocation to the nucleus in response to pressure overload, which may explain why 
this particular isoform shows a more severe phenotype when deleted. This somewhat 
mirrors the JNK1translocation to the nucleus that is also seen during IR (Mizukami et 
al, 1997). Interestingly, another group showed that loss of MEKK1-JNK signalling in 
the heart attenuates Gq-induced hypertrophy (Minamino et al, 2002). However, 
subsequent studies using this model have shown that loss of MEKK1-JNK signalling 
does not prevent hypertrophy in response to pressure overload (Sadoshima et al, 2002). 
Other studies have demonstrated that JNK signaling is an important part of endothelin-
1-mediated hypertrophic signalling in cultured myocytes (Irukayama-Tomobe et al, 
2004; Shimojo et al, 2006). This further indicates that JNK may have differential roles 
dependent on the stimuli. Furthermore, in vivo JNK activation in various transgenic 
animal models failed to induce cardiac hypertrophy. Activation of JNK in the heart by 
overexpression of constitutively active MKK7 activated the fetal gene program and 
ventricular remodelling, but did not induce hypertrophy (Petrich et al, 2004; Petrich et 
al, 2002). Utilizing a cre-loxP-mediated gene-switch approach, Petrich et al. (2003) 
were able to temporally regulate JNK activation in the adult myocardium. As with other 
studies, JNK activation in this manner led to pathological remodelling in the absence of 
ventricular hypertrophy but with a marked induction of fetal gene expression.  
Given the conflicting results that have been obtained from both in vitro and in vivo 
studies, it has been hard to delineate the exact mechanism behind the JNK signalling 
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during hypertrophy. As mentioned previously, JNK's regulation of NFAT may be one 
mechanism (Liang et al, 2003; Liu et al, 2009). JunD, a downstream target of JNK, has 
been shown both in vivo and in vitro to block the cardiomyocyte hypertrophic response 
to both pressure overload and phenylephrine (PE) (Hilfiker-Kleiner et al, 2006; 
Hilfiker-Kleiner et al, 2005; Ricci et al, 2005). It has been suggested that this may be 
one explanation for the lack of hypertrophy in response to JNK activation. However, at 
least in vitro, phosphorylation of JunD by JNK is not required for its ability to prevent 
PE-induced hypertrophy (Hilfiker-Kleiner et al, 2006). Finally, recent work has shown 
that binding of growth arrest and DNA-damage-inducible beta (GADD45B) to MKK7 
decreases its activity and prevents JNK-mediated cardiac hypertrophy (Wang et al, 
2008). While studies in vitro have suggested that JNKs are prohypertrophic, the 
majority of studies in vivo do not support that conclusion; rather, JNKs appear to be 
more antihypertrophic, acting in part via excluding NF-ATs from the nucleus and 
upregulating JunD.  
2. Cardioprotection versus myocardial cell death 
Similar to the hypertrophy scenario, JNK's role in IR is also unclear. Numerous studies 
both in vitro and in vivo have shown the JNK is activated as a result of reoxygenation 
upon reperfusion (Fryer et al, 2001; Knight and Buxton, 1996; Laderoute and Webster, 
1997; Sekoet al, 1997; Yinet al, 1997). While its activation during the ischemic phase is 
less well established, a few studies have suggested that it occurs (Ping et al, 1999; 
Shimizuet al, 1998; Yue et al, 2000). As a stress-induced signaling pathway, JNK has 
both protective and pathological roles in different cell types. This dichotomy is also 
observed in cardiomyocytes. JNK1, but not JNK2, has been shown to be proapoptotic 
during in vitro IR experiments (Hreniuk et al, 2001). Likewise, treatment with various 
JNK-selective inhibitors reduces infarct size and apoptosis in response to IR (Ferrandi 
et al, 2004; Milanoet al, 2007). Furthermore, JNK activity contributes to the detrimental 
effects of a number of proteins known to increase myocardial injury following IR, 
including the receptor for advanced glycation end-products (RAGE) (Aleshin et al, 
2008), PKC-β (Kong et al, 2008), β-adrenergic receptors (Remondino et al, 2003), 
uncleaved HB-EGF (Uetani et al, 2009), Rho-kinase (Zhang et al, 2009), and 
poly(ADP-ribose) polymerase (Song et al, 2008). Most recently, JNK has been shown 
to be activated and promote apoptosis during IR by atrogin-1, an E3 ubiquitin ligase 
(Xie et al, 2009). Atrogin-1 targets MAPK phosphatase-1 (MKP-1) for degradation, 
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resulting in a sustained activation of JNK and increased apoptosis through increasing 
cleaved caspase-9, caspase-3, and Bax and by decreasing Bcl-2. JNK has been reported 
to associate with the mitochondria, possibly interacting with proapoptotic proteins 
(Aoki et al, 2002; Baines et al, 2002), and has also been shown to mediate apoptosis-
inducing factor (AIF) translocation from the mitochondria to the nucleus (Song et al, 
2008; Zhang et al, 2009). However, convincing as these data are, the complexity of the 
system is probably best exemplified by Kaiser et al. (2005), who reported enhanced 
myocyte survival after IR with both JNK activation and inhibition. JNK has also been 
viewed as antiapoptotic in response to nitric oxide (NO) in vitro (Andreka et al, 2001). 
Similarly, blocking JNK activity increased apoptosis and the activity of both caspase-9 
(Dougherty et al, 2002) and caspase-3 (Engelbrecht et al, 2004) in another in vitro IR 
model. This has been proposed to be mediated by the interaction of JNK with Apaf-1, 
which delays the activation of caspase-9 by the apoptosome (Tran et al, 2007). It has 
also been suggested that part of JNK's cardioprotective effect is due to activation of Akt, 
a key prosurvival protein in postischemic cardiomyocytes (Shao et al, 2006).                  
In short, like in hypertrophy, the role of the JNK pathway in IR injury remains 
controversial, perhaps reflecting the complexity of multistage, multi-targeted signalling 
networks involved in this process.  
3. Cardiac remodelling 
Transgenic activation of the JNK pathway in the heart resulted in a lethal restrictive 
cardiomyopathy with selective extracellular matrix remodelling (Petrich et al, 2004). 
(Collagen deposition was not increased, but fibronectin levels were markedly 
increased.) Prolonged activation of JNK activity in heart was also associated with 
abnormal gap junction structure, loss of the main component (connexin-43), and slowed 
conduction velocity in the heart (Petrich et al, 2002). Recent evidence suggests that the 
loss of gap junctions in JNK-activated heart is associated with the loss of connexin-43 
protein expression as well as improper intracellular targeting (Ursitti et al, 2007). On 
the other hand, deletion of JNK1 in the heart resulted in an increase in fibrosis 
following pressure overload (Tachibana et al, 2006). Similarly, chronic treatment with a 
JNK inhibitor led to increased apoptosis and cardiac fibrosis in the cardiomyopathic 
hamster model (Kyoi et al, 2006). Likewise, another study showed the loss of toll-like 
receptor 4 (TLR4) improved cardiac function and reduced cardiac remodelling 
following ischemic injury in the heart (Riad et al., 2008). In this study, the wild-type 
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animals displayed a significant decrease in JNK activity following ischemia that did not 
occur in the TLR4 animals. Interestingly, the higher JNK level in the TLR knockout 
animals following ischemia was also accompanied by a significant decrease in 
calcineurin, indicating that the cross-talk between these two pathways as discussed 
previously may also play an important role in cardiac remodelling. These results 
indicate that JNK activity functions to keep some aspects of cardiac remodelling in 
check while promoting the dysregulation of others.  
JNK has also been implicated in promoting cardiac remodelling downstream of various 
pathways. For example, ASK-1/JNK has been shown to play a role in β-adrenergic-
induced cardiac remodelling and apoptosis in vivo (Fan et al, 2006). Hsp20, a protein 
with known cardioprotective effects (Fan et al, 2005), inhibited the activation of JNK in 
this setting. In a rat model of pressure overload, treatment with RA inhibited cardiac 
remodelling by inhibiting MAPK signaling, including JNK activity, by upregulating 
MKP-1 and MKP-2 (Chouldharyet al, 2008). Likewise, in a model of ANG II-induced 
hypertrophy, mice deficient for ASK1-JNK signalling demonstrated an attenuation of 
cardiac fibrosis and remodelling (Izumiyaet al, 2003). JNK activation downstream of 
ET-1 has also been implicated in perivascular remodelling in rat (Jesmi et al, 2006). 
Finally, matrix metalloproteinases (MMP) are well known to contribute to cardiac 
remodelling. Recent in vitro studies have shown that in response to β-adrenergic 
signalling, extracellular matrix metalloproteinase inducer (EMMPRIN) expression and 
MMP-2 activity was increased in a JNK-dependent manner in cardiomyocytes (Siwik et 
al, 2008). These findings are supported by other in vitro work in which JNK activation 
in H9c2 cardiomyoblasts resulted in the upregulation of MMP-2 (but not MMP-9) 
activity (Chenget al, 2009). Likewise, in vivo studies on the loss of β1-integrins showed 
increased JNK activity was associated with increased MMP-2 but not MMP-9 activity, 
which corresponded with less cardiac fibrosis in this setting ( Krishnamurthy et al, 
2007). ROS signalling is emerging as an important player in cardiac remodeling. Since 
JNK activation is a downstream consequence of ROS induction, there might be a larger 
role for JNK in cardiac remodelling than originally thought (Anilkumar et al, 2009; 
Hori and Nishida, 2009). Finally, ASK-1/JNK is a downstream pathway of ER stress 
signalling (Nagai et al, 2007), which is also gaining more appreciation as an important 
aspect of stress signalling in the diseased heart (Toth et al, 2007, Xu et al, 2005). For 
example, Kerkela and co-workers (Force and  Kerkela, 2008; Kerkela et al, 2006) have 
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found that ER stress and ensuing JNK activation is responsible for mitochondrial 
defects and severe cardiomyopathy as a result of anticancer therapy targeted to the 
tyrosine kinase c-abl.  
These results may indicate that JNK's role in cardiac pathological remodelling may 
depend on the activating stimuli. However, because hypertrophy and remodelling often 
go hand in hand, it is hard to determine whether the remodelling observed in some of 
these cases is a specific and direct result of JNK activation or secondary to the ensuing 
hypertrophy recruitment of other signalling pathways.  
 
C. p38 
 
1. Cardiac hypertrophy 
Despite a great deal of interest in p38, much of its role in the heart is yet to be clarified. 
Initial in vitro studies of this pathway suggested that p38 promotes cardiac growth and 
hypertrophy. Inhibition of the pathway using small molecule inhibitors (SB203580 or 
SB202190) or dominant negative p38 adenovirus inhibits myocyte growth in response 
to hypertrophic stimuli (Liang and Molketin, 2003; Nemoto et al, 1998; Zechner et al, 
1997). In addition, multiple groups have shown that overactivation of the p38 pathway 
induces hypertrophic changes in vitro (Nemoto et al, 1998;Wang et al, 1998;Zechner et 
al, 1997). However, other studies suggest that p38 is not necessary for agonist-induced 
hypertrophy in cultured myocytes (Choukroun et al, 1998) and that p38 inhibition is 
actually associated with calcineurin induced hypertrophy via induced expression of 
MAPK phosphatase-1 (Lim et al, 2001).  
Results from in vivo studies showed that targeted activation of p38 in the heart did not 
produce any significant degree of cardiac hypertrophy (Liao et al, 2001). Instead, 
transgenic overexpression of either MKK3 or MKK6 in the heart increased interstitial 
fibrosis, ventricular wall thinning, and premature death due to cardiac failure. These 
findings are supported by Klein et al. (2005) in which loss of PKC-ε resulted in 
increased activation of p38 in the myocardium following pressure overload. These 
animals displayed a similar phenotype to the MKK3/MKK6 animals, including no 
increase in hypertrophy but a significant increase in fibrosis and impaired diastolic 
function. These findings indicate that, in vivo, p38 activity alone is not sufficient to 
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promote cardiomyocyte hypertrophy. Conversely, initial studies involving cardiac-
specific p38 dominant negative transgenic mice showed that loss of p38 activity either 
had no effect on hypertrophy (Zhang et al, 2003) or sensitized the heart to hypertrophy 
(Braz et al, 2003) in response to pressure overload. The enhanced hypertrophy in this 
setting is suggested to be the result of loss of p38's antagonizing effect on NFAT-
mediated transcriptional activity (Braz et al, 2003; Molkentin, 2004; Yang et al, 2002). 
Cardiac-specific deletion of p38 did not alter pressure overload hypertrophy. It resulted 
in a similar degree of myocyte hypertrophy between p38 CKO and wild-type animals 
following pressure overload (Nishida et al, 2004). However, these mice did exhibit an 
increase in apoptosis, fibrosis, and chamber dilation as well as reduced LV function 
(Nishida et al, 2004). Taken together, these findings would indicate that p38 activity is 
not involved in promoting hypertrophy in vivo, but may play an important role in 
pathological remodelling.  
Recent findings have implicated p38 in physiological hypertrophy. In response to 
swimming, loss of p38, either by deletion of ASK1 (an upstream activator) or by 
conditional knockout of p38 from the myocardium, resulted in increased hypertrophy 
without increasing fibrosis (Taniike et al, 2008). These authors proposed that the loss of 
p38 activity resulted in an increase in AKT activity, a known inducer of physiological 
hypertrophy. Conversely, p38 dominant negative transgenic mice did not experience an 
increase in hypertrophy in response to swimming (Watanabe et al, 2007). This may 
mirror the different results obtained from the dominant negative transgenic model and 
the conditional knockout model in response to pressure overload discussed above. 
Furthermore, an increase in p38 activation in response to loss of the regulatory protein 
14–3-3 resulted in maladaptive hypertrophy with increased fibrosis and apoptosis in 
response to swimming (Watanabe et al, 2007).  
While gain-of-function and loss-of-function studies through genetic manipulation have 
shown that p38 is not sufficient for hypertrophy, at least in vivo, studies involving 
upstream activators still imply a role for p38 in the hypertrophic process. Multiple 
studies have shown that the protective effects of estrogen on the myocardium are 
mediated in part through activation of the p38 pathway. In response to both pressure 
overload and activation of Gqα signalling, administration of estrogen in vivo blocks 
hypertrophy in a p38-mediated manner (Babiker et al, 2006; Satoh et al, 2007). 
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Likewise, p38 dominant negative transgenic female mice exhibited greater hypertrophy 
than either males or ovariectomized females in response to pressure overload (Liu et al, 
2006). In vitro studies have produced similar results. In contrast, activation of thyroid 
receptor (TRα1) has been shown to cause myocyte hypertrophy via TAK-1/p38 activity 
in vitro (Kinugawa et al, 2005). Likewise, leptin induces hypertrophy of cultured 
neonatal myocytes as a result of caveolae and RhoA-mediated phospho-p38 
translocation to the nucleus (Zeidan et al, 2008). These results and others like them may 
indicate that the role of p38 in cardiac hypertrophy is a conflicting one. While acute 
activation of p38 appears to be prohypertrophic, chronic activation of p38 can lead to 
suppression of hypertrophic growth in heart. However, it is clear from both in vitro and 
in vivo studies that p38 activation has a detrimental effect on cardiac function and 
normal gene expression. Therefore, p38 induction is more closely related to 
pathological form of hypertrophy than to physiological compensation.  
 
 
2. Cardioprotection versus myocardial cell death 
The role of p38 during IR has been well reported in the literature. However, the 
conclusions are often contradictory, with some evidence pointing toward a protective 
role and other results indicating a detrimental role (Clark et al, 2007; Steenbergen, 
2002). Similar conflicting results have also been noted regarding the role of p38 in 
ischemic preconditioning (Bell et al, 2008; Steenbergen, 2002). These contradictions 
are likely due, at least in part, to a number of variables including use of different 
protocols, species, method of p38 inhibition, and measured outcomes. That said, some 
studies that employed similar species and protocols still resulted in opposing 
conclusions (Bell et al, 2008).  
Shortly after its identification, investigators demonstrated that p38 was robustly 
activated by ischemia in the isolated perfused rat heart (Bogoyevitsch et al, 1996). This 
activation is both rapid in its onset and transient in its duration after induction of 
ischemia. To date, however, the exact role that this temporal activation plays in 
ischemia still eludes investigators. A number of studies have indicated that activation of 
p38 during ischemia leads to increased injury (Barancik et al, 2000; Bellet al, 2008; Ma 
et al, 1999; Mackay and Mochly - Rosen , 1999; Martin et al, 2001; Nagarkatti and 
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Sha’afi, 1998, Sanada et al, 2001; Saurin et al, 2000). Likewise, an equal number of 
studies have shown that p38 activity during ischemia serves a protective role (Martin et 
al, 1999; Mauliket al, 1998; Mocanu et al, 2000; Weinbrenner et al, 1997; Zechner et 
al, 1997). This last point is seen mostly in the context of ischemic preconditioning, the 
process by which small repeated periods of ischemia impart cardioprotection against 
more sustained ischemic periods. A number of investigators have shown that p38 
activity increases during preconditioning (Steenbergen, 2002). Interestingly, this too 
appears to be phasic in nature. Ping et al. (1999) have shown that p38 activity is 
increased with brief periods of ischemia, but with repetitive cycles of ischemia and 
reperfusion, the level of p38 activity returns to baseline within 6 cycles. Furthermore, 
multiple cycles of ischemia and reperfusion lead to less p38 activation during sustained 
periods of ischemia following the preconditioning when compared with 
nonpreconditioned hearts (Gysemberghet al, 2001; Maraiset al, 2001; Schneider et al, 
2001). Furthermore, inhibiting p38 activity during prolonged periods of ischemia 
reduces infarct size only in non-preconditioned hearts and that inhibition of p38 during 
preconditioning eliminates its cardioprotective effects (Béguinet al, 2007; Gysembergh 
et al, 2001; Sanada et al, 2001). Although appearing to be contradictory, these results 
may be reconciled based on the hypothesis that a negative-feedback mechanism 
recruited by the modestly induced p38 activity during preconditioning contributes to 
minimize the detrimental impact of IR. Identifying the molecular basis of this 
preconditioning-induced protective mechanism remains a major challenge in the 
biology of ischemia and has the potential to translate this phenomenon into a viable 
therapy for ischemic disease. In addition, Engel et al. (2006) have suggested that 
inhibiting p38 activity can help preserve cardiac function following ischemia by 
reducing scarring and promoting myocyte proliferation. This new aspect of p38-
mediated cardioprotection opens up a new and exciting avenue by which p38 may be 
manipulated for therapeutic benefit in the heart.  
Another confounding factor adding to the complexity of p38 study is the presence of 
multiple p38 isoforms in the heart. While p38α is the predominant isoform in the heart, 
p38β is also present and has been shown to have different physiological consequences. 
Initial studies in neonatal rat ventricular myocytes revealed that overexpression of p38α 
impart pro-apoptotic effects, while overexpression of p38β leads to myocyte 
hypertrophy (Wang et al, 1998). Studies investigating the role of different p38 isoforms 
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during ischemia have discovered possible differential roles for the α- and β-isoforms. 
Following adenoviral-mediated overexpression and simulated ischemia, Saurin et al. 
(2000) have shown that p38α activity is increased while p38β activity is decreased. 
Furthermore, these authors demonstrate that inhibition of only the α-isoform was 
protective. Subsequently, multiple studies have indicated that p38β may be the isoform 
that imparts cardioprotection (Kimet al, 2005; Kim et al, 2006). Recently, in vivo 
studies utilizing overexpression of a cardiac-specific kinase dead p38β mutant revealed 
that loss of p38β, but not p38α, activity in the myocardium resulted in increased 
ischemic injury (Cross et al, 2009). This is similar to previous work in which mice 
either overexpressing a dominant negative form or lacking one allele of p38α were 
significantly protected from IR injury (Kaiser et al, 2004; Otsu et al, 2003). These 
results may provide some clue as to the discrepancy of previous results regarding the 
protective versus detrimental role of p38 during ischemia. Many early studies utilized 
p38 inhibitors that block both the α- and β-isoform. If the two isoforms do indeed have 
different activation profiles and functional roles during ischemia, then experimental 
results may be confounded by inadvertently blocking both isoforms. Furthermore, it has 
been shown that the most common p38 inhibitor, SB203580, can actually inhibit other 
kinases depending on the concentration used (Borsch-Haubold et al, 1998; Clerk and 
Sugden , 1998; Hall-Jackson et al, 1999; Lali et al, 2000). Finally, it has begun to be 
recognized that p38 activation can be mediated by more than the canonical kinase 
cascade as described earlier, but also via a noncanonical mechanism involving TAB-1 
induced autophosphorylation (Ge et al, 2002). Indeed, TAB-1-mediated p38 activation 
is observed in ischemic heart and implicated in cardiac injury (Li et al, 2005; Tanno et 
al, 2003). However, although one study showed TAB-1 induced p38 activation in 
cardiomycoyte caused apoptosis similar to canonically activated p38 activity, another 
showed TAB-1 interaction with p38 led to its intracellular localization and downstream 
signalling distinct from the canonical pathway (Fiedler et al, 2006; Lu et al, 2006). 
Although mainly observed in brain and thymocytes, p38 can also function as an 
alternative mechanism of GSK-3β inactivation, thus further complicating the functional 
outcome of p38 activation/inactivation in the heart (Thornton et al, 2008).  
The upstream and downstream signalling that contributes to p38's role in insulin 
resistance has yet to be fully determined. Multiple studies, however, have begun to 
examine such events. For instance, in a setting of insulin-induced cardioprotection, rat 
63 
 
hearts treated with insulin followed by IR showed improved functional recovery and an 
increase in phospho-Hsp27 (Li et al, 2008). This protective effect was abolished by 
treatment with the p38 inhibitor SB203580. p38-mediated Hsp27 activation has also 
been shown to play a protective role during IR in response to pretreatment of the hearts 
with H2O2 (Blunt et al, 2007). In this case, the protective effect was determined to be 
due to Hsp27's ability to prevent Ca
2+
-induced proteolysis of myofilament proteins. 
Hsp27 has been shown in other studies to have cardioprotective properties (Hollander et 
al, 2004; Martinet al, 1999; Martin et al, 1997). p38's ability to activate Hsp27 may 
explain some of the results showing that p38 is cardioprotective. However, transgenic 
expression of both wild-type and a nonphosphorylatable from of Hsp27 were both 
cardioprotective following IR, suggesting that phosphorylation by p38 is not an absolute 
requirement for its cardioprotective effects (Hollander et al, 2004). Interestingly, Gorog 
et al. (2009) have demonstrated that loss of MAPK APK2, the kinase that functions 
between p38 and Hsp27, resulted in the loss of ischemia-induced Hsp27 
phosphorylation but did not exacerbate the ischemic injury.  
While the previous examples discuss p38 activation and signaling in terms of 
cardioprotection, other studies have investigated how inhibition of p38 is 
cardioprotective. As mentioned previously, p38 activity in myocytes can be 
proapoptotic. Work by Dhingra et al. (2007) has shown that p38 activity is important in 
TNF-α-mediated myocyte apoptosis, in part, due to ROS production. Moreover, p38 
inhibition has also been shown to prevent mitochondrial ROS production and Ca
2+
 
overload during IR (Sucher et al, 2009). p38's role in mitochondrial-mediated cell death 
events was also examined by Schwertz et al. (2007). In their proteomic approach, they 
identified a number of proteins altered following IR in rabbit heart. Most interestingly, 
they noted that phosphorylation of VDAC-1, a mitochondrial porin with possible links 
to mitochondrial permeability transition pore (MPTP)-mediated cell death, was 
increased four fold following IR. This phosphorylation was significantly decreased, and 
cardioprotection was increased with treatment with the p38 inhibitor PD169316. p38 
inhibition has also been shown to impart its cardioprotective effects by altering glucose 
utilization (Jaswal et  al, 2007; Jaswal et al, 2007). Finally, endogenous p38 inhibition 
has also been shown to be cardioprotective during IR. Treatment of rats with the 
glucocoticoid dexamethasone was shown to be cardioprotective through induction of 
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the dual-specific phosphatase MKP-1 which resulted in a decrease in p38 
phosphorylation (Fan et al, 2009).  
As can been seen, the role of p38 in cardiac protection and injury is a complicated one. 
The specific contribution of p38 kinase in ischemic injury and protection is determined 
by the level, duration, mode, and timing of induction involving different isoforms and 
upstream/downstream pathways.  
3. Cardiac remodeling 
As with JNK, the other stress-activated MAPK, p38 appears to play an important role in 
cardiac remodelling after injury. Liao et al. (2001) discovered that targeted p38 
activation in the myocardium led to a restrictive cardiomyopathy with significant 
amounts of interstitial fibrosis. In this setting, p38 was shown to induce cytokine release 
from myocytes, including TNF-α and IL-6 (Liet al, 2005). Interestingly, in these in vitro 
studies, blocking p38 activity did not appear to prevent cytokine production in the 
myocytes, only their release from the cell. Proinflammatory cytokines such as TNF-α 
and IL-6 are known to act in both autocrine and paracrine fashions. Acting in an 
autocrine fashion, they are known to have negative inotropic effects (Prabhu, 2004). 
Acting in a paracrine fashion, they play a large role in myocardial remodeling (Nian et 
al, 2004). These initial studies are supported by findings of Tenhunen et al. (2006) in 
which DNA microarray analysis of animals with cardiac-specific overexpression of p38 
revealed that genes related to inflammation and fibrosis were among the most 
significantly upregulated.  
p38 is also activated by proinflammatory cytokines, including transforming growth 
factor (TGF)-β. This type of p38 activation also contributes to cardiac remodelling. 
Indeed, p38 is activated via a TGF-β1/TAK1-dependent mechanism in myocytes 
following myocardial infarction in rats (Matsumoto-Ida et al, 2006). As discussed 
previously, p38 activity can induce cytokine production, thus creating a type of feed-
forward mechanism for cytokine action and production. This autocrine and paracrine 
signalling can lead to recruitment and proliferation of cardiac fibroblasts and 
inflammatory cells resulting in remodelling. Recent work in aged hypertensive rats 
(which naturally develop significant amounts of cardiac fibrosis) has shown that 
treatment with a TGF-β antagonist dramatically reduces both hypertrophy and 
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interstitial fibrosis.  This was accompanied by a decrease in phospho-p38 levels. This 
fits with other studies that have shown inhibition of p38 reduces remodelling following 
myocardial infarction (Liu et al, 2005; See et al, 2004). Interestingly, recent work by 
Frantz et al. (2007) indicated that long-term (9 wk) inhibition of p38 starting 1 wk after 
induced cardiac ischemia reduced cytokine production but did not affect other aspects of 
cardiac remodelling, including collagen deposits (Frantz et al, 2007). This finding, 
however, is in contrast to work by others which showed significant reduction in cardiac 
fibrosis and hypertrophy following IR with long-term p38 inhibition (Kompa et al, 
2008). While the protocols for these two studies were similar, the difference in outcome 
may be due to the different p38 inhibitors used (SB239063 and RWJ67657, 
respectively).  
In addition to extracellular matrix remodelling, p38 can also regulate myocyte 
contractility. Activation of p38 has been shown to have negative inotropic effects in 
myocytes (Chen et al, 2003; Liao et al, 2002; Zechner et al, 1997). Moreover, recent 
work by Szokodi et al. (2008) has shown that increased contractility in response to ET-1 
treatment was due to ERK signalling and was further augmented by inhibition of p38. In 
this setting, it appears that p38 may play a regulatory function by counterbalancing the 
effects of ERK. While the precise mechanism by which p38 influences myocyte 
contractility is not fully understood, it appears to be due, at least in part, to 
modifications of structural proteins. Initial work described p38's role in contractility as 
Ca
2+
 transient independent (Liao et al, 2002), but suggested that it may be due to 
modifications of sarcomeric proteins (Chen et al, 2003). Most recently, Vahebi et al. 
(2007) have suggested that a p38-mediated decreased phosphorylation of α-tropomyosin 
is one of the mechanisms involved. Furthermore, p38 has the potential to affect myocyte 
contractility by promoting transcription of the Na
+
/Ca
2+
 exchanger (NCX1), a key 
regulator of Ca
2+
 homeostasis in both the healthy and pathological myocardium 
(Menich et al, 2007). Interestingly, a recent study found that inhibiting NCX1 actually 
resulted in upregulation of the NCX1 gene in a p38-dependent manner and that this 
increase was accompanied by NCX-p38 complex formation (Xu et al, 2009). With the 
proposal of NCX1 inhibitors as a therapeutic treatment for heart failure, more work 
needs to be done to better understand the interplay between these two proteins. Finally, 
p38 has also been shown to downregulate SERCA expression and prolong the Ca
2+
 
transient in cultured myocytes (Andrews et al, 2003). Although more work needs to be 
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done, given the importance of Ca
2+
 handling in cardiac pathologies, it is important to 
better understand the role the p38 signalling may play on this front. In short, chronic 
induction of p38 activity in postinjury hearts plays an important role in cellular and 
myocardial remodelling by affecting both the contractility of myocytes and the 
extracellular matrix.  
 
Akt module 
AKT is a serine/threonine protein kinase that regulates a variety of cellular functions in 
different tissues. AKT is the effector of PI3K and is essential during postnatal cardiac 
development that is achieved predominantly by hypertrophy rather than hyperplasia of 
individual cardiomyocytes (Shiojima and Walsch, 2006). There are three isoforms of 
AKT, AKT1, AKT2, and AKT3. It has been shown that AKT1 KO mice have slightly 
diminished growth and that these mice are susceptible for spontaneous and stress-
induced apoptosis (Chen et al, 2001; Cho et al, 2001). AKT2 KO mice have normal 
body size but are mildly insulin resistant (Cho et al, 2001), while AKT3 KO mice have 
reduced brain size that is attributed to decrease in cell number and cell size (Easton et 
al, 2005). The combined deletion of AKT1 and AKT2 or AKT1 and AKT3 genes result 
in perinatal lethality with multiple developmental defects, indicating a large degree of 
functional overlap between the three isoforms of AKT (Bae et al, 2003; Peng et al, 
2003). On the other hand, increased AKT signalling in β-cells promotes hypertrophy 
and hyperplasia (Jetton et al, 2005), whereas increased AKT function in T-lymphocytes 
and prostate cells promotes lymphoma (Rathmell et al, 2003) and prostate cancer 
(Majumber and Sellers, 2005), respectively.  
In the heart, short-term AKT1 activation promotes physiological hypertrophy (Shiojima 
et al, 2002) whereas long-term AKT1 activation induces pathological hypertrophy 
(Kemi et al, 2008; Matsui et al, 2003). Physiological and pathological hypertrophy are 
morphologically, functionally, and molecularly distinct from each others. Physiological 
hypertrophy occurs during postnatal cardiac development and in trained athletes and is 
characterized by normal or enhanced contractile function, normal architecture, and 
organization of cardiac structure without increases in interstitial fibrosis. Clinically, 
pathological hypertrophy is observed in patients with uncontrolled hypertension, 
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myocardial infarction, and aortic stenosis. In its advanced stages, it is characterized by 
contractile dysfunction, interstitial fibrosis, and expression of foetal cardiac genes such 
as atrial natriuretic peptide and β-myosin heavy chain (β-MHC) (Mann et al, 2010; 
Shah and Solomon, 2010). Pathological hypertrophy is associated with increased 
morbidity and mortality and eventually the sustained pressure overload leads to 
myocardial contractile dysfunction, dilatation, and development of heart failure (HF) 
through poorly understood mechanisms (Mann et al, 2010; Shah and Solomon, 2010). 
In endothelial cells, brief AKT activation attenuates damage to ischaemia, whereas 
prolonged AKT activation leads to increased but unorganized blood vessel formation, 
reminiscent of tumour vasculature (Phung et al, 2006). Hence, AKT signalling plays an 
important role in maintaining vascular homeostasis and that tight control of the AKT 
signal in endothelial cells is required for normal vascular patterning and remodelling. 
Growth factors such as insulin and insulin growth factor as well as exercise activate 
AKT through its recruitment to the cell membrane and its phosphorylation at Thr 308 
and Ser 473 by PDK1 and mTORC2, respectively. On the other hand, absence of 
growth factors and sedentary lifestyle lead to decreased phosphorylation and hence 
inactivation of AKT (Kemi et al, 2008; Longnus et al, 2005). However, in stressed 
cardiac myocytes, such as in oxidative stress or in ischaemia reperfusion, AKT 
signalling and its interaction with its downstream effectors are altered or are overridden 
by other signalling pathways as discussed below. This review will address the role of 
AKT in promoting coronary angiogenesis and in modulating cardiac function with 
specific emphasis on the role of AKT in altering programmed types of cell death, such 
as autophagic and apoptotic cell death in cardiomyocytes and in HF.  
 
AKT and angiogenesis 
In endothelial cells, AKT phosphorylates a wide variety of target proteins that regulate 
cell proliferation, survival, permeability, release of nitric oxide, and cell migration 
(Shiojima and Walsch, 2002; Somanath et al, 2006). AKT is essential in vascular 
endothelial growth factor (VEGF)-mediated angiogenesis and regulates the migration of 
endothelial cells necessary for vessel sprouting, branching, and the formation of 
networks during angiogenesis via the phosphorylation of Girdin, an actin binding 
protein, at Ser 1416 to regulate its subcellular localization and cell migration in 
fibroblasts ( Enomoto et al, 2005). Kitamura et al. (2005) have shown that the delivery 
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of adenovirus harbouring Girdin short interfering RNA in Matrigel embedded in mice, 
markedly inhibited VEGF-mediated angiogenesis. Targeted disruption of the Girdin 
gene in mice impaired vessel remodelling in the retina and angiogenesis from aortic 
rings; however, Girdin was unessential for embryonic vasculogenesis. These findings 
demonstrate that the AKT/Girdin signalling pathway is essential in VEGF-mediated 
postneonatal angiogenesis. Short-term AKT activation in inducible transgenic AKT1 
mice induces physiological hypertrophy with maintained vascular density. Coronary 
angiogenesis is enhanced to keep pace with the growth of the myocardium. The increase 
in vascular density is directly related to the increase in VEGF and angiopoietin-2 during 
short-term AKT1 activation (Shiojima and Walsch, 2002; Kitamura et al, 2008). On the 
other hand, prolonged AKT activation leads to pathological hypertrophy. Under these 
conditions, VEGF and angiopoietin-2 are downregulated and capillary density is 
reduced. The decrease in coronary angiogenesis could in part explain the decrease in 
cardiac function during long-term AKT activation. It has been shown that VEGF 
blockade in pressure overload reduces capillary density and results in an accelerated 
transition from compensated hypertrophy to HF (Izumiya et al, 2006). Thus, the balance 
between cardiac growth and coronary angiogenesis is critical and that the cross-talk 
between cardiac myocytes and coronary vasculature is essential for the maintenance of 
the contractile function, especially in pathological hypertrophy and in HF.  
 
AKT and cell death 
Cardiac myocyte loss in HF via the form of necrotic, apoptotic, and autophagic cell 
death may in part contribute to the worsening in cardiac contractile function and to left 
ventricular remodelling. Strong evidence in the literature suggests that short-term 
activation of AKT have beneficial effects via the inhibition of apoptotic cell death. 
Matsui et al (1999) showed that adenoviral gene transfer of activated AKT1 protects 
cardiomyocytes from apoptosis in response to hypoxia in vitro. Cardiomyocytes were 
infected with either a control adenovirus (Ad.EGFP) or adenoviruses carrying 
constitutively active forms of PI 3-kinase (Ad.BD110) or AKT (Ad.myr-AKT-HA). 
Ad.BD110 significantly inhibited apoptosis of hypoxic cardiomyocytes compared with 
Ad.EGFP. Ad.myr-AKT-HA even more dramatically inhibited apoptosis of hypoxic 
cardiomyocytes. Moreover, adenovirus-mediated AKT1 gene transfer in the heart 
diminishes cardiomyocyte apoptosis and limits infarct size following 
69 
 
ischaemia/reperfusion injury (Matsui et al, 2001) and ameliorates doxorubicin-induced 
contractile dysfunction (Taniyama and Walsch, 2002). Beside its anti-apoptotic effect, 
AKT1 controls autophagic cell death by phosphorylating and thus inhibiting the 
translocation of forkhead box O (FOXO) family, particularly FOXO3a, from the 
cytoplasm into the nucleus and thus inhibits FOXO3a effector, BNIP3, from initiating 
mitochondrial autophagy and mitochondrial defragmentation (Mammucari et al, 2008). 
This effect of AKT is mainly seen in the presence of growth stimuli and is lost with 
their absence such as during starvation (Mammucari et al, 2007; Sandri, 2008). 
However, in stressed cardiomyocytes, AKT regulates the autophagic activity, on the 
short term, via c-Jun N-Terminal Kinases (JNKs) signaling. Our data suggest that the 
expression of the mitochondrial autophagic marker (BNIP3)is significantly upregulated 
2h after cardiomyocyte stress with phenylephrine (PE).  Moreover, Shao et al (2006)  
showed that JNKs can mediate reactivation of AKT and cardiomyocyte survival after 
hypoxic injury in vitro and in vivo. The authors demonstrate that reactivation of AKT 
after resolution of hypoxia is regulated by JNKs and suggest that this is likely a central 
mechanism of the myocyte protective effect of JNKs.  
 
AKT and calcium cycling proteins 
AKT1 signalling may also improve contractile function by influencing myocardial 
calcium cycling, which plays a critical role in contractility and relaxation of 
cardiomyocytes. During excitation of the cardiomyocyte, small calcium influx via the 
L-type calcium channels (LTCC) leads to massive release of calcium from the 
endoplasmic reticulum via the ryanodine receptors, a phenomenon known as calcium-
induced calcium release. The increase in intracellular calcium leads to contraction of the 
cardiomyocyte and to the activation of the sarcoendoplasmic reticulum calcium ATPase 
(SERCA2a), which pumps calcium from the cytoplasm into the sarcoplasmic reticulum. 
The activity of SERCA2a is inhibited by phospholamban (PLB). During diastole there 
is inhibition of PLB by its phosphorylation at two different sites; one is activated by 
protein kinase A (PKA) in response to β-adrenergic stimulation and the other is 
activated by calcium ions and calmodulin, thus promoting and enhancing the activity of 
SERCA2a. One of the other proteins that affects the function of SERCA2a is the protein 
phosphatase 1 (PP1) and its inhibitor-1 (I-1). Phosphatase 1 is a serine/threonine 
phosphatase that is localized to the sarcoplasmic reticulum and is inhibited by I-1, 
70 
 
which becomes active upon phosphorylation of threonine-35 of PLB protein by PKA. 
This results in inhibition of PP1 and therefore enhanced PKA-mediated phosphorylation 
of PLB, leading to amplification of the β-adrenergic response in the heart. AKT1 
appears to positively regulate contraction by increasing calcium influx through the 
LTCC (Catalucci et al, 2009), by increase in SERCA2a protein levels (Kim et al, 2008), 
and by augmenting PLB phosphorylation (Catalucci et al, 2009), possibly through 
down-regulation of PP1. Whether AKT1 is directly involved in the phosphorylation of 
LTCC, PLB, or in the activation of I-1 awaits further investigation.  
 
AKT and metabolism 
AKT1 modulates glucose and fatty acid metabolism. AKT may promote glucose 
oxidation by enhancing glucose uptake through glucose transporters and attenuates fatty 
acid oxidation through down-regulation of peroxisome proliferator-activated receptor-α 
(PPARα) and its coactivator, PPARγ coactivator-1(PGC-1), which transcriptionally 
activate the genes in fatty acid oxidation pathway. Under normal conditions, adenosine 
triphosphate (ATP) is produced up to 10–40% from oxidation of glucose and lactate and 
up to 60–90% from β-oxidation of free fatty acids. Fatty acids generate more ATP per 
gram of substrate than lactate or glucose, and are energy efficient, whereas glucose and 
lactate generate more ATP than fatty acids for each mole of oxygen and are oxygen 
efficient. Therefore, if the supply of oxygen is limited, glucose oxidation will provide 
more energy per equal amount of oxygen and support more work than fatty acids. 
Moreover, during ischaemia the accumulation of free fatty acids is toxic and induces 
damage to the cell membrane and death of the cell. Stimulation of glucose oxidation 
may be beneficial under ischaemic conditions, and the cardioprotective effects of 
glucose–insulin–potassium (GIK) infusion in the reperfusion phase or fatty acid 
oxidation inhibitors as shown in animal models of ischaemia reperfusion (Zhang et al, 
2006) support this notion (Diaz et al, 2007). Therefore, the cardioprotective and 
beneficial effect of short-term activation of AKT1 in the reperfusion phase may be 
attributed in part to the switch from fatty acid to glucose metabolism leading to the 
efficient myocardial consumption of oxygen.  
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Exercise and AKT signalling in heart failure 
 
Heart failure is a growing problem in the industrialized world and has reached epidemic 
proportions in the USA. Although the central effects of HF are pulmonary and 
peripheral vascular congestion, many patients believe that exercise limitation is the 
most troubling feature. Traditional therapies, such as angiotensin-converting enzyme 
inhibitors, β-blockers, and spironolactone show impressive reductions in mortality with 
somewhat less significant improvement in functional capacity. Exercise training was 
once prohibited in HF patients out of concern for patient safety. However, it is now 
recognized as a therapeutic option for improving functional capacity, especially that 
mechanical function and functional capacity do not always have a direct correlation in 
HF subjects (Davies et al, 2010). Clinical trials of exercise training in HF show 
improvements in exercise time, functional capacity, and peak oxygen consumption and 
that exercise training seemed to be safe and well tolerated in HF patients (O’Connoret 
al, 2009; Whellan et al, 2007; Gianuzzi et al, 1997; McKelvie et al, 1995). The 
cardiomyocyte signalling pathways driving this beneficial effect of exercise were not 
fully understood until recently. Miyachi et al.(2009) explored the signalling pathways 
involved in the beneficial effect of exercise on left ventricular geometry in a HF model 
of Dahl Salt-Sensitive hypertensive rats. The authors found that exercise training had a 
beneficial effect on cardiac remodelling and attenuated HF in hypertensive rats, with 
these effects likely being attributable to the attenuation of left ventricular concentricity 
and restoration of coronary angiogenesis through the activation of phosphatidylinositol 
3-kinase(p110α)-AKT-mammalian target of rapamycin signalling (Miyachi et al, 2009). 
Moreover, Konhilas et al. (2004) have shown that there are sex differences with regard 
to exercise-induced cardiac adaptation in mice. The authors found that sex/gender is a 
dominant factor in exercise performance and found that female animals have greater 
capacity to increase their cardiac mass in response to similar amounts of exercise. They 
attributed these differences to significant increase in calcium/calmodulin-dependent 
protein kinase (CaMK) activity in females compared with males in response to exercise. 
The phosphorylation of glycogen synthase kinase-3 (GSK-3) was evident after 7 days of 
cage-wheel exposure in both sexes and remained elevated in females only by 21 days of 
exercise. However, there were no sex differences with regard to exercise-induced AKT 
phosphorylation (Konhilas et al, 2004).  
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Exercise also has beneficial effects on the musculoskeletal system in HF subjects 
(Ventura-Clapier et al, 2007; You Fang and Marwick, 2003). Skeletal muscle 
abnormalities in patients with HF include atrophy of highly oxidative, fatigue-resistant 
type I muscle fibres, decreased mitochondrial oxidative enzyme concentration and 
activity, reduced mitochondrial volume and density, and reduced muscle bulk and 
strength (Ventura-Clapier et al, 2002). Exercise enhances cardiac and skeletal muscle 
metabolism by increasing mitochondrial biogenesis and by enhancing fatty acid β-
oxidation via PGC-1α signalling (Ventura-Clapier et al, 2007). Recently, Toth et 
al.(2011) have shown that chronic HF reduces AKT phosphorylation in human skeletal 
muscle compared with patients with normal cardiac function. The decrease in AKT 
phosphorylation in skeletal muscle of HF subjects could partly be related to the decrease 
in blood and nutrient supply to the highly oxidative, fatigue-resistant type I muscle 
fibres. Decrease in phosphorylated AKT in skeletal muscle will lead to decrease in 
protein synthesis and enhances protein breakdown via the activation of FOXO 
transcription factors and the transcription of E3 ubiquitin ligases important for muscle 
proteolysis such as Atrogin-1 and MurF-1. Hence, the cardiovascular and the 
musculoskeletal systems are interrelated in the sense that functional deterioration in one 
system is negatively reflected on the other one.  
 
Figure 1.7:Three different MAPK signaling pathways named ERK pathway, 
SAPK/JNK pathway, and p38 pathway  are well established and involved in the 
intracellular signaling of myocardial remodelling. From these MAPK pathways, various 
transcription factors such as Elk1, ATF-2 (CREB), AP-1, NF- B, and Sp1 are activated 
and start the transcription of target genes (Taken from Diwan and Dorn, 2007). 
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Protein kinase C 
Protein kinase C (PKC) is a family of serine/threonine kinases. PKCs are major 
mediators of signal transduction pathways and have been shown to regulate sets of 
biological functions as diverse as cell growth, differentiation, apoptosis, transformation 
and tumorigenicity (Nishizuka, 1984; Nishizuka, 1992; Nishizuka, 1995). All PKCs 
have a common general structure with 2 principal modules: a NH2-terminal regulatory 
domain that contains the membrane-targeting motifs and a COOH-terminal catalytic 
domain that binds ATP and substrates. Throughout the primary sequence of the 
enzymes, there is an alternation of conserved (C1–C4) and variable (V1–V5) regions. 
According to differences in the binding capability of their regulatory domain, the 
presently known 10 members of the PKC family have been grouped into 3 classes: the 
classical PKCs (α, β with 2 isoforms β1 and β2, γ) which are regulated by calcium, 
diacylglycerol (DAG) and phospholipids, the novel PKCs (δ, ε, θ) which are regulated 
by DAG and phospholipids but lack the calcium binding domain and the atypical 
subgroup (ζ, λ or i, the mouse ortholog of λ in humans) which are insensible to both 
calcium and DAG. The relative content of each isozyme in the heart has been a 
controversial issue since it was found as different in different species. In one of the first 
reports characterizing the expression of PKC isozymes in the heart, PKCε was 
described as the principal, if not the only PKC isozyme to be expressed in the ratheart 
(Bogoyevitsch et al, 1993). Later, many other PKC were found in the heart, principally 
PKCα, PKCδ, and PKCζ (see Mackay and Mochly-Rosen, 2001 for review). Even 
PKCγ, that was considered to be present only in the brain was found by us (Rouet-
Benzineb et al, 1996) and others (Ping et al, 1997) in the rabbitheart. However, PKCγ   
present in the heart originates from non-muscle cells and 2 PKC isozymes of the group 
of novel PKC isozymes, PKCε and PKCδ, are among the principally expressed PKCs in 
cardiomyocytes along with PKCα in human and rodenthearts. 
Although they are members of the same subgroup (the so-called novel group), PKCδ 
and PKCε mediate contrasting and even opposing effects. Overexpression of PKCε 
stimulates growth and is oncogenic in mouse, rat, and humanfibroblasts(Mischak et al, 
1993; Cacase et al, 1993; Perletti et al, 1996). In contrast, PKC-δ inhibits cell growth in 
fibroblasts(Mischak et al, 1993; Watanabe et al, 1992). When overexpressed in vascular 
smooth muscle cells, PKCδ but not PKCε induces apoptosis in response to PMA 
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(phorbol 12-myristate 13-acetate) treatment (an activator of classical and novel PKCs) 
(Mischaket al, 1993). In salivary glandacinar cells, PKC-δ is essential for etoposide-
induced apoptosis (Reyland, 1999). 
In general, PKCε appears thus as the “bad” due to its oncogenic properties. It has even 
been proposed as a tumor marker (Gorin and Pan, 2009). In contrast, PKCδ appears as 
the “good” with proapoptotic properties in cancers and it is an antioncogene. 
Surprisingly, for cardiologists, at least in the domain of ischemia, PKCε is the “good” 
since it has been shown to be a major actor in the mechanisms inducing preconditioning 
(the process by which short periods of ischemia protect the heart against a long 
ischemic period of ensuing ischemia). In contrast, inhibition of PKCδ during 
reperfusion protects the heart from reperfusion-induced damage (Budas et al, 2007) 
although both were shown to have parallel hypertrophic effects (Chen et al, 2001). 
 
PKC delta and epsilon 
PKCδ and PKCε have a 41% amino acid homology with 9% gaps. This score is 
relatively low. It can be compared to that between PKCα and PKCβ that shows 81% 
homology with 0% gaps and it is similar to that between PKCδ and PKCζ (39% 
homology with 5% gaps) which are members of 2 different subgroups (novel and 
atypical). The structural differences between PKCδ and PKCε lie not only in the 
variable domains but also in the C1 and C2 regions of the regulatory domain. 
In contrast with preconditioning to ischemia in which PKCδ and PKCε have opposite 
roles, both act in the same direction during the development of hypertrophy (Chen et al, 
2001). The activation of PKCε may be a factor that induces ventricular hypertrophy 
with its positive effect on cell growth. In this line, the relation between PKCε and the 
cytoskeleton is a mechanism that potentially initiates hypertrophy via phosphorylation 
of proteins in the costameres, which then transmit signalling to the Z-disk for parallel or 
series addition of thin filaments regulated via actin capping ( Russel et al, 2010). 
The activation of PKCε was shown during stretch of cardiomyocytes (Vincentet al, 
2006). In isolated guinea-pighearts, stretch, one of the principal activators of ventricular 
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hypertrophy, has been shown to induce a PKCε translocation to membranes that was 
partially inhibited by losartan (Paul et al, 1997). In vivo, an induction of concentric 
cardiac hypertrophy with an overexpression of constitutively active PKCε (Takeishi et 
al, 2000) or with the expression of cardiac specific PKCε activator (Mochly-Rosen et 
al, 2000) was shown. The effect of PKCε is in general considered to lead to a concentric 
hypertrophy. However, in mice overexpressing PKCε (Goldspink et al, 2004), the 
evolution of hypertrophy was quite deleterious since it led to a dilated cardiomyopathy. 
Thus, the effect of PKCε may differ depending upon its level of expression. 
PKC activity has been generally described as increased with different behaviours of 
different isozymes. In general, PKCε and PKCδ increased content and translocation 
towards the membrane fraction were found but this is not a universal finding in all types 
of hypertrophy. In aortic banding in rats(Gu and Bishop, 1994), guinea pigs Takeishi et 
al, 1999) and in severe human aortic stenosis (Simonis et al, 2007) an increased 
concentration of PKCε was found in membranes. In contrast, PKCδ content was found 
as unchanged in nuclear–cytoskeletal fraction in the model of rat aortic banding (Gu and 
Bishop, 1994). Other workers found the same translocation in a completely different 
type of hypertrophy, right ventricular hypertrophy induced by pulmonary hypertension 
due to chronic hypoxia in rats (Morel et al, 2003). However, opposite results were 
described in hypertrophy or heart failure by others (Mohammadi et al, 1997; Fryer et al, 
1998; Rouet-Benzineb et al, 1996; Braun et al, 2004, Koide et al, 2003; Bowling et al, 
1999). In human failing hearts, left ventricular PKCε content was decreased (Bowlinget 
al, 1999). In rabbit left ventricular hypertrophy (Mohammadi et al, 1997) and heart 
failure (Rouet-Benzineb et al, 1996), researchers have found a decreased cardiac 
content of PKCε and a similar down-regulation was demonstrated  in a model of genetic 
hypertension while PKCδ was unaffected (Fryer et al, 1998). In contrast, PKCε activity 
was found to be unchanged in rat aorto-caval fistulas while PKCδ was increased (Braun 
et al, 2004). During the development of heart failure in Dahl salt sensitive rats, PKCε 
and PKCδ contents were increased in the hypertrophy phase but PKCε content tended to 
be in heart failure while PKCδ remained elevated (Koide et al, 2003). Thus, although 
PKCε is an actor in the development of hypertrophy, its expression in the myocardium 
and its translocation are not found as increased in all models. 
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Many interactions of PKCε with other proteins have been published. Using proteomic 
analysis, PKCε was shown to be associated with at least 36 proteins including the 
potential downstream targets of PKCε, such as Src and Lcktyrosine kinases, mitogen-
activated protein kinases (p38 MAPKs, JNKs, and ERKs), and upstream modulators of 
PKCε, such as PI3 kinases and their substrate, PKB/Akt (Ping et al, 2001). As 
previously noted, these kinases had also been implicated in preconditioning, suggesting 
a potentially important mechanisms for the transmission and integration of signals 
during preconditioning. The presence of two isozymes of nitric oxide synthase (NOS) 
(inducible [iNOS] and constitutive [eNOS]) in the PKCε signalling complexes was also 
found (Ping et al, 2001). 
PKCε has been shown to bind scaffold proteins. The first interaction of this type has 
been that of PKCε with AKAP79/150 that also binds the phosphatase PP2B, calcineurin 
(Klauck et al, 1996). PKCε and calcineurin were shown to bind an anchoring protein 
called CG-NAP in the Golgi in a hypophosphorylated inactive form PKCε and we also 
found a direct interaction between this kinase and this phosphatase during cellular 
stretch (Vincent et al, 2006). Actin filaments also function as scaffold proteins for 
signaling complexes. In the central nervous system, a protein–protein interaction of 
PKCε with actin, unique to PKCε (Prekeris et al, 1996), was shown to be sufficient to 
maintain PKCε in a catalytically active conformation, thereby, eventually regulating 
cytoskeletal dynamics (Prekeris et al, 1998; Nakhost et al, 1998). In the heart, F-actin 
bound PKCε selectively over PKCδ (Huang and Walker, 2004) and it was shown that 
the binding interface between PKCε and cardiac myofilaments was mainly on the V1 
region of PKCε and the interface between PKCε and F-actin was mainly on the C1 
region of PKCε (Huang and Walker, 2004). 
 
PKCalpha  
With respect to the conventional isoforms, PKCα is the predominant subtype expressed 
in the mouse, human, and rabbit hearts, while PKCβ and PKCγ are detectable but 
expressed at substantially lower levels (Hambleton et al, 2006; Pass et al, 2001; Ping et 
al, 1997). Numerous reports have also associated PKCα activation or an increase in 
PKCα expression with hypertrophy, dilated cardiomyopathy, ischemic injury, or 
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mitogen stimulation (Dorn and Force, 2005). For example, haemodynamic pressure 
overload in rodents promotes translocation and presumed activation of PKCα during the 
hypertrophic phase or during the later stages of heart failure (Gu and Bishop, 1994; 
Jalili et al, 1999; De Windt et al, 2000; Bayer el al, 2003; Braun et al, 2002). Increased 
expression of PKCα was also observed following myocardial infarction (Wang et al, 
2005; Simonis et al, 2007). Human heart failure has also been associated with increased 
activation of conventional PKC isoforms, including PKCα (Simonis et al, 2007; 
Bowling el al, 1999). Thus, PKCα fits an important criterion as a therapeutic target; its 
expression and activity are increased during heart disease. 
A number of independent molecular mechanisms have been associated with the known 
protection from heart failure by PKCα inhibition, although all of these mechanisms have 
so far been associated with modulation of cardiac contractility. The first identified 
mechanism whereby PKCα inhibition enhances cardiac contractility is through SR Ca2+ 
loading (Braz el al, 2004). Specifically, PKCα phosphorylates inhibitor 1 (I-1) at Ser67, 
resulting in greater protein phosphatase 1 activity, leading to greater phospholamban 
(PLN)  and less activity of the SR Ca
2+
 ATPase (SERCA2) pump (Braz et al, 2004). 
Less SERCA2 activity reduces SR Ca
2+
 load leading to reduced Ca
2+
 release during 
systole, hence reduced contractility. Thus, inhibition of PKCα with a drug or dominant 
negative mutant would reduce PP1 activity for PLN, making PLN less inhibitory 
towards SERCA2 and leading to mild enhancements in SR Ca
2+
 load to augment 
contractility. Greater SR Ca
2+
 loads and cycling have been shown to benefit the mouse 
from numerous insults that would otherwise cause heart failure (Dorn and Molkentin, 
2004). Indeed, gene therapy trials using SERCA2 overexpression in the hearts of 
humans with failure have already shown early promise. 
Another mechanism whereby PKCα can directly alter cardiac contractility is through 
phosphorylation of G-protein-coupled receptor kinase 2 (GRK2). Indeed, cardiac-
specific activation of PKCα led to increased GRK2phosphorylation and activity, blunted 
cyclase activity, and impaired β-agonist-stimulated ventricular function (Malhota et al, 
2010). GRK2 is known to directly control β-adrenergic receptor function and cardiac 
contractility (Koch, 2004). Consistent with these observations, mice overexpressing the 
cPKC activating peptide in the heart showed uncoupling in β-adrenergic receptors 
(Hahn el al, 2003). 
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PKCα also appears to directly phosphorylate key myofilament proteins including 
cardiac troponin I (cTnI), cTnT, titin, and myosin binding protein C, which leads to 
decreased myofilament Ca
2+
 sensitivity and reduced contractility in myocytes (Belin et 
al, 2007; Sumandea et al, 2003; Kooij et al, 2010; Hidalgo et al, 2009). These 
myofilament proteins could also be phosphorylated by other cPKC isoforms (Huang et 
al, 2001; Wang et al, 2006). Moreover, PKCα has also been shown to phosphorylate the 
α1c subunit of the L-type Ca2+ channel , an effect that could alter contractility as well 
(Yang et al, 2009). Similarly, PKCβI, βII, and γ can also phosphorylate serine residues 
in the α1c subunit (Yang et al, 2009). These data further suggest the possible 
promiscuous nature of the cPKCs in the regulation of protein phosphorylation, Ca
2+
 
cycling, and cell contractility. Despite these similarities in targets, PKCα functions are 
different from PKCβ and γ in altering contractility because adult cardiac myocytes from 
PKCβ overexpressing TG mice showed increased Ca2+ transients and increased 
contractility (Huang et al, 2001), while PKCα overexpressing TG mice showed 
depressed cardiac contractility (Braz et al, 2004). Moreover, myocytes from adult PKCα 
null hearts showed increased contractility and augmented Ca
2+
 transients (Braz et al, 
2004). 
In addition to these specific molecular targets that all appear to alter cardiac 
contractility, it remains possible that inhibition of PKCα protects the myocardium 
through other unknown mechanisms that are unrelated to contractility. For instance, 
PKC-mediated phosphorylation has been correlated with myofibril degeneration in 
cardiomyocytes, while preservation of myofilament integrity may represent another 
potential mechanism for the beneficial effects of PKC inhibition (Sussman et al, 1997). 
Other potential PKCα targets may include structural proteins, signalling proteins, and 
transcription factors (Palaniyandi et al, 2009). Outside of a myocyte intrinsic effect, 
PKCα inhibition can also protect the entire cardiovascular system by limiting thrombus 
formation through a platelet specific mechanism (Konopatskaya et al, 2009). 
The results in genetically modified animal models and in isolated adult myocytes 
clearly show a cardioprotective effect with PKCα inhibition. Such results suggested that 
a nontoxic and tissue available pharmacological inhibitor with selectivity toward PKCα 
might be of significant therapeutic value. Thus, the effects of cPKC inhibitors of the 
bisindolylmaleimide class, such as ruboxistaurin (LY333531), Ro-32-0432, or Ro-31-
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8220, were tested in different rodentheart failure models. For example, short-term 
infusion of Ro-32-0432 or Ro-31-8220 significantly enhanced contractility and left 
ventricular developed pressure in isolated mouse hearts (Hambleton et al, 2006). 
Importantly, Ro-31-0432 or Ro-31-8220 did not significantly augment cardiac 
contractility in PKCα−/− mice, strongly supporting the conclusion that the biological 
effect of the bisindolylmaleimide compounds on contractility are due to PKCα. 
Moreover, general activation of both classic and novel PKC isozymes in the heart by 
short-term infusion of PMA produces a dramatic decrease in contractility in wild type 
mice but not in PKCα−/− mice (Hambleton et al, 2006). This result also suggests that 
PKCα is the primary negative regulator of cardiac contractility after global activation of 
all PKC isozymes in the heart. With respect to heart failure, short-term or long-term 
treatment with Ro-31-8220 in the Csrp3 null mouse model of heart failure augmented 
cardiac contractility and restored pump function. PKC inhibition with Ro-31-8220 or 
Ro-32-0432 also reduced mortality and cardiac contractile abnormalities in a mouse 
model of myotonic dystrophy type 1 (DM1) (Wang et al, 2009). 
Another PKCα/β inhibitor, ruboxistaurin, has been through late-stage clinical trials for 
diabetic macular edema and shown to be well tolerated and hence was extensively 
analyzed in both mouse and rat models of heart failure (The PKC-DRS Study Group, 
2007). Although ruboxistaurin was originally reported to be PKCβ selective (Jirousek et 
al, 1996), it is equally selective for PKCα (IC50 of 14 nmol/L for PKCα versus 19 
nmol/L for PKCβII). Moreover, given that PKCα protein levels are much higher than 
PKCβ in the human and mouse hearts(Hambleton et al, 2006), it further suggests that 
ruboxistaurin functions predominantly through a PKCα-dependent mechanism. 
Ruboxistaurin increased baseline contractility by 28% in rats with acute infusion 
(Hambleton et al, 2006),  Acute infusion of ruboxistaurin also augmented cardiac 
contractility in wild type and PKCβγ–/– mice but not PKCα–/– mice ( Liu et al, 2009). 
These results indicate that ruboxistaurin enhances cardiac function specifically through 
effects on PKCα but not PKCβ or PKCγ. Ruboxistaurin also prevented death in wild 
type mice throughout 10 weeks of pressure overload stimulation, reduced ventricular 
dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary 
edema comparable to or better than metoprolol treatment (Liu et al, 2009). 
Ruboxistaurinwhen administered to PKCβγ null mice subjected to pressure overload, 
resulting in less death and heart failure, further suggesting PKCα as the primary target 
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of this drug in mitigating heart disease (Liu et al, 2009). In addition, Boyle et al. (2005) 
showed that ruboxistaurin reduced ventricular fibrosis and dysfunction following 
myocardial infarction in rats. Ruboxistaurin treatment also significantly decreased 
infarct size and enhanced recovery of left ventricular function and reduced markers of 
cellular necrosis in mice subjected to 30 min of ischemia followed by 48 h of 
reperfusion (Kong et al, 2008). Connelly et al. (2009) demonstrated that ruboxistaurin 
attenuated diastolic dysfunction, myocytehypertrophy, collagen deposition, and 
preserved cardiac contractility in a rat diabetic heart failure model. These results in 
rodents overwhelmingly support the contention that PKCα inhibition with ruboxistaurin, 
or related compounds, protects the heart from failure after injury. Hence, cPKC 
inhibitors, such as ruboxistaurin, should be evaluated in heart failure patients, especially 
given its apparent safety in late phase clinical trials in humans (The PKC-DRS Study 
Group, 2007). A related cPKC inhibitory compound from Novartis, AEB071, was also 
shown to be safe in human clinical trials for psoriasis and could be a candidate for 
translation in the heart failure area (Skvara et al, 2008). 
While there is a clear need for novel inotropes to support late-stage heart failure, there 
may also be a therapeutic niche in the earlier stages of heart failure if the inotrope is 
selective. One unique aspect associated with PKCα inhibition is that contractility is only 
moderately increased, which may have a safer profile compared with traditional 
inotropes. In addition, PKC inhibition is not subject to significant desensitization as is 
characteristic of β-agonists (Hambleton et al, 2006). More importantly, PKCα inhibition 
has a prominent effect on SR Ca
2+
 cycling and the myofilament proteins as a means for 
altering cardiac contractility. These mechanisms of action are significantly downstream 
of how traditional β-adrenergic receptor agonists function and hence might bypass the 
negative effects of traditional inotropes that promote arrhythmia and myocyte death. 
The inhibition of PKCα may also benefit a failing myocardium independent of 
contractility regulation because PKCα is involved in reactive signalling within the heart 
that participates in hypertrophy, pathological remodelling, and decompensation. 
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The diabetic heart  
Diabetic Cardiomyopathy; phenotypic characteristics and potential 
pathophysiological mechanisms  
The diabetic cardiomyopathy’s progression seems to be divided into three stages. The 
early stage is characterized by metabolic disturbances (glucose, fatty acid metabolism, 
Ca homeostasis etc), without significant functional and structural cardiac changes. At 
the middle stage, necrosisand apoptosis of the myocytes lead to fibrosis and 
hypertrophy. The left ventricle’s mass begins to increase and the diastolic function is 
altered. The systolic function may be normal. Hypertrophy and diastolic abnormalities 
are observed most commonly and earlier than systolic abnormalities. The late stage of 
the diabetic cardiomyopathy is characterized by changes in the small vessels and 
increased left ventricle’s mass. Both the diastolic and systolic function is altered (Fang 
et al, 2004). 
The body weight is significantly smaller in streptozotocin-induced diabetic rats than in 
control rats. On the contrary heart weight and the left ventricular weight normalized for 
the body weight were higher in diabetic rats. The higher left ventricular mass 
normalized for body weight reveals the eccentric hypertrophy in this ventricle. The end-
diastolic and the end-systolic dimensions were similar in diabetic and control animals, 
but when corrected for body weight were higher in the diabetic groups (Bollano et al, 
2006).The left ventricular end-diastolic pressure was higher,but the dP / dT  was 
depressed in these animals. These results indicate the diastolic and systolic dysfunction 
in the diabetic heart. The heart rate was significantly lower in diabetic rats. There was 
also a collagen content significantly higher in diabetic left ventricular tissues (Bollano 
et al, 2006). 
 
Changes in contractile proteins  
Alterations in proteins involved in the regulation of the actomyosin system, (Malhotra 
and Sanghi, 1997) and a shift in the myosin heavy chain from type α to β (Takeda et al, 
1998), have been observed in diabetic myocardium resulting in reduced systolic tension 
development. Calcium homeostasis is also affected in diabetic heart. Sarcoplasmic 
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reticulum calcium pump protein (SERCA2a) expression is reduced with reduced 
sarcoplasmic reticulum calcium sequestration and intracellular calcium overload, a 
situation which may account for the impaired relaxation (Depre et al, 2000). There is 
also a reduction in the sarcoplasmic reticulum Ca-ATPase (Abe et al, 2002) and in 
sarcolemmal Na/K ATPase and Calcium-binding activities.  
 
Changes in metabolism  
Metabolic changes in diabetic heart consist of a defect in the utilization of the glucose 
(Chen et al, 1984). This is caused by the depletion of glucose transporters (GLUT 1-
GLUT 4), that carry glucose across the sarcolemmal membrane (Eckel and Reinauer, 
1990; Garvey et al, 1993) and by the down-regulation of the glycolytic proteins. The 
glucose uptake from the diabetic heart is also reduced because of the insulin deficiency 
or resistance (Kaestnet et al, 1991; Kinulainen et al 1994). Insulin deficiency reduces 
the activation of glycogen synthase and phosphatase activity (Miller, 
1983).Furthermore, the enhanced fatty acid oxidation exerts an inhibitory effect on 
glucose oxidation (Liedtke et al, 1988) and consequently on the entry of glucose into the 
cardiac cell. Thus, the cardiac metabolism is shifted from the glucose utilization towards 
the free fatty acids. The enhanced fatty acid metabolism leads to the accumulation of 
toxic intermediates (Rodrigues et al, 1998).The inhibition of glucose oxidation by the 
fatty acids could be a major factor for the development of diabetic cardiomyopathy. 
 
Apoptosis/necrosis  
Increased cell death is another characteristic of diabetic cardiomyopathy. Loss of 
myocytes leads to impaired cardiac function, in adult myocardium. Oxidative stress 
caused by reactive oxygen and nitrogen species due to hyperglycemia may activate the 
process of apoptosis and myocyte necrosis (Venero et al, 2005). On the other hand, 
necrosis causes extracellular widening and deposition of collagen in a diffuse or 
scattered manner (Falcao-Pires et al, 2009; Jin et al, 2009). Collagen deposition is 
referred to an increase in type III collagen in the diabetic heart (Falcao-Pires et al, 
2009). 
83 
 
The Streptozotocin-induced type 1 diabetic rat model 
A significant part of the current understanding of the pathophysiology and pathogenesis 
of cardiac disease in DM can be attributed to experimentation in the rodent model 
system. The rodent model shares many phenotypic similarities to human disease and 
meaningful correlates can be drawn in metabolism and physiology. With regard to the 
influence of DM on cardiac structure and function, rat models have been effectively 
used to study structural phenotypes, physiology of altered energy flux and storage, 
insulin secretion and action and numerous other metabolic parameters (McNeill, 1999; 
Kahn, 2005). Considering the limitations of invasive testing in human tissues and 
ethical and logistical constraints herewith, rat models provide invaluable opportunities 
to study detailed molecular mechanisms underlying the pathophysiology of diabetes in 
controlled conditions accounting for microbiological, chemical, genetic and 
environmental factors. Other advantages include relatively short generation intervals, 
adaptability to invasive testing and other economic considerations. 
Rat models mimicking physiological and pathological states unique to each diabetes 
subtype have been developed to investigate inherent etiopathologic 
heterogeneities.Chemically induced type-1 diabetes is by far the most common model 
of animal DM and frequently involves administration of agents that produce the desired 
pathology by producing toxic effects on the beta cells of the pancreas. Alloxan and STZ 
are widely used diabetogenic agents owing to their specific action on β cells resulting in 
lesions that quite accurately resemble β cell destruction characteristic of T1DM and the 
sustenance of a relatively permanent diseased state to enable investigation of chronic 
effects of DM (Lenzen, 2008). Compared to alloxan (cyclic urea analog), STZ is 
reported to have a greater specificity to β cells, a longer half life and is associated with 
lower mortality rates (Lenzen, 2008), making it the agent of choice for chemical 
induction of experimental diabetes in this study. 
The antimicrobial STZ [2-deoxy-2(3-methyl-3-nitrosourea)1-D-glucopyranose], is a 
product of Streptomyces achromogens and has been used as a chemotherapeutic 
alkylating agent.  Declared diabetogenic in 1963, by Rakieten et al., STZ results in a 
metabolic milieu characterised by insulinopenia termed ‘STZ-diabetes’  resulting from 
targeted β  cell necrosis via processes of methylation, free radical generation and NO 
production. Post administration, the GLUT-2 transporter transports STZ into pancreatic 
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cells wherein it generates highly reactive carbonium ions(CH
3+
) that alkylate and 
fragment DNA bases along a defined sequence of events. DNA damage results in the 
activation and overstimulation of the pro-survival, cell repair nuclear enzyme 
poly(ADP-ribose) polymerase and concomitant reduction in β cell NAD+ and ATP 
stores (Sandler and Swenne, 1983; Elsner et al., 2000). This alteration in redox states 
and histological changes in the affected cells ultimately result in β cell necrosis. Other 
supplementary hypotheses in the diabetogenic potential of STZ include its ability to act 
as an intracellular nitric oxide (NO) donor, generating 3',5'-cyclic guanosine 
monophosphate (cGMP) and NO that participate in DNA damage by inhibiting 
aconitase (Turk et al., 1993). Finally, the participation of STZ in xanthine metabolism 
has been associated with increases in ROS that may further accelerate cell death and 
inhibition of insulin synthesis (Nukatsuka et al., 1990). In aggregate, these mechanisms 
result in deficits in insulin biosynthesis, glucose-induced insulin secretion and glucose 
transport and metabolism culminating in diabetes that resembles human hyperglycemic 
nonketotic DM (Weir et al., 1981).  
 
Impact of diabetes on cardiac remodeling after myocardial infarction 
Cardiac remodelling may be viewed as stress response to an index event such as 
myocardial ischaemia or imposition of mechanical load which leads to a series of 
structural and functional changes in the viable myocardium. Early in the course of this 
process, a variety of compensatory mechanisms are in operation, such as activation of 
neuro-hormonal and inflammatory systems. In the short term, this response seems to 
restore cardiovascular function to a normal homeostatic range but with time, sustained 
activation of these systems can lead to secondary end–organ damage (Swynghedauw, 
1999).  
Conflicting data are available concerning the effects of diabetes on post-AMI LV 
remodelling. Furthermore, considerable controversy exists regarding the underlying 
pathophysiological mechanisms. In streptozotocin (STZ)–induced hyperglycemia, AMI   
exacerbated LV chamber dilatation and contractile dysfunction (Shiomi et al, 2003). In 
diabetic MI mice models, apoptosis in association with interstitial fibrosis were more 
enhanced in diabetic post-MI hearts (Matsusaka et al, 2006).Similarly, STZ-induced 
diabetes in rats resulted in prolonged cardiomyocyte apoptosis after MI (Backlund et al, 
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2004). Enhanced apoptosis was found to be in parallel with increased LV enlargement 
and fibrosis (Backlund et al, 2004). 
In a model of type 2 diabetes in  rats, heart failure progression was accelerated 8 wk 
after coronary artery ligation as assessed by enhanced LV remodelling and contractile 
dysfunction, (Chandler et al, 2007). This response was accompanied by greater 
increases in atrial natriuretic factor and skeletal alpha-actin, while a decrease in 
peroxisome proliferator-activated receptor-alpha-regulated genes in association with 
increased myocardial triglyceride levels were observed (Chandler et al, 2007). These 
results indicate that diabetes may accelerate post-MI remodelling through mechanisms 
which are not fully understood. 
 
New insights in cardiac remodelling:the role of thyroid hormone  
Heart failure remains one of the main causes of death in the modern world despite the 
advances in the treatment of this syndrome (Morrissey et al., 2010; Roger, 2010). 
Current therapies are rather limited to medical treatments aiming to optimize cardiac 
haemodynamics than to restore the damaged myocardium. The potential of rebuilding 
the injured heart has only recently been appreciated with cell base therapies to be a 
promising therapeutic approach.  However, despite the progress made in this field, there 
still remain issues of the optimal cell type to transplant, cell delivery, homing  of the 
cells, electrical coupling and so forth (Tongers et al., 2011).  
A growing body of evidence obtained from studies on nature’s models of regeneration 
reveals that a natural healing process may exist in the heart (Chablais et al., 2011; 
Schnabel et al., 2011). The  concept of tissue regeneration  has been described in  Greek  
mythology  with  chained  Prometheus to watch his own liver regenerate every time it 
was devoured by an eagle and Hydra  to regenerate its many heads  The potential of 
cardiac muscle regeneration has been an issue discussed as early as 1852. Interestingly,  
Zielonko, in 1874, under the supervision of Virchow,  did the first experimental work  
studying hearts from  rabbits and frogs and came to the conclusion that hypertrophy is 
not only due to the enlargement of individual muscle fibers but also to cellular 
hyperplasia.  Since then the issue remains largely controversial due to the lack of 
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understanding of the underlying mechanisms of this process (King, 1940; Robledo, 
1956). 
The importance of thyroid hormone (TH) in organ remodelling has been recently 
revealed in studies concerning   models of tissue and organ  regeneration  such as  the  
amphibian metamorphosis or the zebra fish regeneration  (Bouzaffour et al., 2010; 
Furlow and  Neff, 2006; Jopling et al., 2010; Sato et al., 2007; Slack et al., 2008). 
Intriguingly, the process of amphibian metamorphosis that allowed life to emerge from 
the aquatic environment to earth is entirely dependent on TH. This gene programming is 
evolutionary conserved in mammals with TH being  critical for  embryonic heart 
development and the control of various aspects of regeneration  by reactivating 
developmental gene programming  later in adult life (Pantos et al., 2011a).  
 
Thyroid hormone and cardiac remodeling  
 
Re-activation of the fetal phenotype: a window for regeneration 
 
Cardiac remodeling is a stress response process to an index event such as ischemia, 
mechanical loading, metabolic alterations etc. Early in this process, a variety of 
compensatory mechanisms are in operation, such as activation of the inflammatory and 
neuro-hormonal systems. In the short term, this response seems to restore 
cardiovascular function to a normal homeostatic range but with time, sustained 
activation of these systems can lead to end-organ damage. One of the main 
characteristics of this response is the reactivation of the fetal gene programming that 
drives cells to de-differentiate. Thus, features of fetal heart metabolism re-emerge and 
include the preference of glucose metabolism over fatty acids as substrates for energy 
provision while early response genes, such as c-myc and c-fos are highly expressed with 
isoform switches of many other proteins, including metabolic enzymes and sarcomeric 
proteins (decrease in α -MHC and increase in β-MHC expression) (Rajabi et al., 2007; 
Swynghedauw, 1999; Taegtmeyer et al., 2010). The physiological relevance of the 
return of the heart to fetal gene programming remains still a debatable issue.  Heart 
failure physiologists view this process as a maladaptive response which leads to the 
progressive decline in cardiac function. However, fetal re-programming may also result 
in a ‘low energy state’ which adapts and protects the damaged myocardium upon stress 
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(Rajabi et al., 2007). In fact, the remodeled myocardium appears to be resistant to 
hypoxia or ischemia–reperfusion injury (Pantos et al., 2005b; Pantos et al., 2007b). 
An expanded view regarding the biological significance of the reactivation of fetal 
phenotype after stress comes recently from observations showing that amphibians or 
mammals can retain the ability to regenerate at early stages of development (Slack et al., 
2008; Herdrich et al., 2011; Porrello et al., 2011). Thus, the return to fetal phenotype 
which occurs after stress may be  thought as a permissive state for regeneration 
(Witman et al., 2011).  In fact, de-differentiated cells retain the ability to proliferate and 
/ or grow and then to re-differentiate to specialized cells that comprise the regenerated 
structure or organ (Bouzaffour et al., 2010; Jopling et al., 2010; Odelberg, 2002). This 
mechanism appeared early in species evolution and allowed living organisms to adapt to 
the environmental stresses (Sanchez Alvarado, 2000).  The molecular control of this 
process until now remains largely unknown. 
 
Thyroid hormone (TH) :  the same player in organ embryonic development and 
response to stress  
The potential link of  TH to organ development and regeneration  has been  revealed in 
studies on  the amphibian metamorphosis (Sato et al., 2007). Amphibian metamorphosis 
is one of the natures’ paradigms of tissue and organ remodeling and this process seems 
to be entirely controlled by TH. Almost 100 years ago, Gudernatsch made 
theremarkable discovery that equine thyroid extracts could accelerate the 
metamorphosis oftadpole into juvenile frogs (Gudernatsch, 1912). Since then, several 
studies, if not all, have shown that themorphological and functional changes of 
metamorphosis are the result of alterations inthe transcription of specific sets of genes 
induced by TH (Berry et al., 1998; Shi et al., 2001; Furlow et al., 2004; Furlow and  
Neff, 2006). 
 
Action of TH 
Thyroxine (T4) is secreted by thyrocytes and enters the cell through various 
mechanisms. Passage of T4 may be passive, given the lipophilic nature or transporter- 
and energy-dependent (Hennemann, 2005). T4 is converted to triiodothyronine (T3) by 
deiodinases which are seleno-proteins (type-1 and type-2 deiodinases, D1 and D2), 
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while T3 is degraded by type-3 deiodinase, D3 (Bianco et al., 2002). D1 can also 
inactivate TH by converting T4 to reverse T3 (rT3) (Bianco and  Kim, 2006). Cellular 
actions of TH may be initiated within the cell nucleus, at the plasma membrane, in the 
cytoplasm, and at the mitochondrion.  
Thyroid hormone system seemsto be an ancestral hormone system and interestingly, 
thyroid hormone receptor (TR) geneis present at the base of biletarians before TH 
production, indicating an importantphysiological role of this receptor. Living organisms 
acquired the ability of producing THwith increasing evolutionary complexity (Bianco et 
al., 2002).TH nuclear receptors (TRs) mediate the biological activities of T3 via 
transcriptional regulation. Two TR genes, αand β, encode four T3-binding receptor 
isoforms (α1, β1, β2, and β3). The transcriptional activity of TRs is regulated at multiple 
levels. Besides being regulated by T3, transcriptional activity depends on the type of TH 
response elements located on the promoters of T3 target genes, by the developmental- 
and tissue-dependent expression of TR isoforms, and by nuclear co-regulatory proteins. 
Nuclear co-regulatory proteins modulate the transcription activity of TRs in a T3-
dependent manner. In the absence of T3, co-repressors act to repress the basal 
transcriptional activity, whereas in the presence of T3, co-activators function to activate 
transcription.  In addition to ligand binding, phosphorylation events play important roles 
in nuclear receptor action at the molecular level including modulation of hormone 
binding, co-factor recruitment, ligand-dependent gene transcription and cytosolic-
nuclear trafficking.  Phosphorylation of TRs is mediated via kinase intracellular 
signaling (Nicoll et al., 2003).  
The distinct function of TR isoforms has been identified by phenotypic analysis of  
mutant mice strains, in transfection studies and in studies using thyroid analogs  
(Kinugawa et al., 2001; Flamant and  Samarut, 2003; Kinugawa et al., 2005; Pantos et 
al., 2005a; Pantos et al., 2007d; Pantos et al., 2008c).  TRα1 seems to be critical for 
most of TH actions in cardiac and non cardiac tissues. Thus, TRα1 ensures the 
maintenance of homeostasis by controlling heart rate ( Wikstrom et al., 1998; Tavi et 
al., 2005), adaptive thermogenesis (Wikstrom et al., 1998) stress response (Venero et 
al., 2005), and food intake (Pantos et al., 2005a; Pantos et al., 2007d). Furthermore, 
TRα1 controls DNA damage–induced tissue repair (Kress et al., 2008). TRα1 is 
predominantly expressed in the myocardium and regulates important genes related to 
the contractile function, pacemaker activity, conduction and metabolism. Thus, myosin 
isoform expression ( Kinugawa et al 2001; Flamant and Samarut, 2003; Kinugawa et 
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al., 2005; Pantos et al., 2005a; Pantos et al., 2007d; Pantos et al., 2008c), SERCA 
inhibitory protein phospholamban (PLB) (Belakavadi et al., 2010), connexin-43 (Stock 
and  Sies, 2000), potassium channels (Gloss et al., 2001; Mansen et al., 2011) and 
glucose utilization  are all found to be regulated by TRα1 (Esaki et al., 2004).   
 
TH and the developing heart  : the relevance of TRα1  receptor  
 
The role of TH as developmental signal has been demonstrated in several studies with 
Xenopus laevis to be an ideal system for ascertaining the developmental roles of TH 
and its receptor (Slack et al., 2008). Interestingly, this system reveals that regulation of 
TH/TR axis can allow the same simple molecule TH to induce completely opposite 
morphological responses in distinct tissues. In this context, TRα seems to play an 
importantphysiological role due to its dual function (liganded  vs  un-liganded state). 
Thus, at earlydevelopmental stages in which TH is low, TRα receptor is highly 
expressed and atits un-liganded state acts as a repressor of TH positive regulated genes 
andprevents precocious metamorphosis (Sato et al., 2007). At later stages, the rise in TH 
levels resultsin the conversion of the un-liganded to the liganded TRα state and triggers 
celldifferentiation and completes metamorphosis (Furlow & Neff, 2006). Similarly, in 
mammals, during fetal life, TRα1 is increased while TH levels remain low and 
decreases after birth with the rising of the circulating TH (White et al., 2001). 
Based on this evidence, subsequent studies using mammal cell based models have 
shown that this developmental program has been conserved in mammals. Thus, in the 
embryonic heart derived cell line (H9c2) which is considered  an established model to 
study skeletal and heart muscle differentiation,  TH was shown to be critical in this 
process ( van der Putten et al., 2002;  van der Heide et al., 2007). In fact, intracellular 
T4 and T3 increase during the progression of cell differentiation with a concomitant 
increase in the expression of TRα1 and this response could be  prevented by 
pharmacological inhibition of thyroid hormone binding to TRα1 (van der Putten et al., 
2002; van der Heide et al., 2007; Meischl et al., 2008; Pantow et al., 2008c). The 
potential role of TRα1 in cell differentiation/de-differentiation process has been further 
documented in transfection studies using   neonatal cardiomyocytes. Thus, neonatal 
cardiac cells over-expressingTRα1 and treated with TH were able to differentiate into 
adult cardiac cells (Kinugawa et al., 2005). On the contrary, untreated cardiomyocytes 
remained undifferentiated and this response was characterized by an increase in cell 
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growth with a fetal pattern of myosin heavy chain (MHC) isoform expression 
(Kinugawa et al., 2005).  This novel action was shown to be a unique feature of TRα1 
receptor. In fact, the over-expression of TRβ1 could promote cell differentiation 
regardless the presence or absence of TH.  
The effect of TH on cell differentiation appears to be mediated via the activation of 
distinct kinase signalling pathways. Thus, transient activation of ERK is involved in TH 
induced changes in cell shape while the effect on cell growth is p38 MAPK and/or 
mTOR dependent (Kinugawa et al., 2005; Pantos et al., 2007e;  Ojamaa, 2010). These 
data have recently been confirmed in fetal ovine cardiomyocytes (Chattergoon et al 
2011). 
 
TH and the response of the myocardium to stress: the relevance of TRα1 receptor  
 
There is a growing body of evidence that  a fetal pattern of thyroid hormone signalling 
is reactivated in the damaged myocardium which may be of physiological relevance 
(Witman et al., 2011). Thus, myocardial ischemia  was shown to  induce various 
changes in TH–TR homeostasis  which closely resemble those occurring during 
embryonic development  of the heart (Pantos et al., 2008b). The most characteristic 
feature of this response is the re-expression of TRα1 along with the increased activation 
of growth kinase signaling (ERK and mTOR) during the development of reactive 
cardiac hypertrophy and its decline during the transition to heart failure (Pantos et al., 
2010). This association indicates that a potential link of TRα1 to growth signalling may 
exist.  Thus, in a model of phenylephrine (PE, anα1-adrenergic agonist) induced 
pathological cell growth, PE resulted in a redistribution of TRα1 receptor from the 
cytosol to nucleus. This unique response was found to be an ERK dependent process 
which required an intact mTOR signaling. These changes were subsequently shown to 
be of physiological relevance regarding the cellular response to stress.  With the 
removal of TH from culture medium, TRα1, which  remained un-liganded, displayed a 
repressive action resulting in cell de-differentiation with large cells of  undefined shape 
and filopodia like structures containing  disoriented, dense myofibrils and increased 
amount of  β-MHC (Pantos et al., 2008). On the contrary the addition of TH in the  
culture medium resulted in  cell differentiation by switching the TRα1  to the liganded 
state (Pantos et al., 2008). These series of experiments revealed for the first time that 
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TH signaling is critical for the response of the cardiac cell to stress and TH can rescue 
cardiomyocytes from the stress induced cell de-differentiation.  
 
TH promotes endogenous regeneration by activating developmental gene 
programming  
 
In accordance with the observations  made  in   cell based models, several proofs of 
concept studies in animals with myocardial infarction showed that that thyroid 
hormone, while having a detrimental effect on healthy tissue,  could  have  a reparative 
effect on the injured myocardium ( Ojamaa et al., 2000; Degens et al., 2003; Pantos et 
al., 2007c;  Chen et al., 2008;  Pantos et al., 2008a;  Henderson et al., 2009;  Pantos et 
al., 2009a;  Pantos et al., 2009b;   Forini et al., 2010).  Thus, TH or  thyroid analogues  
treatment early after  coronary ligation in animals reduced  apoptosis  (Chen et al., 
2008; Kalofoutis et al., 2010) and  limited  the extent of infarct size  ( Forini et al., 
2010; Abohashem-Aly et al., 2011). More importantly, TH could favorably remodel the 
viable, non-ischemic myocardium. TH accelerated the development of cardiac 
hypertrophy characterized by an adult pattern of MHC isoformexpression. This 
response caused an early normalization of wall stress which is known to be a critical 
determinant of oxygen consumption and myocardial performance ( Grossman et al., 
1975; Dorn, 2007). TH treatment had also a striking effect on cardiac geometry which 
critically determines the mechanical efficiency of the myocardium (Coghlan and  
Hoffman, 2006; Sehgal and Drazner, 2007). TH either early or late after myocardial 
infarction could reshape the heart from spherical to the elipsoid shape (Pantos et al., 
2008a; Pantos et al., 2009b). These favorable changes  were the result of the TH  effect 
on cardiomyocyte remodelling  as indicated by the characteristic changes seen at the 
molecular level (Pantos et al., 2007e; Pantos et al., 2008c).Thus, factors involved in 
mitochondrial DNA transcription and biogenesis, calcium handling  proteins  and 
cardio-protective molecules such as HSP70 were all found to be over-expressed with 
TH treatment ( Pantos et al., 2008a;  Forini et al., 2010). Furthermore, TH modulated 
the regulatory role of PKCε and PKCα on contractile function (Pantos et al., 2007c). 
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Akt : a critical player in  TH-induced favorable effects on cardiac remodeling 
  
One of the major players in the response of the cardiac cell to stress is the Akt signaling 
pathway. Moreover, Akt is a critical regulator of physiological growth. Thus, chronic 
Akt blockade aggravates pathological hypertrophy while inhibits exercise- induced 
physiological hypertrophy (Buss et al2011).  Furthermore, the effect of stem cell 
transplantation after myocardial infarction in mice was shown to be Akt dependent 
(Tseng et al. 2010). However, the level of phosphorylation of this kinase is of important 
physiological relevance. In fact, in transgenic animals, chronic Akt activation caused a 
spectrum of phenotypes from moderate cardiac hypertrophy with preserved systolic 
function and cardio-protection to massive cardiac dilatation and sudden death.  Along 
this line, TH administration in mice with myocardial infarction had a beneficial or 
detrimental effect depending on the extent of Akt phosphorylation induced by TH. 
Thus, mild activation of Akt caused by the replacement dose of TH resulted in favorable 
effects on the myocardial performance of the post-infarcted heart, while further 
induction of Akt by higher dose of TH was accompanied by detrimental effects (Pantos,  
2010).  
 
Thyroid hormone and cardio-preservation: The thyroid hormone ‘paradox’ 
 
Unlike the long held belief, TH can protect the heart against ischemia  despite the fact 
that  it increases oxygen consumption (by accelerating heart rhythm and increasing 
cardiac contractility) and depletes the heart from glycogen (Pantos et al., 2001; Pantos 
et al., 2002; Pantos et al., 2003a; Pantos et al., 2003b; Pantos et al., 2006). TH pre-
treatment and ischemic pre-conditioning had a similar functional response to ischaemic 
insult which was characterized by a marked increase in post-ischaemic recovery of 
function despite the exacerbation of diastolic dysfunction during  the ischemic period 
(ischemic contracture). This effect was shown to be mediated via the suppression of the 
pro-apoptotic p38 MAPK signalling pathway (Pantos et al., 2003b). The explanation of 
this paradox lies on the fact that the differentiation/physiological growth process can 
share common pathways with those involved in stress response. Thus, the activation of 
redox regulated signaling pathways which mediate cell differentiation, results also in 
the up-regulation of redox regulated cardio-protective molecules, such as heat shock 
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proteins which can increase tolerance of the cell against ischemia ( Strandness and 
Bernstein, 1997; Pantos et al., 2003a; Pantos et al., 2006).  
Studies in the isolated rat heart models further revealed that TH is able to acutely 
protect the myocardium via its non genomic action. Thus,T3, although had no effect on 
uninjured myocardium, it significantly improved post-ischemic recovery of function 
and limited apoptosis in the injured myocardium. This effect was also mediated by the 
suppression of the pro-apoptotic p38 MAPK.  Intriguingly, the non-genomic effect of 
T3 was shown to be initiated at the cytosolic TRα1 receptor, a mechanism which 
probably explains the failure of T4 to limit reperfusion injury ( Pantos et al., 2009a;  
Pantos et al., 2011b).  
 
 
Clinical implications  
 
 Can ‘low T3 syndrome’ be either a bystander or player?  An expanded overview  
 
Several studies have provided evidence that TH metabolism is altered under cardiac and 
non-cardiac illnesses and after cardiac surgery, a condition known as non thyroidal 
illness or ‘low T3 syndrome’ . The cause of low T3 state seems to be  multi-factorial 
with cytokines  to be major contributors to this response (Abo-Zenah et al., 2008).Thus, 
interferon- α and interleukin-6 (IL-6) can cause a response similar to ‘‘low-T3 
syndrome’’ and in patients with acute myocardial infarction a negative correlation 
between IL-6 or CRP and T3 levels has been observed (Kimura et al., 2000).  
Thephysiological relevance of ‘‘low-T3 syndrome’’until now remains elusive. 
However, low T3 levels have been correlated with the severity of the clinical 
assessment of heart dysfunction (NYHA) in patients with congestive heart failure and 
were the only predictor of NYHA at the multivariate analysis that included several 
neuro-hormonal parameters which change in heart failure (Iervasi et al., 2003; Pingitore 
et al., 2006). Along this line, total T3 in plasma was strongly correlated with the 
maximal oxygen consumption (peak VO2) in patients with dilated cardiomyopathy 
(ischaemic and non ischaemic)  as assessed by cardio-respiratory stress testing (Pantos 
et al., 2007a). In addition low T3 plasma levels were found to be an independent risk 
factor for increased mortality in patients with heart failure (Iervasi et al., 2003). T3 
levels in serum decline within 48 h after acute myocardial infarction  (Eber et al., 1995) 
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or within 6–24 h after cardiac surgery (Holland et al., 1991). Lower T3 levels appear to 
be an independent predictor of mortality after myocardial infarction (Friberg et al., 
2002). Furthermore,  T3 levels  are strongly correlated to early and late recovery of 
cardiac function with T3 levels at six months to be  an independent predictor of the 
recovery of the  myocardium (Lymvaios et al., 2011).  Interestingly, patients who 
spontaneously  recover  T3 levels  in plasma after myocardial infarction are those with 
markedly improved cardiac functional recovery (Lymvaios et al., 2011). It is of interest 
that T3 has also be found to be an independent determinant of atherosclerosis 
progression (Barth et al., 1987; Baxter and Webb, 2009; Ichiki, 2010). 
 
TH  in  cardiac surgery  
 
TH has long been used in cardiac surgery as inotrope and vasodilator. The efficacy and  
safety of TH as postoperative  treatment has been recently assessed in a systematic 
review of all the randomized controlled studies comparing T3 to placebo (Kaptein et al., 
2010). Thus, both high-and low-dose iv T3 therapy were shown to improve cardiac 
index after coronary artery bypass surgery. Mortality was not significantly altered by 
high-dose iv T3 therapy and could not be assessed for low-dose iv or oral T3. Effects on 
systemic vascular resistance, heart rate, pulmonary capillary wedge pressure, new onset 
atrial fibrillation, inotrope use, serum TSH and T4 were inconclusive. This study calls 
for further large scale  investigations with particular emphasis on T3 effects on 
reperfusion injury (Kaptein et al., 2010).  
The potential effect of T3 on limiting reperfusion injury has recently been addressed in 
patients undergoing cardiac surgery and has been compared to an established cardio-
protective regime the glucose-insulin potassium (GIK) treatment. A total of 440 patients 
were recruited and randomized to either placebo (5% dextrose) (n = 160), GIK (40% 
dextrose, K
+
 100 mmol L
-1
, insulin 70 μL-1) (0.75 mL kg-1 h-1) (n = 157), T3 (0.8 μg kg-1 
followed by 0.113 μg kg-1 h-1) (n = 63) or GIK + T3 (n = 60). GIK/placebo therapy was 
administered from start of operation until 6 h after removal of aortic cross-clamp (AXC) 
and T3/placebo was administered for a 6-h period from removal of AXC. Serial 
hemodynamic measurements were taken up to 12 h after removal of AXC and troponin 
I (cTnI) levels were assayed to 72 h. Cardiac index (CI) was  significantly increased in 
both the GIK and the GIK/T3 group in the first 6 h compared with placebo and T3 
therapy (Ranasinghe et al., 2006). T3 therapy increased CI versus placebo between 6 
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and 12 h after AXC removal but combination therapy did not. Release of cTnI was 
lower in all treatment groups at 6 and 12 h after removal of AXC (Ranasinghe et al., 
2006). 
The potential of pre-operative TH treatment to precondition the myocardium has also 
been explored. Thus, eighty patients undergoing coronary artery bypass grafting with a 
preoperative EF% less than 30% were randomized to the T3 group (125 μg/day orally 
for 7 days preoperatively and from the first postoperative day till discharge) and to the 
placebo group. Patients in the T3 group had a higher cardiac index than patients in the 
placebo group in the entire post-CPB periods. Furthermore, mean inotropic 
requirements remained lower in the T3 group than in the placebo group (Sirlak et al., 
2004). 
 
TH in myocardial infarction 
 
A phase II, randomized, double blind, placebo-controlled study has been recently 
initiated  testing the  use of substitutive doses of synthetic T3 in patients with STEMI 
(ST-Elevation Myocardial Infarction) and borderline/reduced circulating T3 (Pingitore 
et al., 2011). Treatment with either synthetic TH or placebo starts during the in hospital 
period in presence of stable haemodynamic conditions (i.e. 48-72 hrs after STEMI) and 
will be taken for further 6 months after hospital discharge (Gerdes and  Iervasi, 2010; 
Pingitore et al., 2011). 
 
 
Working hypothesis:  Distinct change in thyroid hormone receptor can lead to cardiac 
remodelling during diabetes-induced heart failure in STZ-induced diabetic rats 
following acute myocardial infarction. 
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Main aims of the study: Based on this evidence, the present study attempted to explore 
the following:  
1. Can DM accelerate post MI remodelling? 
2. Are these responses associated with changes in thyroid hormone signalling? 
3. Can alterations in thyroid hormone signalling result in changes in growth kinase 
signalling and fetal like changes in contractile proteins? 
 4. Can thyroid hormone either prevent or reverse cardiac remodelling in STZ-induced 
diabetic heart 
 
Some specific aims 
1. To develop the STZ-induced type1 DM model and to undertake the relevant 
surgery to induce myocardial infarction. 
2. To undertake physiological and biochemical studies measuring a number of 
physiological and molecular biochemical parameters including TH levels in the 
blood plasma. 
3. To investigate protein  expressions in TH receptors and other signalling proteins 
in the heart. 
4. To analyze the data and write up the PhD thesis 
 
 
 
 
 
97 
 
 
 
 
 
 
CHAPTER   2 
 
 
 
 
 
 
 
 
             MATERIALS AND METHODS 
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Materials 
Animals- Young adult male Wistar rats 
Drugs: Streptozotocin, thyroid hormone, ketamine hydrochloride, thyroid hormones, 
aspirin, iodoacetic acid, phenylbutazone,, sodium salicylate, 
Reagents; SDS-PAGE gel electrophoresis, 2 –mercaptoethanol, Elisa assay kits, buffer 
solutions, acrylamide, agents for western Blotting, specific antibodies for the different 
proteins and kinases, EGTA,EDTA,PMSE. 
Chemicas; Analar grade chemicals 
Equipment; Langendorff’s perfusion set up, ecocardiograph equipment, equipment for 
Westerbn Blotting, SDS-PAGE systemCCD camera, chemiluminescence equipment, 
glucose merer. 
Methods 
Animals   
Male Wistar rats weighing between 280-360 g, were maintained on a 12 h light/dark 
cycle and fed with a standard chow ad libitum. The rats were handled in accordance 
with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health Guide (NIH Pub. No. 83-23, Revised 1996). Approval was 
also granted by the Ethics Review Board Committees of the University of Athens and 
the University of Central Lancashire. 
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Induction of Diabetes  
Diabetes mellitus (DM) was induced by a single injection of streptozotocin (STZ; either 
35 mg/kg bw or 60 mg/kg bw; i.p) prepared in 0.1 M sodium citrate buffer, pH 4.5 
(Sigma, Munich, Germany) as described previously ( Shao et al, 2010; Kalofoutis et al, 
2010; Lymvaios et al, 2011). STZ induced diabetes within 2-3 days following injection 
by destroying the pancreatic beta cells. Age-matched non-diabetic Wistar rats were 
injected with sodium citrate buffer alone and used as healthy controls. Diabetic animals 
and non-diabetic age –matched control group were kept in metabolic cages individually 
and separately under normal feeding and drinking conditions as well as metabolism 
control state for the first 4 days after STZ injection. Water consumption and urine 
volume were measured in (ml) on a daily basis.  Four days after the injection of STZ, 
urine samples were tested for glucose and ketone levels using Keto-Diastix (Bayer). The 
dose of 35 mg/kg;   i.p. STZ was selected after preliminary experiments that showed 
successful induction of glucosuria without significant keto-acidosis. In fact, urine 
volume increased in STZ-treated rats from 8.7 ± 0.6 ml on Day 0 to 31.9 ± 1.9 ml on 
day 4 while glucose concentration in urine had a mean value of 626 ± 54)  mg/dL.  Rats 
were subjected to surgical procedure 30 days after STZ injection. 
 
Experimental model of myocardial infarction (MI) 
 
Myocardial infarction was induced by ligation of the left coronary artery as previously 
described (Pantos et al, 2007a, 2007b; Kalofoutis et al, 2010; Lymvaios et al, 2011). 
Rats were anaesthetized with an intraperitoneal (ip) injection of ketamine (70 mg/kg) 
and midazolame (0.1 mg/kg), intubated and ventilated via a tracheal cannula using a 
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constant-volume rodent ventilator (Harvard Apparatus, Inspira, 50 breaths/min, 1 
ml/100 g tidal volume). Anaesthesia was maintained by inhalation of small doses of 
sevoflurane (1-2%). Left thoracotomy was performed at the fourth intercostal space 
followed by pericardiotomy. Left coronary artery was then ligated with a 6-0 silk round-
bodied suture. The heart was quickly returned to the chest cavity, the chest was closed 
and the rats were allowed to recover using assist mode ventilation.  Atelectasis was 
prevented by using positive end-expiratory pressure at the end of the surgical procedure.  
Continuous electrocardiogram (ECG) recordings were used to monitor heart rate and 
any changes due to ischaemia after coronary artery ligation. Body temperature was 
maintained at 37
o 
C by using a heating blanket (Harvard Homeothermic Blanket, 50-
7061). The mortality rate was up to 15-20% in the infarction control group, while it 
increased up to 30-40% in the diabetic infarction group in the first 24 h following the 
surgical procedure. Myocardial infarctions which produced a scar area of 60 mm
2
 to 105 
mm
2
 were included in this study, corresponding to 25%-40% of the left ventricle (see 
Figure 2.1). The animals were left to recover for 2 weeks after myocardial infarction.  
The same procedure was followed for sham-operated control animals, but the coronary 
artery was not ligated.  
101 
 
 
 
(A) Ligation of coronary artery-acute MI in rats  
 
            (B)  
 
Figure 2.1: Rat heart subjected to coronary artery ligation mounted on a Langendorff’s 
apparatus (A). Scar area can be seen (upper image).  Cross-sections of  the left ventricle 
of post-infarcted rat heart.  Scar tissue and viable hypertrophic myocardium can be seen 
((B). Typical of 7-8 such different experiments for control and diabetic hearts. 
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Functional and structural assessment  
Echocardiography 
Following 2 weeks of experimental surgery, rats were sedated with ketamine 
hydrochloric acid (100 mg/Kg) and heart function was evaluated by echocardiography 
as previously described (Pantos et al, 2007a, 2007b; Kalofoutis et al, 2010; Lymvaios et 
al, 2011).  Short and long-axis images were acquired using a digital ultrasound system 
(Vivid 7 version Pro, GE Healthcare) with the 14.0-MHz i13L probe. A large number of 
consecutive measurements were performed and analysed by two independent operators.  
Left ventricular (LV)  internal diameter at the diastolic phase (LVIDd), LV internal 
diameter at  the systolic phase (LVIDs),  posterior wall thickness at the diastolic phase 
(LVPW), systolic velocity of the  posterior wall radial displacement (SVPW) and the 
ejection fraction (EF%) were measured. EF% was calculated using the Simpson 
equation. SVPW was measured from two-dimensional guided M-mode recordings 
obtained at the mid-ventricular level as previously described (Pantos et al, 2007a; 
2007b; Shao et al, 2010; Kalofoutis et al, 2010; Lymvaios et al, 2011). SVPW was used 
to assess the segmental contractile function of the non-infarcted myocardium, while 
EF% was used to determine the global contractile LV function. Wall tension index 
(WTI) was defined as the ratio (LVIDd2*/Posterior Wall thickness) as previously 
described (Pantos et al, 2007a ; 2007b; Shao et al, 2010; Kalofoutis et al, 2010; 
Lymvaios et al, 2011). WTI was measured in order to indirectly assess myocardial wall 
stress. In addition, sphericity index (SI), defined as the ratio of maximum long axis (in 
mm) to maximum short axis (in mm) of the left ventricle was determined in order to 
assess LV geometry. All measurements were averaged for at least 3 consecutive cardiac 
cycles (see Figure 2.2).  
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Figure 2.2: Long-axis view images (A), short-axis view images at diastole (B) and at 
systole (C) and (D) M-mode images obtained by transthoracic echocardiography. 
Typical of 7-8 such different experiments for either control or diabetic rats. 
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Echocardiographic analysis of myocardial deformation 
The typical images in Figure 2.2 were processed in a workstation with software 
(EchoPAC Q analysis, General Electric). The method has been previously described 
(Pantos et al, 2007a ; 2007b; Shao et al, 2010; Kalofoutis et al, 2010; Lymvaios et al, 
2011) . The endocardial border was traced in an end-systolic frame. The software 
automatically selected 6 equidistant tissue-tracking regions of interest in the 
myocardium. The outer border was adjusted to approximate the epicardial border. The 
software automatically selected suitable stable acoustic objects for tracking, searched 
for them in the next frame using absolute differences algorithm. The computer provided 
a profile of radial strain (%) with time. On parasternal short-axis view, radial strain was 
deformation toward the LV center. Outcome measurements included end-systolic strain 
as the point during systole when the strain rate became zero from a previously positive 
value (radial strain rate) using the strain rate by time graph of the software analysis 
package. This time point of zero strain rate represented the transition from contraction 
to relaxation and had been previously used to define the end of systole and the initiation 
of diastole.  
 
Isolated heart preparation 
A non-ejecting isolated rat heart preparation was perfused at a constant flow according 
to the Langendorff‘s technique (Pantos et al, 2007a ; 2007b; Shao et al, 2010; 
Kalofoutis et al, 2010; Lymvaios et al, 2011). Rats were anaesthetized with ketamine 
hydrochloric acid and heparin 1000 IU/kg was given intravenously before thoracotomy. 
The hearts were rapidly excised, placed in ice-cold Krebs-Henseleit buffer solution and 
mounted on the aortic cannula of the Langendorff’s perfusion system(see Figure 2.3).. 
Hearts were paced at 320 beats/min with a Harvard pacemaker. An intra-ventricular 
balloon allowed measurement of contractility. Left ventricular balloon volume was 
adjusted to produce an average initial left ventricular end-diastolic pressure of 7-8 
mmHg in all groups. The water filled balloon was connected to a pressure transducer 
and the LV pressure signal was transferred to a computer using data analysis software 
(IOX, Emka Technologies) which allowed continuous monitoring and recording of 
heart function. 
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Left ventricular developed pressure (LVDP), defined as the difference between left 
ventricular peak systolic pressure and left ventricular end-diastolic pressure, represented 
a contractility index obtained under isometric conditions. Left ventricular systolic 
function was assessed by recording the left ventricular developed pressure (LVDP, 
mmHg) and the positive and negative first derivative of LVDP; +dp/dt (mm Hg/sec), -
dp/dt (mm Hg/sec).  
All preparations were perfused for 20 min and measurements were performed at the end 
of this period (Figure 2.3). The preparations included in this study were stable for at 
least the last 10 min of the perfusion period. Isolated hearts that did not produce stable 
measurements of LVDP, LV end-diastolic pressure and perfusion pressure for the last 
10 min of the perfusion period were excluded from the analysis. 
 
 
 
Figure 2.3:  A photograph showing an isolated rat heart apparatus (Langendorff ‘s       
preparation).With organ bath,water jacket, transducer, stimulator chest recorder and 
computer to record the responses. 
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(A) 
 
(B) 
 Figure 2.4: Photograph of a heart in the organ bath (A) and traces (B) showing 
procedure for protein isolation and measurement using sodium dodecyl sulfate-protein 
polyacrylamide (SDS-PAGE) gel electrophoresis and immuno detection system. 
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Measurement – Protein expressions 
Left ventricular tissues were homogenized in an  ice-cold buffer solution  (A) 
containing 10 mM Hepes (pH: 7.8), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 
mM PMSF, 1 mM DTT and 10 μg/ml leupeptin.  A volume of 200 μl of 10% Igepal 
was added and samples were left in ice for 30 min. Homogenization was repeated and a 
small fraction of total lysis was kept for myosin heavy chain isoform analysis. The rest 
of the homogenate was centrifuged at 1000 g for 5 min, 4
o
C and the pellet containing 
the nuclear fraction, was washed again in buffer (A) with 1% Igepal, while the 
supernatant containing the cytosolic fraction was stored at -80
o
C. The final pellet was  
resuspended in 300 μl buffer (B) containing 20 mM Hepes (pH: 7.8), 420 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 1 mM DTT, 10 μg/ml leupeptin and 10% 
glycerol. The samples were incubated at 4
o
C for 60 min (under agitation) followed by 
centrifugation at 10000 g for 5 min, 4
o
C. The supernatant containing the nuclear 
fraction was separated and stored at -80
o
C, while the pellet containing cellular debris 
and cytoskeleton were discarded (Pantos et al 2007a; 2007b; Kalofoutis et al 2010). TRs 
protein expression was determined in nuclear fraction and signal tranducing kinases 
were determined in cytosolic fraction. Protein concentrations were determined by the 
BSA method. Cytosolic samples were prepared for sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) by boiling for 5 min in Laemmli 
sample buffer containing 5% 2-mercaptoethanol. Either 20 μg (nuclear fraction) or 35 
μg (cytosolic fraction) of total protein was loaded onto 7% or 10% (w/v) acrylamide 
gels and subjected to SDS-PAGE in a Bio-Rad Mini Protean gel apparatus. For Western 
blotting, following SDS-PAGE, proteins were transferred electrophoretically to a 
nitrocellulose membrane (Hybond ECL) at 100 V and 4 
o
C, for 1.5 h using Towbin 
buffer. After Western blotting, filters were probed with specific antibodies against After 
Western blotting, membranes were probed with specific antibodies against total and 
phospho-ERK, total and phospho-AKT (Ser 473), total and phospho-JNKs and total and 
phospho-p38 (Cell Signalling Technology, dilution 1:1000) overnight at 4
0
C, SERCA 
(Affinity Bioreagents, MA3-919, dilution 1:1000, o/n at 4
0
C), phospholamban (Affinity 
Bioreagents, MA3-922, dilution 1:1000, o/n at 4
0
C), PKCα (BD Biosciences, 610108, 
dilution 1:1000, 2h at R.T.) and PKCε (Affinity Bioreagents,BD Biosciences, 610086, 
dilution 1:1000, o/n at 4
0
C). Membranes were incubated with appropriate anti-mouse 
(Amersham) or anti-rabbit (Cell Signaling) HRP secondary antibodies. 
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Immunoreactivity was detected by enhanced chemiluminescence using Lumiglo 
reagents (New England Biolabs).Chemiluminescence was detected by the image 
analysis system FluorChem HD2 (AlphaInnotech Corporation, 14743, Catalina Street, 
San Leandro, CA) equipped with a CCD camera and  analysis software. Five samples 
from each group were loaded on the same gel. Histone H3 protein expression was used 
in order to normalize slight variations in nuclear protein loading. 
Measurement of myosin heavy chain isoform content 
Homogenates of all samples were diluted 40 fold with Laemmli sample buffer 
containing 5% 2-mercaptoethanol. The composition and preparation of the gels was 
carried out as previously described (Pantos et al, 2007a ; 2007b; Shao et al, 2010; 
Kalofoutis et al, 2010; Lymvaios et al, 2011). Briefly, the stacking and separating gels 
consisted of 4 and 8% acrylamide (wt/vol), respectively, with Acryl:bis-Acryl in the 
ratio of 50:1. The stacking and separating gels included 5% (vol/vol) glycerol. The 
upper running buffer consisted of 0.1 M Tris (base), 150 mM glycine, 0.1% sodium 
dodecyl sulphate (SDS) and 2-mercaptoethanol at a final concentration of 10 mM. The 
lower running buffer consisted of 0.05 M Tris (base), 75 mM glycine and 0.05% SDS. 
The gels were run in Biorad Protean II xi electrophoresis unit at a constant voltage of 
240 V for 22 h at 4
o
C. The gels were fixed and silver-stained (Biorad silver stain kit). 
.Gels were scanned and quantified using the AlphaScan Imaging Densitometer (Alpha 
Innotech Corporation, USA). 
Measurement of thyroid hormones  
Plasma L-thyroxine and 3,5,3' tri-iodothyronine quantitative measurements were 
performed with ELISA, using kits obtained from Alpha Diagnostic International, Texas, 
USA (No 1100 for total T4 and No 1700 for total T3), as previously described.(Pantos et 
al 2005) L-thyroxine and 3,5,3' triiodothyronine levels were expressed as nmol/L of 
plasma. Absorbance measurements were performed at 450 nm with TecanGenios 
ELISA reader (Tecan, Austria). 
Measurement of T3 
 In this study, the total T3 ELISA kit was based on competitive binding of thyroxine 
from serum samples and enzyme-labelled T3 to T3-specific antibodies immobilized on 
microtiter well plates. In the assay, total T3 was released from its binding proteins by a 
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releasing agent present in the assay buffer. After a washing step, chromogenic substrate 
was added and colour developed. The enzymatic reaction (blue color) was inversely 
proportional to the amount of T3 present in the sample. The reaction was terminated by 
adding stopping solution (converts blue to yellow). Absorbance was then measured on a 
micro-titer well ELISA reader at 450 nm and the concentrations of T3 in samples and 
control were read off from the standard curve. All values were expressed as nM. 
 
Detection Limit 
Based on sixteen replicates determinations of the zerostandard, the minimum 
concentration of total T3 detected using this assay was 20 ng/dL. The detection limit 
was defined as the value deviating by 2 SD from the zero standard. 
 
Precision 
Intra-assay precision: 
Three serum samples (mean total T3 concentrations 11, 18, and 160 ng/dL) were eluted 
in three separate runs. The samples showed good intra-assay precision with % CV of 6-
11. 
 
Inter-assay precision: 
Three serum samples (160, 290, and 665 ng/dL) were run in duplicate in sixteen 
independent assays. The samples showed good inter-assay precision (3.0-10% CV). 
 
Linearity 
A serum sample containing 1000 ng/dL was diluted with a series of T3-free serum 
(Figure 2.5). The dilutions were tested and the T3 recoveries were compared with the 
expected concentration. The samples showed excellent mean recoveries of about 105% 
(range 80-113%). 
 
Specificity 
The specificity of total T3 ELISA kit was determined by measuring interference from 
high concentrations of T4, 3,3', 5-triiodothyronine (rT3, up to 1000 ng/ml), 3,5-
diiodothyronine (up to 10 ug/dL), Aspirin (10 mg/dL) iodoacetic acid (10 ug/dL), 
phenylbutazone (10 mg/dL), 3',5-diiodothyronine (T2), and sodium salicylate. No 
significant cross-reaction was observed with any of these compounds. 
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Figure 2.5: Standard assay curve for T3. Typical of 7-8 different such experiments 
 
Measurement of T4 
In this study, total T4 ELISA kit was based on competitive binding of human thyroxine 
from serum samples and enzyme-labeled T4 to T4-specific antibodies immobilized on 
micro-titer well plates. In the assay, total T4 was released from its binding proteinsby a 
releasing agent present in the assay buffer. After a washing step, chromogenic substrate 
was added and colour developed. The enzymatic reaction (blue colour) was inversely 
proportional to the amount of T4 present in the sample. The reaction was terminated by 
adding stopping solution (converts blue to yellow). Absorbance was then measured on a 
micro-titer well ELISA reader at 450 nm and the concentration of T4 in samples and 
control was read off the standard curve (Figure 2.6). All values were expressed in nM. 
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Detection Limit 
Based on sixteen replicates determinations of the zero standard, the minimum 
concentration of total T4 detected using this assay was 0.5 ug/dL. The detection limit 
was defined as the value deviating by 2 Standard deviation from the zero standard. 
 
Precision 
 
Intra-assay precision: 
Three serum samples (mean total T4 concentrations 3.5, 6.8, 13.9 ug/dL) were run in 
five separate runs. The samples showed good intra-assay precision with % CV of 9-11. 
Inter-assay precision: 
Three serum samples (4-15 ug/dL) were run in duplicate in sixteen independent assays. 
The samples showed good inter-assay precision (2.7-4 % CV). 
 
Specificity 
The specificity of total T4 ELISA kit was determined by measuring interference from 
high concentrations of 3,5-diiodothyronine (up to 10 ug/dL), 3,3',5-triiodothyronine 
(rT3,,up to 1000 ng/ml), 3,3',5-triiodothyronine (T3,,up to 59nmol/l), 3,3',5-
triiodothyroacetic acid (up to 42 nmol/l), 3,3',5-triiodothyropropionic acid (up to 63 
nmol/l), Aspirin (10 mg/dL) iodoacetic acid(10 ug/dL), phenylbutazone (10 mg/dL). No 
significant cross-reaction wasobserved with any of these compounds. 
 
Linearity 
A serum sample containing 24 ug/dL was diluted with a series of T4-free serum. The 
dilutions were tested and the T4 recoveries were compared with the expected 
concentration. The samples showed excellent mean recoveries ofabout 102% (range 90-
109%). 
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Figure 2.6:  Standard assay curve for T4. Typical of 5-7 such different experiments. 
 
General experimental protocol in this study 
 Rats were initially rendered diabetic with STZ. Four weeks after STZ-induced diabetes, 
some  control and diabetic animals were induced with AMI. Two days after AMI 
induction, one group of rats (DM combined with AMI) were treated with TH  (0.42 
mg/mg T3 and 1.7 ug/mg T4 mixed with chow) for 2 weeks. Two weeks after the AMI 
surgical procedure, rats were anaesthetized with ketamine hydrochloride, subjected to 
echocardiography analysis and the hearts were removed and washed in ice-cold Krebs 
buffer. Left ventricle (LV) and right ventricle (RV) of the heart were separated and scar 
LV tissue was dissected out and the non- infarcted area was frozen in liquid nitrogen for 
further analysis. Blood was collected from the right atrium in order to measure total T3 
and T4 in serum.  The area of the scar tissue was measured in mm
2 
and the weight in mg.  
For the experimental protocol rats were separated in the following five experimental 
groups; (1) Control sham-operated rats (SHAM, n=20); (2) Diabetic sham-operated rats 
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(DM + SHAM, n=11); (3) Control rats subjected to myocardial infarction (AMI, n=19); 
(4) Diabetic rats subjected to myocardial infarction (DM + AMI, n=13) and (5) Diabetic 
rats subjected to myocardial infarction and thyroid hormone treatment (DM + AMI + 
TH, n=11). 
 
Analysis of data and statistics  
All the results are presented as means (± standrard errors of the means). Unpaired   
Student’s t-test and Mann-Whitney test were used to evaluate differences between 
groups in molecular protein analysis. One-way analysis of variance with Bonferroni or 
Dunnett correction was used for multiple comparisons. Significance was set at 0.05. 
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A.  Preliminary studies – Establishment of experimental model of type-1 
diabetes 
Streptozotocin (STZ) is a well known antibiotic and diabetogenic agent which can 
induce diabetes in rats by destroying the pancreatic beta cells (Bracken et al, 2004). The 
present study initially tested two different doses (35 mg/bw and 60 mg/bw) of STZ 
reported in literature to induce diabetes via intra-peritoneal (ip) injection (Qureshi et al, 
2001; Howarth et al, 2002). Rats were kept in metabolic cages and urine was collected 
on a daily basis to determine volume and glucose and ketone concentrations in the 
urine. Tables 3.1 and 3.2 show analytical data including urine volume, urine glucose 
concentrations and urine ketone concentrations at baseline and 4 days after STZ 
injection employing 35 mg/bw and 60 mg/bw, respectively. The results show that 4 
days after the injection of STZ, both doses (Table 3.1; 35 mg/bw and Table 3.2; 60 
mg/bw) can increase significantly (p<0.05) urine volume and glucose concentrations in 
the urine compared to base line measurements prior to the induction of diabetes. 
However, 35 mg/kg concentration had no significant effect on blood ketone 
concentration compared to 60mg/bw. Thus, a low dose of STZ injection (35 mg/bw) 
was selected as a more appropriate concentration for the rest of the since only small 
amounts traces of ketones were detected in urine samples. As such, the aim of the study 
was to avoid the development of keto-acidosis in blood secondary to high 
concentrations of glucose since acidic pH per se could be a cause of myocardial 
dysfunction. As a result, 35 mg/bw STZ was employed throughout this study. 
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Table 3.1: Table showing urine volume, urine glucose concentration and urine ketone 
concentration at base line and 4 days after STZ injection (ip) using 35 mg/bw.  
 
 
 
 Base line prior to STZ injection 4 days after STZ injection 
GROUP Urine 
volume 
(ml) 
Urine 
Glucose 
(mg/dl) 
Urine 
ketone 
(mg/dl) 
Urine 
volume 
(ml) 
Urine 
Glucose 
(mg/dl) 
Urine 
ketone 
(mg/dl) 
35mg/Kg 13,00 0 0 28,00 600 5,00 
35mg/Kg 9,00 0 0 50,00 500 5,00 
35mg/Kg 13,00 0 0 26,00 500 0,00 
35mg/Kg 7,00 0 5 40,00 1000 0,00 
35mg/Kg 10,00 0 0 34,00 750 0,00 
35mg/Kg 10,00 0 0 40,00 1000 0,00 
35mg/Kg 7,00 0 0 32,00 1000 5,00 
35mg/Kg 8,00 0 5 23,00 500 5,00 
35mg/Kg 12,00 0 0 10,00 250 5,00 
35mg/Kg 5,00 0 0 32,00 1000 5,00 
35mg/Kg 8,00 0 0 22,00 250 5,00 
35mg/Kg 11,50 0 0 40,00 500 0,00 
35mg/Kg 10,00 0 0 40,00 600 5,00 
35mg/Kg 5,50 0 0 40,00 250 0,00 
35mg/Kg 5,00 0 0 34,00 550 5,00 
35mg/Kg 10,00 0 0 22,00 600 15,00 
35mg/Kg 10,00 0 0 35,00 550 5,00 
35mg/Kg 7,00 0 5 31,00 500 5,00 
35mg/Kg 8,00 0 0 28,00 650 0,00 
35mg/Kg 12,00 0 0 32,00 1000 0,00 
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Table 3.2: Table showing urine volume, urine glucose concentration and urine ketone 
concentration at base line and 4 days after STZ injection (ip) employing 60 mg/bw.  
 
 Base line prior to STZ injection 4 days after STZ injection 
GROUP Urine 
volume (ml) 
Urine 
Glucose 
(mg/dl) 
Urine 
ketone 
(mg/dl) 
Urine 
volume 
(ml) 
Urine 
Glucose 
(mg/dl) 
Urine 
ketone 
(mg/dl) 
60mg/K
g 
8,00 0 0 44,00 500 40,00 
60mg/K
g 
9,00 0 0 55,00 1000 80,00 
60mg/K
g 
10,00 0 0 60,00 2000 160,00 
60mg/K
g 
7,00 0 0 50,00 1000 80,00 
60mg/K
g 
12,00 0 0 48,00 1000 40,00 
60mg/K
g 
8,00 0 0 52,00 1000 80,00 
60mg/K
g 
10,00 0 0 58,00 2000 160,00 
60mg/K
g 
11,00 0 5 48,00 1000 80,00 
60mg/K
g 
14,00 0 0 40,00 500 40,00 
60mg/K
g 
6,00 0 0 38,00 500 15,00 
 
Contractile functions 
Preliminary experiments in isolated rat heart preparation of normal and diabetic rats 
(treated with 35 mg/bw streptozocin) showed that indices of contractile function such as 
LVDP  ( Figure 3.1) and the positive and negative first derivative of LVDP (+dp/dt and 
–dp/dt)  (Figure 3.2) were not significantly different between the 2 groups. 
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Figure 3.1: Bar chart showing that left ventricular developed pressure (LVDP in mm 
Hg) was not significantly different between normal (NORM) and diabetic (DM) rat 
hearts.). Data are mean and represent SEM., n=6-8 for each group. 
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Figure 3.2:  Bar chart showing tha the rate of increase (+dp/dt) and decrease (-dp/dt) of 
left ventricular developed pressure (LVDP) in mm Hg/sec were not significantly 
different between normal (NORM) and diabetic (DM) rat hearts. Data are mean ±  
SEM., n=6-8 for each group. 
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B. General characteristics of all five groups of rats 
 
Table 3.3:  General characteristics of the experimental animals. (Student’s t-test ). Data 
are mean ± SEM (numbers are represented in brackets).* P<0.05 vs SHAM, **P<0.05 
vs DM + SHAM and DM + AMI,   
&
P<0.05 vs DM + SHAM, 
#
P<0.05 vs DM + AMI 
 
 
SHAM  
(n=20) 
AMI      
(n=11) 
DM-SHAM 
(n=19) 
DM-AMI 
(n=13) 
DM-
AMI+TH 
(n=11) 
Initial  Body 
weight (g) 
356 (9) 343 (12) 367 (16) 372 (16) 352 (15) 
Final  Body 
weight (g) 
363 (7) 340 (10)* 348 (13)* 336 (12)* 337 (14)* 
Heart weight 
(mg) 
845 (27) 859 (34) 767 (28) 908 (22)
&
 975 (34)
&
 
HW/BW ratio 2.3 (0.06) 2.5 (0.07) 2.3 (0.08) 2.7 (0.14)* 2.93 (0.14)** 
Heart Rate 
(bpm)  
363 (12) 332 (13) 329 (16) 309 (11)* 370 (17)** 
Lung Weight 
(LW in g) 
1.25 (0.04) 1.33 (0.05) 1.15 (0.07) 1.75 (0.24) 1.43 (0.11) 
LW/BW ratio 3.3 (0.1) 3.9 (0.19) 3.2 (0.13) 5.0 (0.8)
&
 3.8 (0.14)
 #
 
 
 
 Table 3.3 shows the general characteristics of the rats from the five different 
experimental groups. The results show no significant difference in the initial and final 
body weights for all groups. However, it must be noted that the three groups of diabetic 
animals and the AMI control show a trend to decrease body weights between the 
beginning and the end of the experiment as compared to non-diabetic animals. This 
finding is expected due to increased catabolism observed in diabetes. The heart weights 
were also significantly (P<0.05) increased the DM + AMI and DM + AMI+TH groups 
compared to either DM+SHAM or control SHAM groups. In addition, heart weight to 
body weight ratio was found to be significantly  increased only in the DM + AMI 
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animals either with or without thyroid hormone treatment indicating the induction of 
cardiac hypertrophy.  It should be also noted that lung weight to body weight ratio was 
significantly (P<0.05) increased in DM+AMI rats dictating the development of 
pulmonary congestion, while in animals treated with thyroid hormone the ratio was 
significantly  decreased to almost normal values. 
 
Physiological studies 
Response of the diabetic heart after myocardial infarction 
Cardiac hypertrophy, wall tension and geometry  
 
 The results presented in Table 3.4 and figures 3.3-3.13 show cardiac hypertrophy, wall 
tension and geometry. The ratio of left ventricular weight (LVW) to body weight  (BW) 
was shown to be similar in SHAM, DM+SHAM, AMI and DM+AMI hearts, 
p>0.05(figure 3.7).  LVPW was found to be significantly (p<0.05) increased in AMI 
hearts as compared to SHAM indicating the development of mild cardiac hypertrophy 
(see table 3.4).  On the contrary, LVPW was similar between DM+AMI and 
DM+SHAM hearts, indicating attenuation of this response in diabetic hearts (table 3.4).  
LV diastolic diameter (LVIDd) was found to be increased significantly (p<0.05)   in 
AMI and  DM+AMI  hearts as compared to SHAM and DM+SHAM hearts 
respectively, with a trend towards an increased LVIDd  in DM+AMI as compared to 
AMI hearts (figure 3.8). These changes were translated to marked alterations in the 
WTI. Thus, while a mild,  but a significant (p<0.05) increase in WTI was observed in 
AMI as compared to SHAM hearts,  a marked, but also a significant (p<0.05) increase 
in WTI was observed in DM+AMI  as compared to AMI  hearts (figure 3.6A). The 
results also show that  sphericity index  (SI) was found to be similarly decreased 
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significantly (p<0.05) in AMI and  DM+AMI  hearts as compared to SHAM and 
DM+SHAM hearts, respectively (figure 3.6B).  
 
Left ventricular function and heart rate  
A small reduction in contractile function was found in DM+SHAM as compared to 
SHAM. In fact, only SVPW was found to be significantly (p<0.05) reduced in 
DM+SHAM vs SHAM (figure 3.4), while EF% and LVIDs were similar between the 2 
groups (figures 3.3 and 3.8, respectively).  Significant (p<0.05) reductions in all indices 
(EF%, LVIDs, SVPW, LVDP, +dp/dt and –dp/dt) were seen in AMI as compared to 
SHAM hearts (figures 3.3-3.5;3.7-3.8). In addition, in DM+AMI hearts, further 
reductions in all contractile indices were observed as compared to AMI group (see table 
3.4). Heart rate was found to be significantly (p<0.05)  reduced only in AMI hearts as 
compared to SHAM.  
 
Systolic radial myocardial deformation 
Regional systolic radial myocardial strain is also shown in table 3.6. Radial strain in 
antero-septal, anterior and antero-lateral segments corresponding to scar areas were 
greatly reduced almost equally in AMI and DM+AMI hearts as compared to SHAM and 
DM+SHAM (figure 3.9-3.13). Furthermore, in postero-lateral, posterior and postero-
septal segments  corresponding to viable remodeled myocardium, radial strain was 
significantly (p<0.05)  reduced in AMI as compared to SHAM, but further reduced in 
DM+AMI, as compared to AMI.  In fact, global systolic radial myocardial strain of the 
left ventricle was significantly (p>0.05) reduced in AMI vs SHAM and further reduced 
in DM+AMI as compared to AMI (figures 3.11-3.13). 
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Table 3.4:   Left ventricular weight (LVW in mg), LVW to body weight ratio 
(LVW/BW, mg/g) and echocardiographic measurements of posterior wall thickness at 
diastolic phase (LVPW), wall tension index (WTI, LVIDd/2* LVPW) and sphericity 
index, left ventricular internal diameter at diastolic phase (LVIDd) and at systolic phase 
(LVIDs) and ejection fraction (EF%), in sham-operated rats (SHAM), sham-operated 
diabetic rats (DM-SHAM), post-infarcted rats (AMI) and post-infarcted diabetic rats 
(DM-AMI) after 2 weeks. (Student’s t-test), Data are mean ± SEM (number are shown 
in brackets); P<0.05 and ** P<0.01 
 
* P<0.05 vs SHAM,  ** p<0.05 vs DM-SHAM and AMI,  
† 
p<0.05 vs AMI,      
&
 p<0.05 vs 
DM-SHAM,  
 
Parameters 
measured 
SHAM         
(n=20) 
AMI             
(n=19) 
DM-SHAM      
(n=11) 
DM-AMI         
(n=13) 
LVW/BW 1.87 (0.03) 2.0 (0.04) 2.04 (0.09) 1.94 (0.05) 
LVPW(mm) 1.85 (0.02) 1.96 (0.03)* 1.92 (0.06) 1.91 (0.03) 
WTI 1.74 (0.02) 2.03 (0.05)* 1.73 (0.05) 2.26 (0.07)** 
Sphericity Index 1.94 (0.02) 1.63 (0.04)* 1.85 (0.04) 1.58 (0.03)
&
 
LVIDd 
(mm) 
6.5 (0.06) 8.0 (0.15)* 6.6 (0.1) 8.6 (0.15)
&
 
LVIDs 
(mm) 
3.7 (0.1) 6.1 (0.2)* 3.9 (0.1) 7.1 (0.2)** 
EF% 75.7 (1.6) 49 (1.4)* 74.7 (1.9) 38.5 (1.7)** 
SVPW    (mm/s) 38.4 (1.4) 28.6 (1.0)* 31.3 (1.9)* 24.3 (0.9)
†
 
LVDP 126 (1.8) 105.3 (2.6)* 113.5(5.9) 85.3 (4.9)** 
+dp/dt 4517 (181) 3405 (127)* 3671 (269)* 2558 (144)** 
-dp/dt 2361 (50) 2077 (47)* 2106(131) 1667 (110)
†
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Thyroid hormones levels in plasma  
 Scar areas and weights as well as plasma levels of T3, and T4 and heart rate are shown in 
table 3.5. The results show no differences in either scar areas, scar weights and   thyroid 
hormone levels in serum that were observed between groups. Heart rate was similar 
between SHAM, DM+SHAM and AMI hearts, while it was significantly (p\<0.05) 
reduced in DM+AMI as compared to SHAM. 
 
Table 3.5:   Thyroxine (T4) and triiodothyronine (T3) levels in plasma, heart rate (in 
beats per min) andthe calculated area(mm²) of the scar tissue and the weight(mg) of the 
scar in non-diabetic sham-operated rats (SHAM), sham-operated diabetic rats 
(DM+SHAM), post-infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats 
treated with thyroid hormone (DM+AMI+TH) after 2 weeks are presented in this table. 
(Student’s t-test) .  Data are mean ± SEM (numbers represented in brackets) * P<0.05 
vs SHAM.  
 
 
 
 
Parameters 
Measured 
SHAM         
(n=20) 
AMI             
(n=19) 
DM-SHAM 
(n=11) 
DM-AMI         
(n=13) 
T4 
(nM) 
50.7 (2.9) 50.3 (2.3) 44.5 (2.8) 52.3 (3.1) 
T3 
(nM) 
1.01 (0.05) 1.02 (0.06) 1.08 (0.08) 1.09 (0.08) 
Heart  rate 
363 (12) 332 (13) 329(16) 309 (11)* 
Scar area 
(mm
2
) 
------- 83.6 (3.4) …….. 83.4 (3.4) 
Scar weight 
(mg) 
------- 188 (10.1) ……… 167 (9.5) 
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Figure 3.3:  Bar chart showing ejection fraction (EF%) measured by echocardiography 
in sham-operated rats (SHAM), sham-operated diabetic rats (DM +SHAM), post-infarcted rats 
(AMI) and post-infarcted diabetic rats (DM + AMI) after 2 weeks. ( ANOVA); Data are mean. 
Bars represent SEM. n=11-20; *P<0.05 for AMI as compared to SHAM. **P<0.05 for 
DM+AMI as compared to SHAM, DM + SHAM and AMI. 
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Figure 3.4: Bar chart showing regional systolic velocity of the posterior wall of the left 
ventricle (SVPW) measured by echocardiography is shown in sham-operated rats 
(SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and 
post-infarcted diabetic rats (DM+AMI) after 2 weeks. Data are mean.  (ANOVA); Bars 
represent SEM. n=11-20; *P<0.05 as compared to SHAM. **P<0.05 as compared to SHAM, 
DM+SHAM and AMI. 
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Figure 3.5:  Left ventricular developed pressure (LVDP) (A)  and  the rate of increase 
and decrease of LVDP (+dp/dt and –dp/dt) (B) are shown  in sham-operated  rats 
(SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and 
post-infarcted diabetic rats (DM-AMI) after 2 weeks.  (ANOVA); Data are mean ± 
SEM. n=11-20,*P<0.05 vs SHAM. **P<0.05 vs SHAM, DM+SHAM and AMI. 
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Figure 3.6:  (A) Wall tension index (defined as the ratio of LVIDd to 2 x LVPW) and 
(B) Sphericity Index (defined as the ratio of diastolic LV length to diastolic LV 
diameter)  in sham-operated  rats (SHAM), sham-operated diabetic rats (DM+SHAM), 
post-infarcted rats (AMI) and post-infarcted diabetic rats (DM+AMI) after 2 weeks .  
(ANOVA); Data are mean ± SEM. n=11-20. *P<0.05 vs SHAM. **P<0.05 vs SHAM, 
DM+SHAM and AMI. 
&
 P<0.05 vs SHAM and DM-SHAM 
& 
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Figure 3.7: (A) Left ventricular weight to body weight (LVW/BW) and (B) Left 
ventricular wall thickness (LVPW) are shown in sham-operated rats (SHAM), sham-
operated diabetic rats (DM-SHAM), post-infarcted rats (AMI) and post-infarcted 
diabetic rats (DM+AMI) after 2 weeks. Data are mean ± SEM. n=11-21.  
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Figure 3.8: Left Ventricular Internal Diameter at (A) the end-diastole (LVIDd) and  (B) 
at the end-systole (LVIDs)  are presented  in sham-operated  rats (SHAM), sham-
operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and post-infarcted 
diabetic rats (DM+AMI) after 2 weeks. (ANOVA); Data are mean ± SEM. n=11-20.  
*P<0.05 vs SHAM. **P<0.05 vs SHAM, DM-SHAM and AMI. 
&
 P<0.05 vs SHAM 
and DM-SHAM 
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Figure 3.9: Representative short axis imaging echocardiographic views at diastole and 
at systole from sham-operated rats (SHAM), post-infarcted rats (AMI) and post-
infarcted diabetic rats (DM+AMI) after 2 weeks. On the right, a schematic drawing  of 
each  image  are shown for comparison. Grey colour represents viable myocardial 
tissue, red colour represents the scar area and dotted line represents the movement of the 
endocardial border during systole. Typical of 11-20 such different experiments for each 
group. 
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Table 3.6:  Regional Systolic radial strain (%) at different segments of left ventricle 
(Student’st-test);* P<0.05 vs SHAM,  ** p<0.05 vs DM-SHAM and AMI,  † p<0.05 vs 
AMI, 
&
 p<0.05 vs DM-SHAM, (n=11-20) 
  Antero-
septal 
Anterior Antero-
lateral 
Postero-
lateral 
Posterio
r 
Postero-
septal 
Strain SHAM 46.3±3.8 48±4.9 45.2±4.1 39.6±4.2 39.1±4.2 41.8±4.0 
DM-
SHAM 
33±4.7* 41±12 41.7±10 40.6±10.
9 
38±9.8 34.3±6.4 
AMI 15.3±5.5* 6.4±4.8* 8.9±3.0* 17.3±4.5
* 
25.1±4.8 26.1±4.6* 
 DM-AMI 9.5±2.6
&
 2.0±0.6& 4.9±3.2& 9.6±3.8*
* 
13.4±4.2
** 
12.9±4.3*
* 
 
 
 
Figure 3.10: Short-axis imaging view of the left ventricle at the level of the papillary 
muscles was used to evaluate systolic radial strain. The evaluated segments of LV are 
shown according to international standards.  8=Antero-septal, 7=Anterior, 12=Antero-
lateral, 11= Postero-lateral, 10= Posterior, 9= Postero-septal. 
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Figure 3.11:  Global systolic radial strain of the left ventricle (defined as the mean of 
the regional systolic radial strains of the different segments of the LV) is shown in 
sham-operated rats (SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted 
rats (AMI) and post-infarcted diabetic rats (DM+AMI) after 2 weeks.  (ANOVA); Data 
are mean. ±SEM. n=11-20; *P<0.05 vs SHAM. **P<0.05 vs SHAM, DM+SHAM and 
AMI. 
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Figure 3.12:  Image showing representative analysis of systolic radial strain of the left 
ventricle in sham-operated rat heart (SHAM). Typical of 11-20 such different 
experiments for each group. 
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(A) 
 
(B) 
 
Figure 3.13: Images showing representative analysis of systolic radial strain of the left 
ventricle in (A) post-infarcted rat heart (AMI) and (B) diabetic post-infarcted rat heart 
(DM-AMI). Typical of 11-20 such different experiments for each group. 
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2. Effects of TH administration on the response of the diabetic heart after myocardial 
infarction 
Heart rate and functional indices after myocardial infarction in diabetic rats  
Scar areas and weights were similar in all the post-infarcted groups as shown in Table 
3.7.Heart rate was found to be significantly (p<0.05) reduced in DM+AMI hearts as 
compared to DM+SHAM. After thyroid hormone treatment, heart rate increased 
significantly (p<0.05) by  20% in DM+AMI+TH hearts as compared to DM+AMI. 
 
Left ventricular function  
The results for left ventricular functions are shown in table 3.8 and figures 3.14-3.21. 
The data show significant (p<0.05) reductions in contractile indices (EF%, LVIDs) for 
DM+AMI hearts as compared to DM+SHAM group. EF% and LVIDs were 
significantly (p<0.05) improved in DM+AMI+TH as compared to DM+AMI hearts (see 
table 3.8; figures 3.14-3.15). Significant (p>0.05) reductions were also seen in 
contractile indices measured under isometric conditions in Langendorff’s preparations 
in DM+AMI hearts as compared to DM+SHAM. In fact, LVDP, +dp/dt and –dp/dt were 
all significantly (p<0.05) reduced in DM+AMI vs DM+SHAM. Furthermore, in 
DM+AMI+TH hearts, LVDP, +dp/dt and –dp/dt were significantly (p<0.05).improved 
as compared to DM+AMI hearts (figures 3.14-3.17; figure 3.21).  
 
Systolic radial myocardial deformation 
Regional systolic radial myocardial deformation (StrainRad) for all groups is shown in 
table 3.9 and figure 3.18-3.20). The results show that the mean global StrainRad (%) was 
significantly (p<0.05). decreased in DM+AMI hearts as compared to DM+SHAM 
hearts [39±4.4% vs 8.7±2.3% ],  respectively. Similarly, in DM+AMI+TH hearts, 
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StrainRad was improved in all segments and mean global StrainRad was significantly 
(p<0.05)   increased [22.5±2.7% vs 8.7±2.3%] in DM±AMI.  
 
Cardiac hypertrophy, wall tension and geometry 
The ratio of LVW to body weight was shown to be similar in DM±SHAM and 
DM+AMI hearts, (p>0.05).  LVPW was similar in DM+AMI and DM+SHAM hearts, 
indicating an attenuation of the hypertrophic response in the diabetic hearts (figure 
3.17). LV diastolic diameter (LVIDd) was found to be significantly (p<0.05) increased 
in DM+AMI hearts as compared to DM+SHAM hearts (figure 3.14). These changes 
were translated to marked alterations in the WTI. Thus, a significant (p<0.05) increase 
in WTI was observed in DM+AMI as compared to DM+SHAM hearts (Table 3.8). 
Sphericity index (SI) was found to be significantly (p<0.05) decreased in DM-AMI 
hearts as compared to DM-SHAM hearts (Table 3.8; figure 3.19). 
After TH treatment, both the ratio of LVW to body weight and LVPW were 
significantly (p<0.05) increased as compared to DM+AMI hearts, indicating the 
development of hypertrophy in those hearts (figure 3.17). In addition, LVIDd was 
significantly (p<0.05) reduced in DM+AMI+TH versus DM+AMI hearts (figure 3.14),. 
As a consequence, WTI was nearly normalized in DM+AMI+TH hearts and this was  
found to be significantly (p<0.05) reduced as compared to DM+AMI hearts (Table 3.8). 
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  Table 3.7:  Thyroxine (T4) and triiodothyronine (T3) levels in serum, heart rate (in 
beats per min) and the calculated areas (mm²) of the scar tissues and the weights (mg) of 
the scar tissues  in sham-operated diabetic rats (DM-SHAM), post-infarcted diabetic 
rats (DM-AMI) and post-infarcted diabetic rats treated with thyroid hormone (DM-
AMI+TH)  after 2 weeks are presented in this table.(Student’s t-test); The values are 
means ± (S.E.M) (numbers in brackets).* P<0.05 vs DM-SHAM,  **P<0.05 vs DM-
AMI,      
&
 P<0.05 vs DM-SHAM and DM-AMI ; n=11-20.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters 
measured 
DM-SHAM DM-AMI DM-AMI+TH 
T4 (nM) 
45.2 (3.1) 53.0 (3.1) 48.3 (2.5) 
T3 (nM) 
1.0 (0.08) 1.1 (0.07) 1.44 (0.07)
&
 
Heart  rate 
(bpm) 
331(17) 299 (12)* 370 (17)** 
Scar area 
(mm
2
) 
…….. 82.5 (3.6) 83.9 (3.7) 
Scar weight 
(mg) 
……… 165 (10) 188 (14) 
139 
 
Table 3.8:   Left ventricular weight (LVW in mg), LVW to body weight ratio 
(LVW/BW, mg/g) and echocardiographic measurements ofposterior wall thickness at 
diastolic phase (LVPW), wall tension index (WTI, LVIDd/2* LVPW) and sphericity 
index, left ventricular internal diameter at diastolic phase (LVIDd) and at systolic phase 
(LVIDs) and ejection fraction (EF%), in sham-operated diabetic rats (DM-SHAM), 
post-infarcted diabetic rats (DM-AMI) and post-infarcted diabetic rats treated with 
thyroid hormone (DM-AMI+TH)  after 2 weeks. (Student’s t-test); The values are 
means (S.E.M) (numbers in brackets).P<0.05 vs DM-SHAM,  **P<0.05 vs DM-AMI & 
*P<0.05 vs DM-SHAM and DM-AMI    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters 
measured 
DM-SHAM DM-AMI DM-AMI+TH 
LVW (mg) 698 (18) 702  (12) 769 (30) 
LVW/BW 2.08 (0.09) 1.97 (0.05) 2.37 (0.13)** 
LVPW(mm) 1.95 (0.06) 1.92 (0.04) 2.10 (0.04)** 
WTI 1.70 (0.05) 2.27 (0.08)* 1.91 (0.06)
&
 
Sphericity 
Index 
1.85(0.04) 1.56 (0.02)* 1.65 (0.03)* 
LVIDd 
(mm) 
6.6(0.1) 8.7 (0.2)* 8.0 (0.1)
&
 
LVIDs 
(mm) 
3.9(0.15) 7.2 (0.24)* 6.0 (0.22)
&
 
EF% 74.5 (2.1) 37.9 (2.0)* 51.1 (1.0)
&
 
SVPW    
(mm/s) 
30.3 (1.9) 24.3 (0.9)
*
 37.3 (2.2)** 
LVDP 113.5 (5.9) 85.3 (4.9)* 105 (5.8)** 
+dp/dt 3671 (269) 2558  (144)* 3291 (253)** 
-dp/dt 2106(131) 1667 (110)
*
 2206 (178)** 
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(A)     
LVIDd (mm) 
 
LVIDs (mm) 
(B)
 
Figure 3.14:  Left Ventricular Internal Diameter at (A) end-diastole (LVIDd) and at (B) 
end-systole (LVIDs) are presented insham-operated diabetic rats (DM+SHAM), post-
infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats with thyroid hormone 
treatment after 2 weeks.  (ANOVA); Data are mean ±SEM; *P<0.05 vs DM+SHAM; 
**P<0.05 vs DM-SHAM and DM+AMI, n=11-20. 
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(A)  
EF%
 
SVPW(mm/sec) 
(B)  
 
Figure 3.15   Ejection fraction (A) and (B) regional systolic velocity of the posterior 
wall of the left ventricle (SVPW) measured by echocardiography are shown in sham-
operated diabetic rats (DM-SHAM), post-infarcted diabetic rats (DM+AMI) and post-
infarcted diabetic rats with thyroid hormone treatment after 2 weeks. (ANOVA); Data 
are mean ± SEM; n=11-21; *P<0.05 vs DM-SHAM; **P<0.05 vs DM+SHAM and 
DM+AMI 
** 
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(A) 
Wall Tension Index 
 
(B) 
Sphericity Index 
 
Figure 3.16:    Wall tension index (defined as the ratio of LVIDd to 2 x LVPW) and 
Sphericity Index (defined as the ratio of diastolic LV length to diastolic LV diameter)  
are shown in sham-operated diabetic rats (DM+SHAM), post-infarcted diabetic rats 
(DM+AMI) and post-infarcted diabetic rats with thyroid hormone treatment after 2 
weeks. (ANOVA); Data are mean ± SEM; n=11-20; *P<0.05 vs DM+SHAM; **P<0.05 
vs DM+SHAM and DM+AMI. 
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(A) 
 
(B) 
 
Figure 3.17: (A) Left Ventricular Weight to Body weight (LVW/BW) and (B) Left 
Ventricular Wall Thickness (LVPW) are shown in sham-operated diabetic rats (DM-
SHAM), post-infarcted diabetic rats (DM-AMI) and post-infarcted diabetic rats with 
thyroid hormone treatment after 2 weeks. (ANOVA); Data are mean ±SEM; n=7-20; 
**P<0.05 vs DM-SHAM and DM-AMI. 
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Figure 3.18:  Representative short axis imaging echocardiographic views at diastole 
and at systole from sham-operated rats (SHAM), post-infarcted rats (AMI) and post-
infarcted diabetic rats (DM+AMI) after 2 weeks. A schematic image of each is shown 
on the right for comparison. Grey colour represents viable myocardial tissue, red colour 
represents the scar area and dotted line represents the movement of the endocardial 
border during systole. Typical of 11-20 such different experiments for each group. 
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Table 3.9:  Regional Systolic radial strain (%)  at different segments of left ventricle. 
(ANOVA); Data are mean +_SEM, n=11-20; 
*P<0.05
 
 
Global  Systolic Radial Strain (%) 
 
 
 
Figure 3.19:  Global systolic radial strain of the left ventricle (defined as the mean of 
the regional systolic radial strains of the different segments of the LV) is shown in 
sham-operated diabetic rats (DM+SHAM), post-infarcted diabetic rats (DM+AMI) and 
post-infarcted diabetic rats with thyroid hormone treatment after 2 weeks.(ANOVA); 
;Data are mean ± SEM; n=117-20; *P<0.05 vs DM+SHAM; **P<0.05 vs DM+SHAM 
and DM-AMI. 
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(A)  
(B)  
Figure 3.20: Images showing representative analysis of systolic radial strain of the left 
ventricle in diabetic post-infarcted rat heart (DM+AMI) and diabetic post-infarcted rat 
heart with thyroid hormone treatment (DM+AMI+TH). Typical of 11-20 such different 
experiments for each group. 
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(A) 
LVDP (mmHg) 
(B)  
 
Figure 3.21:  (A) Left ventricular developed pressure (LVDP) and (B) the rate of 
increase and decrease of LVDP (+dp/dt and –dp/dt) are shown  in sham-operated 
diabetic rats (DM+SHAM), post-infarcted diabetic rats (DM+AMI) and post-infarcted 
diabetic rats with thyroid hormone treatment after 2 weeks. (ANOVA);  Data are mean 
± SEM; n=11-20; *P<0.05 vs DM+SHAM; **P<0.05 vs DM+SHAM and DM+AMI. 
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C. Molecular  Studies  
Thyroid hormone nuclear receptor expression in the myocardium  
Figures 3.22-3.23 show the protein expressions results for thyroid hormone nuclear 
receptor. The data show that nuclear TRα1 and TRβ1 protein expressions were not 
significantly (p>0.05) different either between SHAM and DM+SHAM hearts, or 
between SHAM and NDM+AMI hearts. However, nuclear TRα1 protein expression 
was found to be reduced significantly (P<0.05) by 2.1 fold in DM+AMI hearts 
compared to DM+SHAM (Figure 3.22). Similarly, nuclear TRβ1 protein expression was 
significantly reduced (P<0.05) by 2.0 fold in DM+AMI hearts compared to DM+SHAM 
(Figure 3.23).  
 
Myosin isoform expression and calcium cycling proteins  
Figures 3.24-3.25 show myosin isoform expressions and the calcium cycling proteins in 
the heart under the different experimental conditions. The results in figure 3.24 show 
significant (P<0.05) alterations in the pattern of myosin isoform expression in the viable 
myocardium. For example, the ratio of α-MHC to β-MHC expression was 6:1 in SHAM 
hearts as compared to 2:1 in both DM+SHAM and NDM+AMI hearts, P<0.05. 
Furthermore, in DM-AMI hearts α to β MHC ratio was 1:1, p<0.05 vs both DM+SHAM 
and NDM+AMI hearts. Figure 3.25 shows the expressions of SERCA and 
Phospholamban (PLB) under the different conditions. The results show that there was 
no significant difference in protein expressions for either SERCA or Phospholamban 
under the different experimental conditions. 
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Expression of isoforms alpha, epsilon and delta of protein kinase C  
Figure 3.26 shows the protein expressions of isoforms alpha, epsilon and delta of 
protein kinase C. The results show that the PKCδ was found to be significantly (P<0.05) 
increased by 2.35 fold in AMI as compared to SHAM hearts. In DM+AMI hearts, 
PKCδ was also increased significantly (p<0.05) by 2.5 fold as compared to 
DM+SHAM.  No significant (P>0.05) difference was seen between AMI and DM+AMI 
hearts. Similarly, no significant (P>0.05) difference was found in PKCε levels between 
all groups, PΚCα protein expression was similar in SHAM and DM-SHAM hearts. 
However, there was a significant (P<0.05) increase in PΚCα levels by 2.5 fold in 
DM+AMI as compared to DM+SHAM hearts. A slight trend to increase was seen in 
PΚCα in AMI hearts compared to SHAM. 
 
Activation of intracellular kinase signalling  
Figures 3.27-3.30 show the activation of a number of intracellular kinases under the 
different experimental conditions. The results show no significant (P>0.05) difference in 
JNK kinase and phospho-Akt levels between all groups (Figures 3.28-3.29). In DM-
SHAM hearts, phospho-p38 MAPK levels were also not significantly different from 
SHAM, but significantly (P<0.05) increased in AMI hearts compared to DM combined 
with AMI hearts and significantly (P<0.05) decreased in DM+AMI hearts (figure 3.27) 
compared to AMI hearts. In contrast, the protein expressions for phospho-p44 and p42 
ERK kinases increased significantly (P<0.05) by 1.8 and 2.0 folds, respectively as 
compared to SHAM hearts (figure 3.30). In AMI hearts, phospho-p38 MAPK levels 
were found to be increased 1.9 fold compared SHAM,, while phospho-p44 and p42 
ERK kinases were significantly (P<0.05) increased by 2.0 and 2.2 folds, respectively as 
compared to SHAM hearts. In DM+AMI hearts, phospho-p38 MAPK levels were found 
to be significantly (P<0.05)  reduced by  2.0 fold as compared to AMI, while remained 
unchanged as compared to DM+SHAM hearts, P>0.05. In addition, phospho-p44 and 
p42 ERK kinases were unchanged in DM+AMI as compared to both AMI and DM-
SHAM hearts, P>0.05 (Figures 3.27 -3.30). 
 
150 
 
 
(A) 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
SHAM DM-SHAM AMI DM-AMI
TRα1 protein expression                       
(Arbitrary Units)
**
 
(B) 
 
 
 
Figure 3.22: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of thyroid hormone receptor α1 (TRα1) protein expression in sham-
operated rats (SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats 
(AMI) and post-infarcted diabetic rats (DM+AMI) after 2 weeks. Molecular weights of 
proteins (in kDa) were assessed by molecular weight markers. TRα1 was detected as 
single band with molecular weights around 50 kDa, respectively. Histone H3 was used 
to normalize for slight variations in nuclear protein loading. (Columns are means of 
optical ratio or  arbitrary units. (Mann-Whitney); Data are mean ± SEM; n=11-20; 
**P<0.05 vs SHAM and DM-SHAM. 
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Figure 3.23: (A) Densitometric assessment in arbitrary units and (B) representative  
Western Blots of thyroid hormone receptor β1 (TRβ1) protein expression in sham-
operated rats (SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats 
(AMI) and post-infarcted diabetic rats (DM+AMI) after 2 weeks. Molecular weights of 
proteins (in kDa) were assessed by molecular weight markers. TRβ1 was detected as 
single band with molecular weight around 60 kDa, respectively. Histone H3 was used to 
normalize for slight variations in nuclear protein loading. (Columns are means of optical 
ratios or arbitrary units, ± SEM; Mann-Whitney); **P<0.05 vs DM-SHAM and AMI. 
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Figure 3.24: (A) Densitometric assessment in arbitrary units (%) and (B) representative 
images of myosin heavy chain isoform expression in sham-operated rats (SHAM), 
sham-operated diabetic rats (DM+SHAM), post-infarcted operated rats (AMI) and post-
infarcted diabetic rats (DM+AMI) after 2 weeks. (Columns are means of optical ratios 
or arbitrary units, ± SEM; ANOVA).*P<0.05 vs SHAM; **P<0.05 vs DM+SHAM and 
AMI. 
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     (B) 
 
 
Figure 3.25: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of SERCA and phospholamban (PLB) protein expression in sham-
operated  rats (SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats 
(AMI) and post-infarcted diabetic rats (DM+AMI) after 2 weeks. (Columns are means 
of optical ratios or arbitrary units, ± SEM; Mann-Whitney). Note that there was no 
significant difference in protein expressions for either SCERCA  and PLB between the 
different parameters. 
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(C)  
         (D) 
 
           (E) 
 
Figure 3.26: (A,B and D) Densitometric assessment in arbitrary units and  (C and E) 
representative Western Blots of isoforms α, ε and δ of  PKC  in sham-operated  rats 
(SHAM), sham-operated diabetic rats (DM-SHAM), post-infarcted rats (AMI) and post-
infarcted diabetic rats (DM-AMI) after 2 weeks. (Columns are means of optical ratios or 
arbitrary units, ± SEM; Mann-Whitney); n=12=20; *P<0.05 vs SHAM; **P<0.05 vs 
DM-SHAM and AMI; 
&
P<0.05 vs DM-SHAM 
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              (A). 
 
      (B) 
 
Figure 3.27: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of p38 MAP kinase in sham-operated rats 
(SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and 
post-infarcted diabetic rats (DM+AMI) after 2 weeks. (Columns are means of optical 
ratiosor arbitrary units, ± SEM; Mann-Whitney); n=11-20; * P<0.05 vs SHAM, #P<0.05 
vs DM+SHAM and DM+AMI   
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    (A) 
 
 
                 (B) 
 
Figure 3.28: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of p54 JNK  in sham-operated  rats (SHAM), 
sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and post-infarcted 
diabetic rats (DM+AMI) after 2 weeks. (Columns are means of optical ratios or 
arbitrary units, ± SEM; Mann-Whitney); n=11-20. There is no significant difference 
between the different parameters. 
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Figure 3.29: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of Akt kinase in sham-operated rats (SHAM), 
sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and post-infarcted 
diabetic rats (DM+AMI) after 2 weeks. (Columns are means of optical ratios or 
arbitrary units, ± SEM; Mann-Whitney). Note that there was no significant difference 
between the different parameters .n=11-20.  
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Figure 3.30: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of p44 and p42 ERKs in sham-operated  rats 
(SHAM), sham-operated diabetic rats (DM+SHAM), post-infarcted rats (AMI) and 
post-infarcted diabetic rats (DM+AMI) after 2 weeks. (Columns are means of optical 
ratiosor arbitrary units, ± SEM; Mann-Whitney); n=11-20; .* P<0.05 vs SHAM, 
#
P<0.05 vs DM+SHAM and DM+AMI   
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2. Effects of TH administration on the response of the diabetic heart after myocardial 
infarction 
 
Thyroid hormone nuclear receptor expression in the myocardium 
Figure 3.31 shows the thyroid hormone nuclear receptor expression in the myocardium. 
The results show that the nuclear TRα1 protein expression was found to be reduced 
significantly (P<0.05) by 2.1 fold in DM+AMI hearts compared to DM+SHAM. 
Moreover, nuclear TRβ1 protein expression was 2.0 fold less in DM+AMI hearts, 
P<0.05 compared to DM+SHAM. . In DM+AMI+TH hearts, TRα1 expression was 
increased as compared to DM+AMI hearts but not at a statistically significant level 
(Figure 3.31). Furthermore, in DM+AMI+TH hearts, TRβ1 expression was significantly 
(P<0.05) increased by 2.0 fold as compared to DM+AMI hearts,.  No significant 
changes T4   plasma levels were observed, but there was a significant (P<0.05) increase 
in plasma Tз level for DM+AMI+TH compared to either  DM+AMI or AMI+SHAM 
animals. 
Calcium cycling proteins and myosin isoform expression  
Figures 3.32-3.33 show that functional changes were accompanied by alterations in the 
pattern of myosin isoform expression (figure 3.32) and calcium cycling proteins (figure 
3.33) in the viable myocardium. Thus, in DM+AMI  hearts, SERCA was unchanged 
while phospholamban was found to be slightly increased 1.25 fold as compared to 
DM+SHAM but not at a statistically significant level, p>0.05. Furthermore, the ratio of 
α-MHC to β-MHC expression was 2:1 in DM+SHAM as compared to 1:1 in DM+AMI 
hearts, P<0.05 (Figure 3..33).  TH treatment resulted in 1.8 fold increase in SERCA 
expression (P<0.05) with no accompanying changes in PLB expression in 
DM+AMI+TH hearts as compared to DM+AMI hearts. DM+AMI+TH hearts were 
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found to express only α-MHC, as compared to 1:1 ratio of α-MHC to β-MHC 
expression in DM-AMI hearts, respectively; P<0.05 (Figure 3.33). 
 
Expression of isoforms alpha and epsilon of protein kinase C  
 Figure 3.34 shows the protein expressions of isoforms alpha and epsilon of protein 
kinase C. The results show that in DM+AMI hearts, PKCδ expression was found to be 
significantly (P<0.05) increased by 2.5 fold as compared to DM+SHAM. TH treatment 
resulted in 2.0 fold increase (P<0.05) in PKCδ in DM-AMI+TH hearts as compared to 
DM-SHAM hearts, while no significant (P>0.05) difference was found between 
DM+AMI+TH and DM+AMI hearts (Figure 3.34). In DM+AMI hearts, PKCα 
expression was found to be increased 2.5 fold as compared to DM+SHAM (P<0.05) 
while PKCε remained unchanged as compared to DM+SHAM hearts, P>0.05.( Figure 
3.34). TH treatment resulted in 1.9 fold reduction in PKCα and 1.8 fold reduction in 
PKCε in DM+AMI+TH hearts as compared to DM+AMI hearts, P<0.05 (Figure 3.34). . 
 
Intracellular kinase signalling activation 
Figures 3.36-3.38 show the intracellular kinase signalling activation proteins. The 
results show a significant (P<0.05) difference in the protein expressions for phosphor-
p38 MAPK/total p38 MAPK (measured as arbitrary units) for DM+AMI+TH compared 
to DM+SHAM or DM+AMI. In contrast, the data show  no significant difference in the 
gene expressions for  phospho-Akt, phospho-ERK and phospho-JNK kinase levels  
between DM+SHAM, DM+AMI and DM+AMI+TH hearts;P>0.05 (Figures 3.36-3.38)  
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Figure 3.31:  (A and B) Densitometric assessment in arbitrary units and (C) 
representative Western Blots of thyroid hormone receptor α1 (TRα1) and β1 (TRβ1)  
protein expressions are shown  in  SHAM-operated diabetic rats (DM+SHAM), post-
infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats with thyroid hormone 
treatment after 2 weeks. Histone H3 was used to normalize for slight variations in 
nuclear protein loading. Columns are means of optical ratios, bar=SEM; Mann-
Whitney); n=11-20;.* P<0.05 vs DM-SHAM, ** p<0.05 vs DM-AMIc 
   
163 
 
 (A) 
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Figure 3.32: Densitometric assessment in arbitrary units and representative images of 
myosin heavy chain isoform expression shown in sham-operated diabetic rats 
(DM+SHAM), post-infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats 
with thyroid hormone treatment after 2 weeks.   (Columns are means of optical ratios or 
arbitrary units, ± SEM; ANOVA);  n=11-20; * P<0.05 vs DM+SHAM, ** P<0.05 vs 
DM+SHAM and DM+AMI 
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        (B) 
Figure 3.33: (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of SERCA  and phospholamban protein expressions are shown  in sham-
operated diabetic rats (DM+SHAM), post-infarcted diabetic rats (DM+AMI) and post-
infarcted diabetic rats with thyroid hormone treatment after 2 weeks.  (Columns are 
means of optical ratios or arbitrary units, ± SEM; Mann-Whitney); n=11-20; ** P<0.05 
vs DM-SHAM and DM-AMI. 
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Figure 3.34:  (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of isoforms α, ε and δ of PKC areshown insham-operated diabetic rats 
(DM+SHAM), post-infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats 
with thyroid hormone treatment after 2 weeks.  (Columns are means of optical ratios or 
arbitrary units, ± SEM; Mannn-Whitney); n=11-20; *P<0.05 for DM +AMI vs 
DM+SHAM; *P<0.05 for DM+AMI + TH vs DM+SHAM and AMI. 
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        (A) 
 
 
                (B) 
Figure 3.35:  (A) Densitometric assessment in arbitrary units and  (B) representative 
Western Blots of phosphorylated  levels of p38 MAP kinase are shown  in sham-
operated diabetic rats (DM-SHAM), post-infarcted diabetic rats (DM-AMI) and post-
infarcted diabetic rats with thyroid hormone treatment after 2 weeks. (Columns are 
means of optical ratios or arbitrary units, ± SEM; Mann-Whitney); n=11-20; ** P<0.05 
vs DM+SHAM and DM+AMI 
 
 
168 
 
 
(A) 
 
      (B) 
 
Figure 3.36:  (A) Densitometric assessment in arbitrary units and  (B) representative 
Western Blots of phosphorylated  levels of p54 JNK  in sham-operated diabetic rats 
(DM-SHAM), post-infarcted diabetic rats (DM+AMI) and post-infarcted diabetic rats 
with thyroid hormone treatment after 2 weeks. (Columns are means of optical ratios or 
arbitrary units, ± SEM; Mann-Whitney); n=11-20; Note that there is no significant 
difference in the different parameters. 
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Figure 3.37 (A)  Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of Akt kinase are shown insham-operated 
diabetic rats (DM-SHAM), post-infarcted diabetic rats (DM-AMI) and post-infarcted 
diabetic rats with thyroid hormone treatment after 2 weeks. (Columns are means of 
optical ratios or arbitrary units,  ±SEM; Mann-Whitney).; n=11-20. Note that there is no 
significant difference in the different parameters. 
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Figure 3.38:  (A) Densitometric assessment in arbitrary units and (B) representative 
Western Blots of phosphorylated levels of p44 and p42 ERKs in sham-operated diabetic 
rats (DM-SHAM), post-infarcted diabetic rats (DM-AMI) and post-infarcted diabetic 
rats with thyroid hormone treatment after 2 weeks.  (Columns are means of optical 
ratios or arbitrary units, ±SEM; Mann-Whitney). n=11-20. Note that there is no 
significant difference in the different parameters 
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Preview to discussion 
Diabetes mellitus (DM) is a major global metabolic disorder currently affecting more 
than 300 people worldwide. It is also estimated that another 100 million persons are 
undiagnosed and another 200 persons are pre-diabetics (Zimmet and Alberti, 2006; 
Kumar and Clark, 2007). If left untreated, DM can lead to a number of long term 
complications including neuropathy, nephropathy, retinopathy, cardiovascular diseases 
and others. In general, most diabetics will eventually suffer and subsequently die from 
heart diseases (Kumar and Clark, 2007). To date, we still do not understand fully how 
DM can induce heart failure and moreover, the cellular and molecular mechanisms 
involved in the process. As such, it is vitally important to unravel the scientific problem. 
Hence, this study employed the streptozotocin (STZ) -induced Type 1 diabetic (T1DM) 
rats to investigate plasma thyroid hormone levels, haemodynamic parameters and the 
cellular and molecular mechanisms of cardiac remodelling during diabetes mellitus 
(DM)-induced cardiomyopathy, acute myocardial infarction (AMI) and a combination 
of DM with AMI compared to age matched healthy sham controls. In another series of 
experiments, the investigation further explored  the beneficial role(s) of thyroid 
hormone (TH) treatment in either preventing or reducing the effect of DM in 
combination with AMI on the heart compred to heart from DM sham animal. This 
discussion will be focussed on (a) the experimental model and the role of STZ in 
inducing DM, (b) the general characteristics of the animals, (c) the functional changes 
in the heart in vivo and in vitro employing echocardiography under the different 
experimental conditions and (d) the cellular and molecular mechanisms whereby either 
DM or AMI alone or when combined can induce remodelling of the heart comparing the 
absence and presence of thyroid hormone treatment and in age matched control 
animals.. 
STZ-induced diabetes mellitus 
The STZ induced diabetic model has been in use for several years (Shaffer, 1991) to 
study the effect of type 1 DM on different physiological and biochemical parameters 
employing different organ systems including the heart (Bracken et al, 2003; 2004; 
Howarth and Singh, 1999). STZ, a naturally occurring broad spectrum compound 
(antibiotics), is produced by the bacterium Streptomyces achromogenes and it is a 
cytotoxic glucose analogue that can accumulate in the pancreatic β cells, thus inhibiting 
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insulin secretion via destruction of the beta cells causing a state of insulin-dependent 
DM.  These two effects are attributed to the alkylating properties of STZ (Varva, 
1959/1960). Many cellular actions have been attributed to the effect of STZ including 
damage to pancreatic cell mitochondria (Ganda et al, 1976). STZ is a nitroso-urea 
analogue which is lipophilic and it is rapidly taken up by the plasma membrane of 
tissues. STZ is taken up by the low-affinity GLUT2 transporters in the plasma 
membrane of the pancreatic β cells (Tjalve, 1976). The drug thus accumulates in the cell 
and the DNA alkylating activity of the methyl-nitrosourea moiety, at the O6 position of 
the guanine is the main mechanism of toxicity by the drug. The methyl group is 
transferred from the drug to the DNA molecule causing damage to the pancreatic islets, 
thus resulting in the fragmentation of DNA, through a series of events (Yamamoto, 
1981). The poly (ADP-ribose) polymerase, in an attempt to repair the DNA is over-
stimulated and thus diminishing cellular NAD+ and the ATP stores, resulting in cell 
necrosis. In addition,, protein methylation caused by STZ may contribute to the 
functional defects of the β cells after exposure to STZ (Bennett and Pegg, 1981). 
An alternative hypothesis suggests that a part of the diabetogenic effect of STZ may be 
due to its potential to act as a donor of nitric oxide (NO). STZ contains a nitroso group 
enabling it to release NO, thus increasing the activity of guanylate cyclase and also, the 
formation of cGMP, both being characteristic effects of NO (Delaney, 1985). The 
generation of reactive oxygen species (ROS), such as superoxide and hydroxyl radicals 
deriving from hydrogen peroxide dismutation during hypoxanthine metabolism could 
accompany the effect of STZ, thus accelerating β cells destruction (Nukatsuka, 1990). 
Clinically symptoms and signs of DM are clearly seen in rats within 24 hours following 
single intraperitonial injection of STZ including increased glucose concentration in the 
blood and urine, increase urine volume, and weight loss (Kumar and Clark, 2007; 
Adeghate et al ,2010). Some of these clinical changes depend upon the concentrations 
of the STZ employed in the study (Adephate et al, 2010). Following STZ-induced DM, 
the animals develop long term complications such as retinopathy, neuropathy, 
nephropathy, cardiomyopathy, exocrine gland insufficiencies, foot ulcers and many 
others (Howarth and Singh, 1999; Bracken et al, 2003; 2004; Kumar and Clark, 2007; 
Adeghate et al 2010).  
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General characteristics of the animals 
The results of this study have also shown that the STZ-induced diabetic rats were 
hyperglycaemic and moreover, they had reduced body and heart weights compared to 
age-matched controls (see table 3.3). The reduction in body weight may be due to either  
the DM itself or the animals consumed less chow and more water due to the excess 
urination (polyurea). In addition, from physical examination, the gastrointestinal tract of 
the diabetic animals show signs of swelling and marked inflammation which may be 
associated with the indigestion or exocrine gland insufficiencies (Kumar and Clark, 
2007). In addition, the results show that the heart weight to body weight and the lung 
weight to body weigh in the diabetic rats increased significantly compared to age–
matched control indicating signs of hypertrophy of the heart and congestion of the 
lungs. These characteristics are similar to those reported in the literature (Qureshi et al,, 
2001; Howarth and Singh, 1999; Bracken et al, 2004). One major long term 
complication of DM is cardiomyopathy, in which the heart is unable to pump blood 
efficiently. This could be due to several factors including reduced contraction, 
development of fibrosis, a derangement in calcium homeostasis and carbonylation of 
specific transporting proteins (Hatori et al, 2000; Choi et al, 2002; Bracken et al, 2003; 
D’Ssouza 2010; D’Souza et al, 2011; Shao et al, 2010; 2012). 
Contractile dysfunction is frequently reported in human patients and in experimental 
animals with diabetes mellitus (DM) (Bracken et al. 2003; Kumar and Clark, 2007). 
This metabolic disorder is now accepted as a major risk factor for cardiovascular 
diseases rivalling cigarette smoking, stress, obesity, sedentary lifestyles, cholesterol 
disorders and hypertension (Standl and Schnell, 2000). In the UK alone, over 40,000 
people die annually from DM-induced cardiomyopathy and it costs the National Health 
Service around £5-6 billion per year to diagnose, to treat and to care for diabetic patients 
(Currie, 1997). With over 300 million people affected globally by DM (Amos et al, 
997), most of whom may die from cardiovascular- related diseases, it is imperative that 
we understand the cellular and molecular mechanisms of DM-induced cardiomyopathy 
in order  not only to prolong life, but also to provide a better quality of life for the  
diabetic patients globally. 
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Preliminary studies to establish baseline 
The present study used young male Wistar rats which were maintained on a 12 h 
light/dark cycle and fed with a standard chow ad libitum. DM was induced by a single 
injection of STZ (Kalofoutis et al, 2010; Shao et al, 2010). Induction of experimental 
diabetes in the rat using STZ is very convenient and simple method to use resulting in a 
type 1 diabetic model. In this study, preliminary experiments using low (35 mg/bw) and 
high (60 mg/bw) dose of STZ were performed to select the appropriate dose resulting in 
diabetes with glucosuria but without keto-acidosis. The initial results showed that a low 
dose (35 mg/bw) of STZ was more convenient in inducing  DM with very small traces 
of ketone in the blood compared to 60 mg/bw (Adeghate et al, 2010). Comparing the 
data presented in the tables 3.1 and 3.2 of this study, the results show that those rats 
which were injected with 60 mg/bw STZ had average urine glucose and ketone levels of 
1050 mg/dl and 86.5 mg/dl, respectively. In contrast, rats injected with 35 mg/bw of 
STZ had mean urine glucose and ketone levels of 625 mg/dl and 3.5 mg/dl, 
respectively. With the very high dose of STZ, urine glucose level doubled and urine 
ketone concentration increased by almost 25 times. The rationale for these preliminary 
studies was to eliminate the ketosis in the animals (Kumar and Clark, 2017; Adeghate et 
al, 2010). It is well known that in chronic diabetes, because of the lack in glucose 
entering the cells where it can be used as a form of energy source, the body begins to 
use stores of fats as an alternative source of energy and in turn, the body produces either 
ketones or acidic by-products. There is much evidence that patients who suffer from 
heart failure are ketosis-prone since their ketonaemia is associated with increased 
circulating levels of free fatty acids, growth hormones and cortisols (Lommi et al, 1997; 
Kumar and Clark, 2007).  Ketosis is due to the use of fatty acids as an energy source and this 
occurs during diabetes (Kumar and Clark, 2007). Ketosis is also an additional index to measure 
the severity of heart failure (Lommi et al, 1997). 
Physiological and Biomolecular methods involved with the project 
In tackling the scientific problems a number of novel scientific methods were involved 
in this study. They included STZ-induced diabetic model, induction of myocardial 
infarction, assessment of cardiac function in vivo and in vitro using  the balloon method 
and echocardiography and molecular biological changes or expressions of different 
proteins in the heart (Kalofoutis et al, 2010; Shao et al, 2010). In brief, it is of 
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paramount importance to understand these methods by discussing their relevance in this 
study. 
Induction of myocardial infarction (AMI) 
Acute myocardial infarction is an effective method to induce heart failure and it was 
induced by ligation of the left coronary artery as previously described (Pantos et al, 
2007; Kalofoutis et al, 2010). Rats were anaesthetized with an intraperitoneal (ip) 
injection of ketamine (70 mg/bw) and midazolame (0.1 mg/bw), intubated and 
ventilated via a tracheal cannula using a constant-volume rodent ventilator. Anaesthesia 
was maintained by inhalation of small doses of sevoflurane (1-2%). Left thoracotomy 
was performed at the fourth intercostal space followed by pericardiotomy. Left coronary 
artery was then ligated with a 6-0 silk round-bodied suture. Continuous 
electrocardiogram (ECG) recordings were used to monitor heart rate and any changes 
due to ischaemia after coronary artery ligation. Body temperature was maintained at 37
o 
C by using a heating blanket (Harvard Homeothermic Blanket, 50-7061). This 
procedure resulted in 15-20% mortality within the first 24 h in the infarction control 
group, while it increased by up to 30-40% in the diabetic infarction group. The high 
mortality rate was probably due to a combination of DM with AMI since both DM and 
AMI individually can lead to cardiomyopathy (Kalofoutis et al, 2010).  AMIs which 
produced a scar areas of 60 mm
2
 to 105 mm
2
 were included in this study, corresponding 
to 25%-40% of the left ventricle. The animals were left to recover for 2 weeks after 
myocardial infarction. The same procedure was followed for sham-operated control 
animals, but the coronary artery was not ligated (Pantos et al, 2010; 2011; 2012). In all 
these experiments involving the technique of AMI, special care was taken in order to 
reduce mortality. The method is rather tedious and it requires special training (Pantos et 
al 2010).  
Isolated heart preparation 
A non-ejecting isolated rat heart preparation was perfused at a constant flow according 
to the Langendorff‘s technique. Hearts were paced at a rate of 320 beats/min with a 
Harvard pacemaker. An intra-ventricular balloon allowed measurement of contractility 
(Pantos et al, 2010). Left ventricular balloon volume was adjusted to produce an 
average initial left ventricular end-diastolic pressure of 7-8 mm Hg in all groups. The 
water filled balloon was connected to a pressure transducer and the LV pressure signal 
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was transferred to a computer using data analysis software which allowed continuous 
monitoring and recording of heart function. Left ventricular developed pressure 
(LVDP), defined as the difference between left ventricular peak systolic pressure and 
left ventricular end-diastolic pressure, represented a contractility index obtained under 
isometric conditions. Left ventricular systolic function was assessed by recording the 
left ventricular developed pressure (LVDP, mm Hg) and the positive and negative first 
derivative of LVDP; +dp/dt (mmHg/sec), -dp/dt (mm Hg/sec). These are conventional 
methods used world wide by cardiac Physiologists in measuring cardiac function 
(Pantos et al, 2010; 2011; 2012; Shao et al, 2010; 2012). Like the induction of AMI, 
these experiments are tedious and they required an element of scientific skills.  
Echocardiography  
 Ecocardiography is an effective physiological tool to measure cardiac function in vivo 
(Kalofoutis et al, 2010; Shao et al, 2010; 2012). Short and long-axis images were 
acquired using a digital ultrasound system (Vivid 7 version Pro, GE Healthcare) with 
the 14.0-MHz i13L probe. A large number of consecutive measurements were 
performed and analysed by two independent operators. Left ventricular (LV)  internal 
diameter (LVID) at the diastolic phase (LVIDd), LV internal diameter at  the systolic 
phase (LVIDs),  posterior wall thickness at the diastolic phase (LVPW), systolic 
velocity of the  posterior wall radial displacement (SVPW) and the ejection fraction 
(EF%) were measured to determine cardiac function. EF% was calculated using the 
Simpson’s equation. SVPW was measured from two-dimensional guided M-mode 
recordings obtained at the mid-ventricular level as previously described (Pantos, 2007; 
Shao, 2010; Kalofoutis, 2010; Shao et al, 2010; 2012). SVPW was used to assess the 
segmental contractile function of the non-infarcted myocardium, while EF% was used 
to determine the global contractile LV function. Wall tension index (WTI) was defined 
as the ratio (LVIDd/2*Posterior Wall thickness) as previously described (Pantos et al, 
2007; Shao et al, 2010; 2012). WTI was measured in order to indirectly assess 
myocardial wall stress. In addition, sphericity index (SI), defined as the ratio of 
maximum long axis (in mm) to maximum short axis (in mm) of the left ventricle was 
determined in order to assess LV geometry. All measurements were averaged for at 
least 3 consecutive cardiac cycles.These different measured parameters provide the 
scientist with relevant physiological data of left ventricular function since the left 
ventricule is the most important chamber in the heart to supply blood, nutrients and 
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oxygen to to the different organs and tissues of the body (Kumar and Clark, 2007; 
Vander et al 2007).  
Assessment of Molecular changes  
Cytosolic samples were prepared for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and for Western blotting, following SDS-PAGE and 
proteins were transferred electrophoretically to a nitrocellulose membrane using 
established methods (Pantos et al, 2007; Kalofoutis et al, 2010; Shao et al, 2010; 2012). 
Filters were probed with specific antibodies against total and phospho-ERK, total and 
phospho-AKT (Ser 473), total and phospho-JNKs and total and phospho-p38, SERCA, 
phospholamban, PKCα and PKCε. Immunoreactivity was detected by enhanced 
chemiluminescence using Lumiglo reagents. Chemiluminescence was then detected by 
image analysis system. TRs protein expression was determined in nuclear fraction. 
Protein concentrations were determined by the BCA method. It is now well established 
that cardiac dysfunction is expressed not only at physiological level, but also at 
subcellular and molecular levels involving a number of regulatory proteins in the heart 
(Shao et al 2010; 2012) 
 
Baseline characteristics of the unstressed diabetic myocardium  
A mild cardiac dysfunction was observed in these animals with changes in dp/dt and a 
shift of myosin isoform expression towards β-MHC expression. Interestingly, this 
model appears to be similar to the CIRCO mice model in which insulin receptor has 
been deleted (Sena, 2009). 
Diabetes-induced cardiomyopathy 
 As discussed above, more than 300 million people worldwide have DM mellitus and 
about 70 % of them will develop a unique type of heart failure referred to as diabetic 
cardiomyopathy (World Health Organisation, 2011; American Diabetes Association, 
2011). A significant percentage of these individuals will also succumb prematurely 
from a fatal stress-induced ventricular arrhythmia (American Diabetes Association, 
2011; Bertoni et al, 2004; MacDonald et al, 2008). To date, the mechanisms responsible 
for the reduced basal and stress-induced aberrant ventricular contractions in individuals 
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with diabetes mellitus remain incompletely defined and therapeutic strategies to slow 
their development and or progression is virtually non-existent. Some previous studies 
have shown that thyroid hormone may be of paramount importance in the remodelling 
of the heart during diabetes, thus either delaying or reducing mortality (Pantos et al, 
2005; 2007; 2012).  
This study investigated cardiac function and dysfunction during STZ-induced 
cardiomyopathy over a period of 4 weeks followed by induction of acute myocardial 
infarction for 2 weeks compared to controls. Two days after AMI, the DM+ AMI 
animals were treated with thyroid hormone for two weeks and there after the animals 
and isolated hearts were subjected to a number of in vivo and in vitro measurements. 
For comparison, the study employed 5 groups of experimental animals including control 
sham operated rats (sham), diabetic sham operated rats (DM+SHAM), diabetic rats 
subjected to acute myocardial infarction (DM+AMI) and diabetic rats subjected to acute 
myocardial infarction but treated with thyroid hormone (DM+AMI+TH) for 
comparison. It was of paramount importance to employ the appropriate controls 
throughout the study for comparison. 
Physiological studies 
The results of the study have clearly demonstrated that induction of acute myocardial 
infarction (AMI) can result in significant (P< 0.05) changes in all the different measured 
parameters including LVPW, WTI, sphericity index, LVIDα, LVIDs, EF %, SVPW, 
LVDP, +dp/dt and –dp/dt, except for LVW/BW compared to control sham (see table 
3.4.). These data have indicated that myocardial infarction can lead to a large, but a 
weak heart (left ventricle) which pumps significantly less blood than the sham control 
heart. The results also show that the diabetic sham heart was also significantly (P< 0.05) 
weak compared to control sham heart with marked decreases  in SVPW, LVDP, +dp/dt 
and –dp/dt. Moreover, when the diabetic heart was induced with myocardial infarction 
there were further decreases in the various measured haemodynamic parameters 
compared to rats induced with myocardial infarction alone. These results have clearly 
demonstrated that acute myocardial infarction can lead to the development of a large 
(hypertrophy), but a weak heart and this can be exacerbated or even becomes weaker in 
the STZ –induced diabetic heart subjected to AMI (Pantos et al, 2012).  Similarly, the 
results of the study have also shown that the sphericity index was significantly (P<0.05) 
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decreased in acute myocardial infarction and in DM combined with AMI compared to 
the control sham. Similarly, the data presented in table 3.6 of this study have also shown 
that regional systolic radial strain was significantly (P<0.05) reduced in the different 
segments of the left ventricle of AMI and DM+AMI hearts compared to control sham 
animals (see table 3.6). In the diabetic left ventricle, only the antero-septal strain of the 
left ventricle was significantly (P<0.05) reduced compared to sham control non- 
diabetic left ventricle. The other measured areas of the left ventricle in the DM heart 
were reduced, but not significantly different from control left ventricle sham heart.  
These segments of the left ventricle became even weaker in the infarct diabetic heart 
compared to the normal infarct heart or the normal sham diabetic heart. These data also 
show that diabetes on its own can lead to a weak left ventricle compared to the control 
heart (see table 3.4).These parameters were only reduced, but not significantlt different 
from control sham. Taken together, these physiological data have clearly demonstrated 
that diabetes mellitus can lead to the development of a weak left ventricle of the rat 
heart. Moreover, induction of myocardial infarction can enhance the weakness of the 
left ventricle and myocardial infarction in combination with diabetes can potentiate the 
weakness of the left ventricle, possible leading to left ventricular failure (Pantos et al. 
2012). The results of this study have also shown that the plasma levels of either T3 or 
T4 remained virtually unchanded under control sham, DM, AMI or DM in combination 
with AMI conditions. However, heart rate decreased significantly (P<0.05) in the 
DM+AMI group compared to the other groups (see table 3.5). However there was no 
significant change in either scar area or scar weight comparing AMI with DM+AMI 
hearts.  
The question which this thesis attempted to answer is: whether thyroid hormone (TH) 
treatment can reverse these adverse pathophysiological effects of acute myocardial 
infarction in combination with DM compared to diabetic sham rats and STZ-induced 
diabetic rats subjected to AMI in the absence of TH treatment. Numerous studies have 
demonstrated that thyroid hormone treatment can both repair and regenerate the heart. It 
acts like a natural therapeutic agent leading to cardiac remodelling (Kalofoutis et al, 
2010; Pantos and Mourouzis 2010a; 2010b; Pantos et al, 2010; Lymvaious et al, 2011; 
Pantos et al, 2012). 
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Thyroid hormone (TH) and its effect on the heart.  
The results of the study have also shown that the serum level of the thyroxine (T4) 
increased slightly in DM-AMI-treated animals compared to the DM sham rats but the 
value was not significant. In contrast, serum levels of triiodothyroxine (T3) increased 
significantly in the thyroid-treated DM+AMI rats compared to the non-treated DM-
sham and DM-AMI rats. Thyroid hormone increased heart rate significantly in 
DM+AMI rats compared to DM-sham and DM-AMI untreated rats. In addition, thyroid 
hormone evoked a marked increase in tissue scar weight, but it had no effect on the 
tissue scar area compared to non-treated DM+AMI animals (see table 2.7). These 
results have clearly shown that thyroid hormone treatment had marked beneficial  
effects on post-infarcted diabetic rats in relation to the blood levels of the hormones, 
heart rate and scar weight. These results are in total agreement with previous findings 
(Pantos et al, 2008; 2012).  
Thus, the next logical step of this study was to determine the effect of thyroid hormone 
treatment in the DM+AMI hearts compared to non-treated DM-sham and DM+AMI 
hearts. The results show that thyroid hormone treatment over a period of two weeks had 
a marked and significant effect on the post infracted heart compared to the non-treated 
hearts. LVW, LVW/BW, LVPW, wall tension, sphericity index, LVIDd, LVIDs, %EF  
SVPW, LVDP, +dp/dt and –dp/dt, all significantly  (P<0.05) increased  in the hearts of 
thyroid hormone- treated rats compared to hearts from the non-treated DM-sham  and 
DM+AMI rats. In contrast, most of the measured haemodynamic  parameters of the left 
ventricle of the heart decreased significantly (P<.05) in the non-treated DM+AMI rats 
compared to DM-SHAM rats and DM+AMI thyroid hormone treated rats ( see table 
3.8). Together, the present results show that acute myocardial infarction can have 
detrimental effects on the left ventricle of the STZ-induced diabetic rat heart. However, 
two weeks of treatment of the STZ-induced diabetic rats with thyroid hormone, not only 
reversed the detrimental effects of acute myocardial infarction, but it also enhanced the 
physiological status of the left ventricle compared to hearts from non-treated DM-sham 
rats (Pantos etl al, 2008; 2012). 
  Furthermore, the results presented in this study (see table 3.9) have also demonstrated 
that thyroid hormone can elicit significant beneficial effects on different parts or 
segments of the left ventricle. The data presented in table 3.9 show that the two weeks 
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of treatment of acute infracted diabetic heart with thyroid hormone can lead to a 
significant (P<0.05) increases in the aterio-septal, the whole anterior, the antero-lateral 
and the posterior-lateral segments of the left ventricle compared to the non-treated DM-
AMI left ventricle. The results have further demonstrated that acute myocardial 
infarction can evoke significant (P<0.05) decreases in the sizes of various segments of 
the left ventricles compared to the diabetic+sham non-treated left ventricle. The thyroid 
hormone treatment over two weeks did not completely reverse the detrimental effects of 
acute myocardial infarction compared to DM-sham left ventricle, but the hormone had 
marked and significant beneficial effects compared to the left ventricle from DM-AMI 
non-treated rats (Pantos et al 2008; 2010; 2012). 
These results have clearly highlighted the importance of thyroid hormone in cardiac 
repair and regeneration (Pantos et al, 2012). The hormone is acting like a natural healer 
for the heart during such adverse conditions as DM, AMI and AMI+DM. Numerous 
studies have previously shown the beneficial effects of thyroid hormone in organ and 
tissue remodelling and in repairing and in the regeneration process in the body (Forlow 
and Neff, 2006; Sato et al, 2007; Slack et al, 2008; Bouzaffour et al, 2010; Pantos et al, 
2010; 2012).  It is well known that thyroid hormone plays a major role in the 
development of the embryonic heart and in the control of various aspects of repair 
and/or regeneration. This is probably induced via thyroid hormone reactivating the 
development of gene programming in adult life (Pantos et al, 2011a/b; 2012). It has also 
been demonstrated that thyroid hormone plays a major role in both protecting and 
repairing the myocardium during adverse stress situations as in ischaemia and acute 
myocardial infarction (Pantos et al, 2011a/b; 2012). 
 The question which now arises is: what is responsible for the development of a weak 
left ventricle during diabetes, acute myocardial infarction or during diabetes in 
combination with AMI and how does thyroid hormone act to either protect the weak 
heart or to reverse the adverse effects of diabetes, AMI and DM in combination with 
AMI. In order to answer the question, it is of paramount importance to understand 
firstly  the processes of contraction and relaxation of the heart. 
Excitation – Contraction Coupling (ECC) 
 Excitation contraction-coupling (ECC) is a highly organised process of signal 
transduction pathways that overrides contractile force and function in the heart (Bers, 
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1991; Vander et al 2007). The process is initiated by the depolarisation of the cardiac 
cell membrane, during the cardiac action potential leading to Ca
2+
 entry via the voltage-
gated L-type channels as inward Ca
2+ 
current (Ica) ( Bers 1991a/b; Barry and Bridge 
1993). The sodium/calcium (Na
+
/Ca
+
) exchanger operating in reverse mode has also 
been proposed as a candidate mechanism of Ca
2+ 
entry into the myocyte (Lipp and 
Niggli, 1994; Leblanc and Hume, 1990). This small influx of Ca
2+ 
triggers a much 
larger release of Ca
2+
 from ryanodine receptors (CaRyR) on the surface of the 
sarcoplasmic reticulum (SR). Following the activation of the SR and Ca
2+ 
release, there 
is a transient rise in the cytosolic free Ca
2+ 
concentrations [Ca
2+
]i, typically from a 
diastolic level of 100 nM to a peak systolic level of around 1 µM within a period of 20 
and 40 msec after depolarisation (Beuckelmann and Weir, 1988; Kannel et al, 1987; 
Eisner and Trafford, 2000; Shaoa et al, 2012). This process is referred to as “Ca2+ -
induced Ca
2+ release” (CICR) and is widely accepted as the main mechanism of Ca2+ 
release from the SR (Fabiato, 1983; Letwin and Bridge, 1998; Muller, 1965). Other 
mechanisms leading to the release of Ca
2+ 
from the SR have been proposed, and include 
voltage-activated Ca
2+ 
release (Levi and Ferrier, 1997) and inositol (King et al, 1998; 
Shaffer, 1991) trisphospohate (InsP3)- triggered Ca
2+
 release through (InsP3) receptors 
(Lippet et al,., 2008). The process of contraction is initiated when the Ca
2+
 binds to the 
microfilament troponin-C, which in turn switches the contractile machinery (Bess, 
1991a/b). Relaxation occurs when the Ca
2+ 
transient decays and the Ca
2+
 dissociates 
from the troponin-C leading to the re-uptake of Ca
2+
 into the SR by a SR Ca
2+
 -ATPase-
dependent pump (SERCA) (Bers, 1991a/b; Balk et al, 1994) and the extrusion of Ca
2+ 
from the cell by Na
+
/ Ca
2+
 exchanger and the Ca- ATPase pump (Barcenas-Russ et al, 
1987; Jorgensen et al, 1982). 
 
Calcium dysfunction in the diabetic heart 
In the diabetic heart several workers have reported decreased responsiveness to the beta 
adrenergic stimulation (Seller et al, 2001) and marked changes in cellular calcium 
homeostatis (Howath and Singh, 1999; Bracken, 2003; 2004) including dysfunction of 
the L-type Ca
2+ 
 channels, the sodium-calcium exchanger, the ryanodine receptors and 
the SERCA pump (Bracken et al, 2002; 2003; 2004; Shao et al, 2010; 2012). All these 
proteins play a major role in regulating cellular Ca
2+ 
transport during contraction and 
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relaxation of the heart. In cardiac myocytes, the resting cell [Ca
2+
]i levels are 
determined mainly by Ca
2+ 
 leaking out of the cell. This is counter balanced by the 
sarcolemmal Ca-ATPase pump and the sarcolemmal Na
+
/ Ca
2+
 exchanger (Shaffer and 
Mozattari, 1996). The Na
+
/ Ca
2+
 exchanger provides the predominant mechanism for 
Ca
2+ 
efflux during the cardiac diastole (Golden et al, 2001). 
In a number of previous studies, it was demonstrated that STZ-induced diabetes mellitus 
over four to eight weeks can lead to elevated diastolic Ca
2+ 
 (Lagadic-Grossman et al,, 
1996; Hayashi and Noda 1997; Noda et al, 1992; Bracken et al, 2003; 2004; Shao et al, 
2010; 2012). This elevated cellular calcium is due to asynchronous release of calcium 
from the SR via the ryanodine receptor operated channels (Shao et al, 2010; 2012)  and 
dysfunction of the SERCA pump and the sodium calcium exchanger ( Noda et al, 1992; 
Bracken et al, 2004). There is also much evidence that the activities of the L-type 
calcium channels are reduced during diabetes mellitus (Bracken et al, 2004). These 
changes in cellular Ca
2+ 
homeostasis are responsible for the weak contraction of the 
heart during diabetes. 
   The next question which needs to be addressed is: how does acute myocardial 
infarction (AMI) result in the decrease in cardiac compliance and contraction either in 
the absence or the presence of diabetes mellitus. In order to answer this question, it is 
important to understand the relationship between diabetes and myocardial infarction and 
how the two when combined can worsen the problem. 
 
Diabetes and myocardial infarction 
Diabetic patients have been shown to suffer from more frequent (2.5-5 times) and 
severe myocardial infarction (MI) versus non-diabetics (Pell and Allonso, 1993). 
Studies conducted in the past have demonstrated that male diabetics have  an increased 
likelihood of cardiovascular problems by 2 times the normal risk. Dhalla et al, (1985) 
have suggested three major risk factors that may account for the increased incidence of 
cardiovascular dysfunction in diabetic patients. They included atherosclerosis, 
microvascular alterations and primary myopathic disorder in cardiac muscle. Studies in 
the past have also demonstrated that two months after an AMI, the mortality in diabetic 
patients was approximately 41% in comparison to 15% in non-diabetic patients 
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(Partamian and Bradley, 1965). Even more alarming is the evidence that regardless of 
infarct size, diabetic patients still suffer a higher mortality rate than non-diabetics (Stone 
et al, 1989). The increased incidence of AMI in diabetics has been linked to glycaemic 
status (D’Souza et al, 2009). It has been shown that when the hyperglycaemic state of 
diabetics was stringently controlled, the incidence of AMI fell significantly (Clark et al, 
1985). Hyperglycaemia has also been linked to accelerated atherosclerosis, endothelial 
dysfunction, coronary heart diseaseand hypertension (D’Souza et al, 2009). Moreover, 
hyperglycaemia is a hallmark of DM and it induces a variety of maladaptations at the 
subcellular and cellular levels of vascular tissues which may in part be accounted for the 
vascular complictions. In fact, chronic hyperglycaemia has been suggested as the key 
factor in the pathogenesis of diabetic complications (D’Souza et a, 2009; 2011). The 
pathophysiological alterations due to hyperglycaemia during DM include glucose flux 
through the polyol-sorbitol pathway,,hexosamine pathway, formation of advanced 
glycation-end products (AGEs) and the activation of protein kinace C ( D’Souza et al, 
2009). Another danger has been suggested that increases the mortality in diabetics is the 
occurrence of a silent AMI which has been suggested to be due to the damage of cardiac 
nerves and the inability of afferent nerves to transmit information as a result of visceral 
neuropathy (Faerman et al, 1977). Silent AMI was shown to be more common in the 
diabetic population (Niaken et al, 1986; Theoron et al; 1987) and it is of great concern 
because the patients are unaware that they have suffered an AMI and thus may not 
summon the proper medical attention (Soler et al, 1975). The survival of diabetic 
patients with AMI after 1, 2, and  5 years is 82%, 78% and 58%,  whereas that for non-
diabetic patients with AMI is 94%, 92% and 82%, ,respectively (Pantos et al. 2012). 
In terms of the cellular mechanism of cardiac dysfunction, it is clear that cellular 
calcium homeostasis is further reduced in diabetes combined with myocardial infarction 
(Bracken et al, 2003; 2004).  Acute myocardial infarction is normally associated with 
arrhythmias and beta adrenergic stimulation via the production of cyclic AMP and 
cellular calcium homeostasis overload and in turn, they are responsible for the AMI-
induced arrhythmias (Welhelm et al, 1992). However, it would be expected that 
treatment of patients with calcium channel blockers could stabilize the AMI-induced 
arrhythmias. A previous study had earlier reported that calcium channel blockers did not 
reduce significantly the risk of initial recurrent infarction or death when given routinely 
to patients with acute myocardial infarction or unstable angina (Held et al, 1989). 
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The diabetic heart fibrosis and remodelling  
In relation to the myocardium, the discussion so far addresses the processs of  ECC and 
a derangement of cellular Ca
2+ 
homeostasis during diabetes mellitus and diabetes in 
combination with AMI. The other issue of cardiac deformation during diabetes and 
AMI is the development of cardiac fibrosis (Martinet al, 1990; D’Souza et al, 2010; 
2011) leading to left ventricular remodelling. This is a process by which the size, shape 
and function of the ventricle are regulated by the mechanical, neuro-hormonal and 
genetic factors (Martin et al, 2000). Remodelling is both an adaptive and a 
physiological process during normal growth, a pathophysiological condition due to 
diabetes, AMI, cardiomyopathy, hypertension and other related heart diseases such as 
dysfunction of the valves (Feffer and Braunwold, 1990).  
 Heart failure (HF) may be viewed as a progressive disorder that is initiated in response 
to an index event (that may be acute i.e. AMI, chronic i.e. DM or hereditary) that results 
in either a loss or damage in the functioning of myocytes or alternatively produces a 
decline in the ability of the heart to function as a pump. Irrespective of the inciting 
event, several neurohormonal and inflammatory pathways are activated, including the 
rnin-angiotensin-aldosterone system (RAAS), adrenergic system, inflammatory 
cytokine systems and a host of other autocrine and paracrine mechanisms as 
compensatory mechanisms to maintain stroke volume at a reduced ejection fraction 
(Packer, 1992; Fedak et al, 2005). Thus far, a multitude of mediators and proteins 
including norepinephrine, angiotensin II, endothelin, aldosterone, TGFβ1, tumour 
necrosis factor (TNF) have been implicated into the disease progression of the failing 
heart (Maytin and Colucci, 2002; Fedak et al, 2005; Swynghedauw et al, 2010). These 
processes are initially compensatory and beneficial and in most instances patients 
remain asymptomatic or minimally symptomatic following the initial decline in 
pumping capacity of the heart, or will develop symptoms only after the dysfunction has 
been present for some time (Maytin and Colucci, 2002). As such, the index event 
produces remodelling off the LV frequently along one of the two patterns, either 
hypertrophy or dilation. Myocardial hypertrophy associated remodelling results in 
increased LV mass without any effects on the LV volume in a process termed 
‘concentric remodelling’ that is associated with preserved function, as the ventricle is 
187 
 
capable of generating greater force and higher pressure. The onset of LV dilation is 
characterised by ‘eccentric remodelling’ and substantial increases in intraventricular 
volume with comparable increases in the LV mass that represents a compensatory 
response to augment cardiac output in the face of diminished contractile function. 
Eventually, a functional demand of the myocardium is met; LV dilation progresses 
without appreciable increases in LV mass and in accordance with the Law of Laplace. 
The induction of excessive ventricular wall stresses is known to occur prior to the overt 
heart failure (Swynghedauw, 1999). 
Molecular mechanism of cardiac remodelling  
It is now well documented that cardiac remodelling occurs in response to cues generated 
by mechano-sensors (Connexins, integrins) that couple cellular signalling pathways to 
altered or mechanical stress/injury (D’Souza et al, 2009; 2011). In such cases, the nature 
and extent of signals that are transitorily activated are far from fully understood. 
Moreover,  it is now accepted that the myocardial response toeither injury or altered 
mechanical load involves profound alterations in gene expressions including the 
activation of those that are normally involved in embryogenesis, also known as the 
foetal gene programme (Swynghedauw, 1999; Pantos et al, 2012). In the context of 
AMI-induced cardiac remodelling alone, genome-wide analyses have revealed 
significant coordinated changes in over 1400 genes early and 125 genes late in the 
infarct zone, and nearly 600 genes early and 100 genes late in the non-infarct heart 
(LaFramboise et al, 2005; Pantos et al 2012) 
It is also now well known that foetal gene reprogramming, characteristic of pathological 
remodelling frequently involves an upregulation of foetal isoforms of genes whose 
products regulate cardiac contractility and Ca
2+
 handling. In turn these are paralled  by a 
down-regulation of their adult isoforms (i.e., up-regulation of β-MHC vs down-
regulation of α-MHC) and often includes decreased SERCA2a and increased sodium 
calcium exchanger (NCX) expression (Hilfker-Kleiner et al, 2006). Another important 
feature is that the fetal gene phenotype is markedly expressed in the remodelled 
myocardium that involves the natriuretic peptides ANP and BNP. These are often 
detectable in the circulation where they are used as an indirect marker for myocardial 
injury/overload (D’Souza et al, 2011). These transcriptional changes culminate in 
several molecular and cellular alterations that characterise myocardial remodelling. 
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Moreover, they are broadly categorised into those that occur in the myocyte and 
changes that occur in the volume and composition of the extracellular matrix (ECM). 
Within the myocyte, in addition to the functional changes, the remodelling process is 
invariably associated with sarcomeric reorganisation. Dilation of the heart is associated 
with myocyte re-lengthening, mediated by the generation of new sarcomeres in series 
and enhancement of the length-to width ratio whereas a hypertropic phenotype is the 
result of parallel addition of new sarcomeres. At the molecular level, hypertrophy 
appears to be characterised by increased expression of the adult isoforms of sarcomeric 
genes (Hilfker-Kleiner et al, 2006). Furthermore, biomechanical stretch signalling, 
altered redox states  and pathological stimuli including hyperglycaemia and TGFβ1 may 
include the activation of the phosphatidylinositol 3-kinase (PI3-K)/ protein kinase B 
(Akt) – p70S6K, and/or activation of extracellular signal-regulated kinases (ERK) 
which co-ordinate the hypertrophic response (Selvetella et al, 2004; Wu and Derynck, 
2009).  
Outside changes in the myocyte and structural remodelling in the myocardium are 
associated with alterations in the structure and function of the ECM (D’Souza et al, 
2011). Indeed, ECM deposition is a widely recognised alteration in the failing heart and 
the notion that progressive fibrosis underlies LV dilatation and HF progression has been 
supported by several experimental and clinical studies (Milner and Muller, 2005; Bowes 
et al, 2010). In pathological conditions, the ECM can be temporarily remodelled, 
reversibly remodelled or fully adapted to the changes in biomechanical load. However, 
prolonged overload results in detrimental collagen deposition that can render the heart 
electrically and structurally heterogeneous, resulting in excessive diastolic stiffness 
(Van Heerebeek et al, 2008) and/or induce LV dilatation altogether resulting in overt 
HF. Particular emphasis is now given to the collagenolytic MMPs and their inhibitors, 
the TMPs in underlying LV dilatation. The balance of proteolytic and antiproteolytic 
activity appears to be an important determinant of the rate of ventricular enlargement. 
The general view is that disruption of this balance can result in progressive MMP 
activation leading to degradation of the ECM, myocyte, slippage, thinning of the 
ventricular wall, and ventricular dilation that occurs in the end stage of HF 
(Swynghedauw, 1999; D’Souza et al. 2011).  
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TGFβ1 in cardiac remodelling and failure 
A central role for  transforming growth factor beta 1 (TGFβ1) in the remodelling 
myocardium has come to light, given consistent myocardial upregulation in 
experimental models of AMI, cardiac hypertrophy and  HF, and frequently in patients 
with dilated or hypertrophic cardiomyopathy (Dobaczewski et al, 2010). TGFβ1 is the 
most prevalent forms of TGFβs, a family of pleiotropic cytokines which are implicated 
in a wide variety of cell functions, including regulation of inflammation, ECM 
deposition, cell proliferation, differentiation and growth. The activating stimuli for 
TGFβ1 are varied and they include reactive oxygen species (ROS), integrins-mediated 
interactions and also MMP’s 2 and 9, a phenomenon that couples matrix degradation 
with activation of a molecule that primarily mediates matrix integrity and stability 
(Annes et al, 2003; Shao et al, 2010). Beyond homeostatic roles, TGFβ1 mediates 
phenotype and function of several cell types crucial in tissue injury and repair processes 
including fibroblasts. In addition to enhancing ECM synthesis from fibroblasts, it exerts 
potent matrix preserving actions by suppressing the activity of the MMPs and by 
inducing synthesis of TIMPs (Schiller et al, 2004). TGFβ1 is a key upstream effector of 
CTGF, a fibrogenic mediator that acts in concert with TGFβ to promote persistent 
fibrosis (Leask et al, 2004). The hypertropic effects of TGF-β1 stimulation on 
cardiomyocytes are by TGFβ1-mediated synthesis of foetal contractile proteins (Parker 
et al, 1990). Although there is substantial evidence indicating that TGFβ1 mRNA and 
protein induction is upregulated in the remodelling myocardium, direct evidence of 
increased activity is still lacking (Dobaczewski et al, 2010) and in vivo effects of TGFβ1 
in promoting the myocardial fibrotic and hypertrophic response are supported by over 
expression experiments in transgenic mice (Rosenkranz 2002; Dobaczewski et al, 
2010). Targeting regulatory mechanisms of ECM homeostasis that precedes transition 
to HF remains a vital goal in HF management. As TGF levels often reflect the 
development of cardiac remodelling (Villar et al, 2009), the TGFβ1 system is a 
promising therapeutic target for myocardial infarction and for cardiomyopathic 
conditions such as diabetic cardiomyotpathy that are associated with fibrosis and 
hypertrophy. Also late, but not early, TGFβ blockade has been demonstrated to 
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attenuate remodelling in experimental MI and TGFβ inhibition through administration 
of inhibitory peptides (Hermida et al, 2009), or neutralising antibodies has prevented the 
development of cardiac fibrosis in experimental pressure overload (Kuwahara et al, 
2002). 
The story so far is that STZ-induced diabetes, acute myocardial infarction and diabetes 
in combination with acute myocardial infarction can result in the development of weak 
left ventricular function and subsequent reduced cardiac output. This in turn is probably 
due to a derangement in cellular calcium homeostasis via its various transporting 
proteins and formation and development of fibrosis, all of which lead to the remodelling 
of the heart (Martin et al, 2002). The discussion attempted to show the various events 
includingcellular Ca
2+ 
homeostasis and development of fibrosis are both associated in 
left ventricular failure. 
 
Molecular changes in the heart during a failure 
The next logical question which this investigation needs to address is: what are the 
molecular events involved in the development of a weak left ventricle either during 
STZ-induced DM, AMI or AMI combined with DM compared to age-matched 
controls? This study measured the expressions of several cardiac proteins including 
calcium cycling proteins, several kinases and myosin isoforms expressions in control 
sham, DM-sham, AMI and DM+AMI. The data show variable changes in the different 
proteins under the different experimental measured conditions. The percentage of 
myosin isoforms expression for βMHC increased significantly (P<.05) during either  
DM, AMI or DM combined with AMI compared to sham control. In contrast, myosin 
isoforms expression for αMHC decreased significantly (P<,0.05) under the three 
experimental conditions compared to sham control. Similarly, there were no changes in 
either the protein expression for SERCA or phospholambam (PLB) in either diabetes, 
AMI or DM combined with AMI compared to sham control. These results indicate that 
the SERCA pump is not affected by either diabetes or AMI or during a combination of 
both DM and AMI. 
The SERCA pump is activated by the phospholambam and it plays a major role in 
regulating cytosolic calcium during contraction. SERCA pumps calcium back to the SR 
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following contraction leading to relaxation of the heart and subsequent filling (Vander 
et al, 2007; Shao et al 2010; 2012). It is apparent from this study that neither DM,  AMI 
nor DM combined with AMI had any significant effect on SERCA in the left ventricle 
of the heart compared to sham control hearts. The results also show significant (P<0.05) 
increases in the βMHC and significant decreases in the αMHC in DM, AMI and DM 
combined with AMI compared to control. It is now well known that two isoforms of 
myosin heavy chain (MyHC), alpha and either beta exist in the mammalian ventricular 
myocardium and their relative expression is associated or correlated with the force of 
contraction of the heart (Nako et al, 1997). Several pathophysiological conditions 
including DM, AMI, DM combined with AMI and heart failure can shift the 
composition of both isoforms of MyHC in the ventricle from either alpha to beta 
isoforms. αMHC has a higher ATPase activity than the βMHC. In the heart, the velocity 
of contraction depends on MHC. Hearts expressing αMHC have more rapid contractile 
velocity as in a healthy heart. This allows for greater economy of free generation and 
pumping action of the myocardium. In contrast βMHC increases significantly in a faulty 
heart (Miyata et al, 2000; Reiser et al, 2001; Kalofoutis et al 2010). 
The traditional view is that HF induced by either DM, AMI or hypertension as a 
functional disorder, is precipitated by impaired LV pump performance in response to 
increased haemodynamic burden of the heart and associated defects in myocyte 
contractility (Houser and Marguiles, 2003). HF is associated with a multitude of cellular 
and molecular defects that culminate in electrophysiological dysfunction, depressed 
myocyte contractility, fatal arrhythmias and pump failure. Numerous studies have 
suggested that the failing human cardiac myocytes undergo several changes that might 
be expected leading to a progressive loss of contractile function.These include  
decreased α-myosin heavy chain (MHC) gene expression with a concomitant increase in 
β (MHC) myosin heavy chain expression, progressive loss of myofilaments in cardiac 
myocytes and alterations in cytoskeletal proteins (Schaper et al, 1991; Gupta et al, 2000; 
Kalofoutis et al, 2010; Pantos et al 2012). 
Together, the results obtained in this study following the induction of DM, AMI or DM 
plus AMI are in total agreement with several previous studies reported in the literature 
(see above). It is equally important to ascertain the cellular and molecular mechanisms 
involved in the decrease in expression of αMHC and increase in expressing βMHC 
during HF. It is possible that these changes occur as a result of carbonylation of the 
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regulatory proteins. In addition to oxidative stress, there is noew much evidence in the 
literature that regulatory proteins (eg ryanodine receptors) in the heart, undergo 
carbonylation (Shao et al, 2010; 2012). 
The present study has also shown that the expressions of protein kinase alpha (PKCα) 
increased significantly in DM-AMI and in AMI compared to sham control and 
DM+sham heart. In contrast, there was no significant change in the expression of PKC 
episilon. The PKC isoenzymes have been implicated in such diverse cellular regulations 
including cell proliferation, cardiac contractility, hypertrophy, accelerated diabetic 
induced atherosclerosis and apoptosis (Pal et al, 2004; D’Souza et al, 2009). In a 
previous study, it was demonstrated that PKCα increased significantly in the weak 
diabetic heart (Kang et al, 1999). Several other studies have associated PKCα activation 
or an increase in PKCα expression with cardiac hypertrophy, dilated cardiomyopathy, 
ischaemia, and injury to mitogen stimulation (Dorn and Force, 2005). Elevated PKCα is 
also associated with later stages of heart failure (Bayer et al, 2003; Braun et al, 2002) 
and myocardial infarction (Wang et al, 2005; Simons et al, 2005). PKCα is an ideal 
protein to target during the treatment of either diabetes-induced cardiomyopathy or 
myocardial infarction. Further discussion of the role of PKCα is thoroughly reviewed in 
the introduction of the thesis. 
   The present results have also demonstrated no significant changes in phospho38 
MAPK/Total p38 MAPK in DM-sham compared to sham and DM+AMI.  However, 
there was a significant increase in the phospho38 MAPK/Total P38 MAPK in AMI 
hearts. This was significantly (P<0.05) reduced during DM+AMI. In contrast, there 
were no significant changes in phosphoJNK/Total JNK and in phosphor-Akt/Total Akt 
in either sham control, DM-sham, AMI or DM+AMI hearts. Interestingly, the results of 
the study show significant increases in phospho-ERKs/Total ERKs (p44 and p42) in 
DM-sham, AMI and DM+AMI sham compared to control sham. 
The literature relating to P38-MAPK varied and some studies have reported that P38 
plays a major role in cardiac growth and hypertrophy (Liang and Molketin, 2003; 
Nemoto et al,., 1998). Another study has shown that activation of P38 had no significant 
effect on the degree of cardiac hypertrophy (Liao et al, 2001). However, there were 
marked increased in fibrosis and impaired diastolic function (D’Souza et al 2011). 
Together, these current results and others indicate that the role of p38 in cardiac 
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hypertrophy is a conflicting one. While acute activation of p38 appears to be 
prohypertrophic, chronic activation of p38 can lead to suppression of hypertrophic 
growth in the heart. However, it is clear from both in vitro and in vivo studies that p38 
activation has a detrimental effect on cardiac function and normal gene expression. 
Therefore, p38 induction is more closely related to pathological form of hypertrophy 
than to physiological compensation (Pantos et al, 2012). 
In the present study, P38-MAPK increases at least during acute myocardial infarction 
agreeing with some of the previous studies in the literature (Pantos et al 2012). The 
present results show no significant change in either phosphor JNKs/Total JNKs and 
Phospho Akt/Total Akt in all the experimental conditions with either sham control, 
sham diabetes, AMI or DM+AMI. In contrast phospho-ERKs/Total ERKs increased 
significantly in DM+sham, AMI and DM+AMI conditions. Several other studies have 
demonstrated a relationship for Ras/Raf/MEK1/ERK signalling pathways with cardiac 
hypertrophy (Hunter et al, 1995; Zeng et al, 2004), similar to the results observed in the 
present study. Inhibition of the ERK pathway has been shown to alternate the diabetes 
or AMI induced hypertrophy of the heart (Ueyama et al, 2000; Kontaridis et al, 2008). 
Another study shows that reduction in the ERK activity is not sufficient to prevent 
hypertrophy of the myocardium during various types of hypertrophic stimuli in vivo 
(Purcell et al, 2007). Together, these results in the current and other studies suggest that 
ERK activity is an important biochemical pathway for cardioprotection, but also cardiac 
hypertrophy can proceed via ERK-independent mechanisms. In passing, it is 
particularly noteworthy that excessive beta adrenergic stimulation can also promote 
cardiomyocytic hypertrophy via an interaction between ERK and beta arrestin (Bark-
Harrington, 2004; Salazar et al, 2007). 
The role for JNK in the development of a large weak heart is unclear. The level of JNK 
increased in physiological cardiac hypertrophy due to acute forms exercise (Boluyt et al, 
2003). There is some evidence that a disruption of JNK activity can result in cardiac 
hypertrophy following pressure overload (Lianger et al, 2003). This effect is due to the 
ability of JNK to inhibit NFAT entry into the nucleus (Liang et al, 2003). From present 
study and those reported in the literature, it is clear that JNK has little or no effect on 
cardiac hypertrophy at least in vitro studies (Pantos et al, 2012). 
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The results of this study have shown no significant (P<0.05) change in the activity of 
phosphor Akt/Total Akt in DM+sham, AMI and DM+AMI hearts. Akt is a 
serine/threonine protein kinase that regulates a number of cellular functions in different 
tissues including the heart (Shiojima and Walsch, 2006). Akt plays a major role in post 
natal cardiac development short term Akt activation can promote physiological 
hypertrophy (Shiojima et al, 2002) where as long term Akt activation can lead to a 
pathological hypertrophy (Kemi et al, 2008; Matsui et al, 2003). The latter is associated 
with morbidity and mortality leading to pressure over load, myocardial dysfunction, 
dilatation and subsequently heart failure (Mann et al, 2010; Shah and Soloman, 2010). 
Since no change in Akt was observed in this study, it is tempting to suggest that Akt 
plays no role in either diabetes or AMI-induced cardiomyopathy. 
Role of thyroid hormone in DM, AMI and DM+AMI 
The initial part of the discussion concentrated in the function – dysfunction of the heart 
and molecular events associated with DM+sham, AMI and AMI in combination with 
DM. This part of the discussion will now address the therapeutic or beneficial role of 
thyroid hormone in protecting the pathophysiological heart in the rat when DM was 
combined with AMI.  
To date, heart failure remains one of the main causes of death in the world despite 
advances in drug and significant treatments (Roger, 2012; Mormsey et al, 2011). Most 
treatments aim at improving the pumping action of the heart or improving cardiac 
haemodynamic. The weak heart is deprived of myocytes and as such it becomes fibrotic 
in nature leading to a protective mechanism called remodelling (Martin et al, 2002; 
D’Souza et al. 2011; Pantos et al 2012). During failure, the heart has to regenerate and 
repair itself otherwise the failure process will be exacerbated. The potential for repair 
and regeneration has been evolutionary and it seems to be restricted in only 
developmental staged of life. In recent years, several studies have investigated the role 
of thyroid hormone in the repair and regeneration of several tissues in the body 
including the heart. Thyroid hormone is often described as nature’s own wonder in 
repairing and regeneration of the body (Miyata et al, 2000; Pantos et al, 2001; 
Kalofoutis et al, 2010; Pantos et al, 2011, Lymvaios et al, 2011; Pantos et al 2012). 
Thyroxine (T4) is secreted by the thyrocyte and enters the cell via different transport 
mechanism (Hennemann, 2005). In the body, T4 is converted to triiodothyronine (T3) 
195 
 
by the de-iodinase while T3 is degraded. Either type of the hormone T3 or T4 can be 
reconverted to one another by de-iodinase (Hennemann, 2005). Thyroid hormone 
initiates its effect in the body by activating its receptors which are located in the 
nucleus, the plasma membrane, in the cytoplasm and in mitochondria of the cell (Pantos 
et al, 2010). There are two types of the TH receptors (TRs), namely alpha and beta. The 
two TR genes, α and β encode four T3 binding receptor isoforms (α1, β1, β2 and β3). 
TRs are usually phosphorylated in order to become active and this is mediated via a 
number of stimuli (Nicol et al, 2003). In the heart, the function of TRβ is only apparent 
in the hypothyroid state and this is associated with angiogenesis (Pantos et al, 2010). In 
contrast, TRα ensures the maintenance of homeostasis by controlling heart rate, DNA 
damage, repairing of tissues stress responses and several others (Pantos et al, 2010). 
In several previous studies, thyroid hormone has been shown to play a major role in the 
development and differentiation of cardiac cells (Van-Putten et al, 2002; Van-der Heide 
et al, 2007) via he expression of TRα1 (Meischl et al, 2008; Pantos et al, 2008c). The 
effect of TH on cell differentiation and development is believed to be mediated through 
the activation of a number of distinct endogenous pathways including ERK, P38-
MAPK, mTOR and JNK (Kingawa et al, 2006;  Pantos et al, 2007c; Ojamaa, 2010). 
The numerous beneficial role of TH via activation of its TRα1 and TRβ1 receptors have 
been reviewed in some details in the introduction of the thesis.  
Since TH has been linked to repairing, regeneration and development as previously 
described in the literature (see introduction for details), it was relevant to investigate the 
effect of this “nature’s wonder” on the diabetic, AMI and AMI in consideration with 
DM during heart failure compared to sham healthy control hearts. The results of the 
present study have shown that TH (T4) did not increase significantly either in DM-
sham, DM+AMI compared to  the DM+AMI animals  treated with TH. In fact, the 
DM+AMI treated rats seem to have a small decrease in plasma level of T4 compared to 
DM+AMI untreated animals (see table 3.7).However, in thyroid hormone treated 
DM+AMI rats, the circulating plasma level of T3 increased significantly compared to 
DM+sham or DM+AMI untreated animals. Moreover, thyroid hormone seemed to have 
a significant effect on heart rate in the treated rats compared to the untreated animals 
(Pantos et al, 2012). In addition, thyroid hormone treatment had no significant effect on 
cardiac scar area (see table 3.7), but there was an increase in scar weight compared to 
untreated DM+AMI hearts, but this was not significant (see table 3.7). 
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Thyroid hormone induced changes in the diabetic heart after myocardial 
infarction  
Since DM+sham and DM+sham in conmbination with AMI can have adverse effects on 
the structure and function of the diabetic heart compared to either non diabetic or non 
AMI control sham, it was logical to investigate the effect of thyroid hormone(TH) 
treatment for comparison. The results show that pretreatmentof the diabetic AMI rats 
for two weeks with thyroid hormone  resulted in marked reversal and beneficial effects 
on the diabetic rat heart. Thyroid hormone was able to increase significantly (P<0.05) 
the  LVW, LVW/BW, LVPW, WTI, sphericity index, LVIDα, LVIDs, %,EF  SVPW, 
LVDP  and  +dp/dt and –dp/dt compared to the effect of DM+AMI hearts (see table 
3.8). These results have clearly shown that TH can reverse the adverse effects of AMI in 
the diabetic heart to almost normal diabetic ‘physiological’ level. The results are in 
agreement with those observed in previous studies (Pantos et al, 2002; Lymvaios et al, 
2011).  
The question which now arises is: how does TH act to reverse the deleterious effects of 
AMI on the heart. It is possible that during AMI, TH level is decreased or other events 
like activation of thyroid hormone receptors is decreased leading to a depletion in the 
protective effect of TH (Pantos et al, 2002; Lymvaios et al, 2011). It is now well known 
that only after AMI, cardiac function is compromised because of ishaemic injury. As a 
result of these early changes, a number of neurohormonal and inflammatory event take 
place in the body leading to marked physiological changes. Decrease in TH level is a 
frequent observation in AMI (Pantos et al, 2010) and TH changes early after AMI can 
affect cardiac function adversely with marked haemodynamic consequences (Lymvaios 
et al, 2011). It  also now well known that TH can regulate contratile function of the 
heart via several mechanisns including modulation of contractile protein function, 
enhanced calcium handling and cation channel activities (Iervasi et al, 2003; Pantos et 
al,  2008) 
This study did not investigate the changes in cellular calcium homeostasis either during 
DM, DM + AMI or DM + AMI + TH treatment. However, the study measured a 
number of contractile proteins and signalling kinase molecules as well as changes on 
TRα1 and TRβ1 protein expressions during the different conditions. The present results 
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have shown that thyroid hormone can significantly (P<0.05) increase TRα1 and TRβ1 
protein expressions compared to the levels in DM+AMI hearts in the absence of thyroid 
hormone. Similarly, TH treatment significantly (P<0.05) increased αMHC and 
decreased βMHC in the DM+AMI hearts compared to DM+AMI hearts in the absence 
of thyroid hormone. TH significantly increased SERCA protein expression, but not 
phospholambam protein expression in the DM+AMI hearts compared to DM+AMI 
hearts in the absence of the hormone. 
The present results have also shown that two weeks of pretreatment of DM+AMI rats 
with thyroid hormone had marked and significant effects on a number of signalling 
molecules in the heart compared to the untreated DM+AMI rats. The hormone treatment 
resulted in significant (P<0.05) decreases in the protein expression of PKCδ and 
significant (P<0.05) increases in phosphor-P38 MAPK/ Total P38 MAPK compared to 
untreated animals. However, there were no significant changes in the levels of either 
phospho-JNKs/ Total JNKs protein expressions or phospho-Akt/ Total Akt protein 
expressions in the DM+AMI heart compared to the thyroid hormone DM+AMI- treated 
hearts. Similarly, the present results show that thyroid hormone treatment had no 
significant effect on the protein expressions of phosphor-ERK/Total ERK comparing 
non-treated DM+AMI group with treated DM+AMI groups. These results clearly show 
that TH seems to play a major role in reversing the deleterious effects of DM-AMI, by 
protecting the myocardium and thus, preventing the heart from further damage. 
Moreover, these findings suggest that TH seems to help in protecting the heart and in 
the repairing process (Pantos et al, 2008; Pantos et al, 2010; 2012) 
Cardiac remodelling following acute myocardial infarction results in cardiac 
dysfunction due to myocardial loss and a series of changes in the non ischaemic 
myocardium including alterations in chamber size and shape and interstitial structure 
(Pantos et al, 2012).  One main feature of cardiac remodelling is the recapitulation of 
foetal gene reprogramming leading to cell de-differentiation (Swynghedauw, 1999; 
Taegtmeyer, 2010). The underlying mechanisms of this response are not fully 
understood. However, it is now recognized that hormone signalling related to cell 
differentiation, such as thyroid hormone (TH) may be of physiological relevance in the 
context of cardiac remodelling. Thus, distinct changes in TH–thyroid hormone receptor 
(TR) axis have been identified in the course of cardiac remodelling and have been 
linked to cardiac dysfunction (Pantos et al, 2005, 2007). Consequently, TH treatment 
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early after myocardial infarction can be favorable in remodelling the rat myocardium 
via its pleiotropic effects which include induction of physiological growth, expression 
of contractile proteins and enhanced protection of the myocardium from ischaemia 
(Pantos, 2005).  Co-morbidities may abolish the beneficial effects of cardio-protective 
interventions. Diabetes is common in patients with coronary artery disease and 
significantly increases the risk of death from myocardial infarction (Kumar and Clark, 
2007). Furthermore, recent experimental studies show that diabetes accelerates cardiac 
remodelling after myocardial infarction through mechanisms which are not fully 
understood (Lymvaios et al, 2011).  
 
Potential mechanisms 
The mechanisms of impaired cardiac remodelling of the diabetic heart after myocardial 
infarction remain largely unknown. Thus, the present study made an attempt to give 
some fundamental new insights into the potential mechanisms which may implicate in 
this response. A complex kinase signalling has been implicated in cardiac remodelling 
with ERK and p38 MAPK to be mostly studied in the context of myocardial infarction 
(Gosselin 2006; Kumphune 2009). Activation of these cascades is increased due to 
myocardial stretch and mediates the development of the reactive hypertrophy. As 
previously reviewed in the introduction section, both classic RTK-mediated and GPCR-
mediated ERK activation have significant roles in cardiac hypertrophy and 
cardioprotection. Furthermore, the Ras-Raf-MEK-ERK pathway can induce SR calcium 
defects and arrhythmias in the heart by modulating ion channels, exchangers, and 
pumps and serves as a potential contributor to the contractile defects and sudden cardiac 
arrest. Similarly, multiple groups have shown that over-activation of the p38 pathway 
induces hypertrophic changes in vitro with acute activation of p38 to be pro-
hypertrophic and chronic activation of p38 to lead to the suppression of hypertrophic 
growth in heart. Based on this evidence, the present study explored whether a distinct 
pattern of ERK and p38 MAPK activation occurs in diabetic hearts subjected to 
myocardial infarction which may explain the impaired hypertrophic response seen in 
those hearts. Interestingly, the induction of myocardial infarction resulted in activation 
of both ERK1/2 and p38 MAPK (as assessed by the phosphorylated levels) in the non 
diabetic hearts. On the contrary, this response was different in diabetic hearts since p-
ERK levels were found to be increased at baseline and no further increase was observed 
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after myocardial infarction. Moreover, p-p38 MAPK levels were also not shown to be 
increased in diabetic hearts after myocardial infarction. Here, it is of note that 
imposition of mechanical loading in diabetic heart also failed to result in ERK1/2 
activation and increase wall thickening (Landau, 2008) 
Collectively, these data point out that the response of the diabetic myocardium is 
impaired after myocardial infarction which may be, at least in part, be due to its 
inability to develop reactive hypertrophy to normalize wall stress. This is shown to be 
due to the defects in stretch induced kinase activation. The cause of this defect is not 
known. However, it has recently been shown that ischaemia can induce tissue 
hypothyroidism which can lead to myocardial atrophy (Pantos, 2005). Based on this 
evidence, this study explored whether changes in thyroid hormone receptors occurred in 
diabetic myocardium after myocardial infarction. Surprisingly, the molecular analysis in 
this study showed that, at this early stage, both TRα1 and TRβ1 receptors were down 
regulated in the diabetic hearts while such a response was not observed in the non 
diabetic hearts. Circulating T4 and T3 levels remained unchanged. Thus, acute 
myocardial infarction appears to result early in tissue hypothyroidism in the diabetic 
hearts which may be implicated in the acceleration of post-ischaemic remodelling. 
Several lines of evidence support this notion. First, thyroid hormone is critical for 
cardiac growth and function, mitochondrial biogenesis, metabolism, angiogenesis and 
response to ischaemic stress ( reviewed in introduction) and low thyroid function results 
in cardiac atrophy with chamber dilatation and marked increase of β-MHC expression 
(Tang, 2005) Second, hypothyroidism is shown to exacerbate post-ischaemic 
remodeling by altering myosin expression and cardiac geometry by preventing wall 
thickening and increasing chamber dilatation (Pantos, 2009 ).  
The potential link of tissue hypothyroidism and impaired response of the diabetic heart 
to ischaemia has further been established in this study in experiments in which thyroid 
hormone was administered after myocardial infarction. Interestingly, TH treatment early 
after infarction, prevented changes in TRs receptor expression and resulted in 
significantly reduced β-MHC expression, increased wall thickening with reactivation of 
p38 MAPK levels and improved cardiac function in diabetic animals with myocardial 
infarction (Pantos et al, 2012) 
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From the data obtained in this study, it can be clearly seen that TH can reverse and or 
prevent cardiac damage at least in DM in combination with AMI. It is apparent that TH 
is promoting cell growth, differentiation and repairing of the heart following DM in 
combination with AMI through the distinct intracellular signaling events mentioned 
earlier in this discussion. The evidence from this study is that TH can indeed protect the 
heart against stress, insults and injuries induced by both DM and AMI via a regulation 
of cardiac cardioprotective signalling.The results present in this study were obtained 
from rat models of DM and AMI. It is of clinical importance to follow up this study 
using potential therapeutic application of TH in DM+AMI patients with heart failure 
(Pantos et al 2011a; 2011b)  
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      CONCLUSION 
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This study employed the STZ-induced diabetic rats which were subjected to AMI in the 
absence and presence of TH treatment in order to study the beneficial roles of TH on 
cardiac function compared to the appropriate controls. Preliminary experiments were 
done initially to establish a base line of STZ application. The results showed the STZ at 
35 mg/kg bw was more effective in inducing DM with little or no ketosis compared to a 
high dose of 60 mk/kg bw. Having a good DM model, some animals were induced with 
AMI to investigate the relation between DM, AMI and DM+AMI on cardiac 
dysfunction in the absence and presence of TH measure physiological and biomolecular 
signals in the heart. 
The main conclusions of the study are summarized in the flow diagram of  figure 
5.1A/B. It is proposed that myocardial ischaemia in the diabetic heart induces tissue 
hypothyroidism which results in hypertrophy, decreased haemodynamics, suppression 
of growth kinase signalling molecules and in turn, these result in the inability of the 
diabetic heart to develop reactive hypertrophy and to compensate for the early insult of 
acute myocardial infarction. Administration of TH to the diabetic/AMI animals prevents 
the hypothyroidism and in turn, helps to remodel the heart and thereby  increasing the 
haemodynamic parameters. These processes evoked by TH seem to be mediated via the 
activation of growth kinase signalling in the myocardium.  
In conclusion, the results have clearly show that TH treatment shortly after myocardial 
infarction has beneficial effects on the remodelling of the diabetic heart by preventing 
tissue hypothyroidism, increasing growth kinases and thus, elevating contractile 
function of the heart and in turn haemodynamics. 
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A. Absence of TH                                          B. Presence of TH        
 
 
 
Figure 5.1: A schematic flow diagram showing the effect of myocardial infarction in 
the heart in the absence of TH (left) and in the presence of TH (right). The diagram 
shows clearly that thyroid hormone reverses all the deleterious effects of myocardial 
infarction, thus protecting the heart, preventing hypothyroidism, activating growth 
kinase signalling and improving cardiac contractile function and haemodynamic 
parameters.  
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 For future studies, a number of experiments have been proposed including:- 
1. Investigating the gene expressions of other calcium handling proteins such as 
Na
+
/Ca
2+
 exchanger, the ryanodine receptor or L-type Ca
2+
 channel in the heart 
under different experimental conditions using Western Blotting 
tecnhniques.These experiments will provide circumstantial evidence for a 
derangements in the different calcium transporting proteins in the heart and 
whether TH can repair and reverse any adverse effects. 
2. Investigating the morphology and functions of cardiomyocytes obtained from 
whole hearts under different experimental conditions. Contractile function will 
be done by measureing myocyte kinetics (amplitude of contraction, rate of rise 
in tention, rate of relaxation etc) using the Video Edge System. These results 
will provide substantial evidence for myocyte dysfunction and the beneficial 
role of TH in reversing myocyte dysfunction. In addition, it is possible to 
measure the sizes (length and diameter) of the myocytes for hypertrophy. 
3. Investigating the development of fibrosis and measuring gene expressions for 
the different collagens and related molecules under the different experimental 
conditions using morphogical and molecular biological techniques in the 
absence and presence of thyroid hormone.The work will involve staining for the 
different fibrotic molecules and measuring the expressions for the different 
collagens and extracellular matrix factors (MMPS) and respective inhibitors. 
4. Investigating the role of TH in type II diabetes mellitus experimental models 
employing the different experimental conditions. These studies will involve 
repeating all the experiments described in this thesis. It will also involve the 
measurements of contraction and cellular calcium homeostasis using established 
techniques. 
5. Investigating the effect of thyroid hormone on intracellular free calcium 
concentrations and L-type calcium current activities under different 
experimental conditions. Calcium is the main stay in contraction and a 
derangement in its homestasis is associated with cardiac dysfunction.  Isolated 
myocytes will be loaded with fura -2 for the measurement of intracellular free 
calcium concentrations. Cells will be stimulated electrically and with caffeine.  
Experiments will involve the roles of SERCA, ryanodine recptors, calcium-
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ATPase pump and the sodium calcium exchanger during calcium transport. 
From the data it will be possible to investigate the myofilament calcium 
sensitivity.The Patch Clamp Technique will be used to determine L-type 
calcium current activities under the different experimental conditions.  
6. Investigating the effect of reactive oxygen species and carbonylation in the 
hearts form sham control, DM, AMI and AMI combined with DM in the 
absence and presence of TH treatmen using established methods described in the 
literature. 
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